

Prof. Dr. med. Mathias Freund
Klinik für Innere Medizin III
Universitätsklinikum Rostock AöR
Postfach 10 08 88

18055 Rostock

Tel. 0381 494 7421
Fax 0381 494 7422

e-mail: mathias.freund@med.uni-rostock.de

Privatadresse:
Große Mönchenstraße 2

18055 Rostock



CURRICULUM VITAE UND VERÖFFENTLICHUNGEN

A handwritten signature in black ink, appearing to read 'M. Freund'.

Rostock, den 8.8.2011

A. CURRICULUM VITAE UND LICHTBILD

Personalien	<p>Freund, Prof. Dr. med., Mathias Richard Franz, geboren 4.8.1949 in Schellerten, Landkreis Hildesheim - Marienburg.</p> <p>Verheiratet in 2. Ehe, 3 Kinder</p>
Ausbildung	<p>1956 bis 1960 Grundschule in Schellerten.</p> <p>1960 bis 1968 Besuch des Scharnhorst-Gymnasium in Hildesheim.</p> <p>Am 11.6.1968 Abitur.</p>
Medizinische Ausbildung und Qualifikationen	<p>Oktober 1968 bis 1974 Studium der Medizin an der Eberhard-Karls-Universität Tübingen. Förderung durch die Studienstiftung des Deutschen Volkes.</p> <p>Am 2.8.1974 Staatsexamen an der Universität Tübingen.</p> <p>Oktober 1974 bis Februar 1976 Medizinalassistentenzeit an der Universitäts-Hautklinik Tübingen, an der Chirurgischen Klinik des Kreiskrankenhauses Calw und an der Medizinischen Universitätsklinik Tübingen.</p> <p>Am 1.3.1976 Erteilung der Approbation als Arzt durch das Regierungspräsidium Stuttgart.</p> <p>März 1976 bis März 1981 wissenschaftlicher Assistent in der Abteilung II (Hämatologie) der Medizinischen Universitätsklinik Tübingen unter Leitung von Herrn Prof. Dr. H. D. Waller. Tätigkeit auf verschiedenen allgemein-internistischen Stationen, auf den hämatologischen Schwerpunktstationen, im Gerinnungs-Labor und in der hämatologischen Nachsorgeambulanz. Langjährige Tätigkeit im Labor für Knochenmark-Zytologie. Für ein Jahr Leitung der Internistischen Intensivstation als Stationsarzt. Ausbildung in der Röntgenmorphologie für 6 Monate im Strahleninstitut der Universität unter Leitung von Herrn Prof. Dr. Fromhold.</p> <p>Am 15.4.1981 Anerkennung als Internist mit der Teilgebietsbezeichnung Hämatologie.</p> <p>1.7.1982 bis 30.9.1982 Tätigkeit als Assistent und Vertreter in der Allgemeinarztpraxis meines Vaters, Herrn Dr. med. Wolfgang Freund, in Schellerten, Landkreis Hildesheim.</p> <p>Von Oktober 1982 bis September 1994 Tätigkeit in der Abteilung für Hämatologie und Onkologie der Medizinischen Hochschule Hannover unter Leitung von Herrn Prof. Dr. H. Poliwoda. Anfänglich als wissenschaftlicher Assistent in der Onkologischen Ambulanz in der Arbeitsgruppe Internistische Onkologie unter Herrn Prof. Dr. V. Diehl. Gleichzeitig konsiliarische hämostaseologische Tätigkeit. Ab März 1984 Oberarzt der Abteilung Hämatologie und Onkologie, ab 1985 mit der Geschäftsführung und der Vertretung des Abteilungsleiters betraut. Regelmäßige Teilnahme an den Oberarztdiensten des Zentrums für Innere Medizin. Oberärztliche Tätigkeit auf der hämatologisch-onkologischen Schwerpunktstation und in der hämatologischen Ambulanz. Konsiliarische internistische Tätigkeit auf der Station für Augenheilkunde und den psychiatrischen Stationen. Oberarzt der Medizinischen Poliklinik 1989 bis 1990 und der Interdisziplinären Aufnahmestation der Medizinischen Hochschule von 1989 bis 1993.</p> <p>Ab 1984 nach Studienaufenthalt in Minneapolis, Los Angeles und New York Konzeption und Aufbau der interdisziplinären Arbeitsgruppe für Knochenmarkstransplantation der Abteilungen Hämatologie und Onkologie, Immunologie und Pädiatrische Hämatologie und Onkologie der Medizinischen Hochschule Hannover und ihrer Station. Zwischen 1985 bis 1994 Betreuung der Interdisziplinären Einheit für Knochenmarkstransplantation einschließlich der oberärztlichen Leitung von Knochenmarkentnahmen, Knochenmarkpräparation, der Betreuung der Patienten in der Akutphase der Transplantation und in der Nachsorge.</p> <p>Zwischen 1984 und 1994 konsiliarische Betreuung der Städtischen Krankenhäuser und Kreiskrankenhäuser Helmstedt, Gifhorn, Wolfsburg, des Krankenhauses Siloah (Hannover-Linden) und des Agnes-Karll-Krankenhauses in Hannover-Laatzten, zunächst im Rahmen von Konsiliarvisiten, später im Rahmen des MEDKOM-Projektes für multimediale Kommunikation. Ab 1990 betraut mit der Konzeption der ersten Hämatologisch-Onkologischen Abteilung der Stadt Hannover am Krankenhaus Siloah (Aufnahme des Betriebs unter Herrn Chefarzt Dr. med. H.H. Kirchner 1995).</p> <p>Am 3.9.1989 "European Certification on Medical Oncology" der European Society of Medical Oncology. Die Prüfung zur Erteilung des Zertifikats wurde 1989 zum ersten Mal durchgeführt.</p> <p>Am 27.8.1992 Ernennung zum Außerplanmäßigen Professor für Innere Medizin durch das Niedersächsische Ministerium für Wissenschaft und Kultur.</p> <p>An der Medizinischen Hochschule Hannover ab 1993 Aufbau einer Arbeitsgruppe</p>

für die periphere Stammzelltransplantation sowie erste Durchführung von Transplantationen mit myeloablativer Konditionierung bei Patienten mit hochmalignen Lymphomen außerhalb der KMT-Einheit.

Am 1.10.1994 Ernennung zum C3-Universitätsprofessor und Direktor der Abteilung Hämatologie und Onkologie der Klinik und Poliklinik für Innere Medizin der Universität Rostock.

An der Universität Rostock Aufbau einer Arbeitsgruppe von 14 Wissenschaftlern. Errichtung eines hämatologischen Speziallabors mit allen Möglichkeiten der Diagnostik mittels konventioneller Knochenmarkzytologie und Immunzytologie, Knochenmarkhistologie, Durchflußzytometrie (Ausstattung: 1 FACS-System und 1 FACS-Vantage), Molekularbiologie und Tumorzytogenetik einschließlich FISH und Schaffung aller erforderlichen Voraussetzungen für die Stammzelltechnologie in den Händen der eigenen Abteilung mit Möglichkeit zur Separation, Aufreinigung, Qualitätskontrolle und Cryokonservierung von Blutstammzellen. Etablierung der peripheren Blutstammzelltransplantation, allogenen Knochenmark- und Blutstammzelltransplantation in Rostock mit einer neuen Station (6 Transplantationsbetten) als erstem Zentrum in den neuen Bundesländern nördlich von Berlin. Gesamtumfang der Baumaßnahmen: 13 Mio DM.

September 1996: Zuerkennung der Schwerpunktbezeichnung Hämatologie und Internistische Onkologie durch die Landesärztekammer Mecklenburg-Vorpommern

Juli 1998: Fachkunde gemäß §45, Abs. 2 der Röntgenverordnung

Anerkennung als Begutachter/Fachexperte für medizinische Laboratorien Spezifische Akkreditierungsregeln/DIN ISO 15189 durch die ZLG, gültig bis 25.8.2007

12/2005 bis 12 2007 Berufung in die Off-Label-Use Kommission Onkologie am BfArM

2008 Anerkennung der Zusatzweiterbildung Palliativmedizin

2009 Anerkennung der Zusatzweiterbildung Hämostaseologie

WEHRDIENST

Vom 1.4.1981 bis 30.6.1982. Nach der vierwöchigen Vorbereitungszeit in München Tätigkeit in den inneren Abteilungen der BundeswehrKrankenhäuser Osnabrück und Detmold als Stabsarzt.

WISSENSCHAFTLICHE LAUFBAHN

Promotion am 24.5.1976 über das Thema "Vergleichende Untersuchungen über die Sterblichkeit unter historischem und sozialem Aspekt bei Berücksichtigung von Erkrankungen des Nervensystems" unter Herrn Prof. Dr. Vetter an der Neurologischen Universitätsklinik Tübingen.

Ab 1976 Arbeiten über Aspekte der Übergerinnbarkeit und Schocklunge unter der Leitung von Prof. Dr. P. Ostendorf an der Medizinischen Universitätsklinik Tübingen. Später Arbeiten zu opportunistischen Infektionen und zum ZNS-Befall durch Mammakarzinome und Non-Hodgkin-Lymphome.

Ab Oktober 1982 an der Medizinischen Hochschule Hannover klinische Studien bei Patienten mit akuter myeloischer und akuter lymphatischer Leukämie, Non-Hodgkin-Lymphomen, sowie auf dem Gebiet der supportiven Therapie. Seit 1988 Leitung der multizentrischen Therapiestudie zur Behandlung der rezidivierten akuten lymphatischen Leukämie im Erwachsenenalter im Rahmen der Deutschen ALL-Studiengruppe. Klinische Studien auf dem Gebiet der Zytokine, insbesondere zur Therapie der chronisch myeloischen Leukämie mit rekombinantem Interferon α und Tumor Nekrose Faktor α . Untersuchungen zum Einsatz von hämatopoetischen Wachstumsfaktoren bei Chemotherapie-induzierter Neutropenie, bei Hochdosis-Chemotherapie, bei Myelodysplasien und kongenitalen Neutropenien und zur Mobilisierung von peripheren Blutstammzellen. Durchführung von Studien zur Hochdosis-Therapie mit Support durch Reinfusion von peripheren Stammzellen (PBSCT) bei Patienten mit lymphoiden Neoplasien.

Die wissenschaftliche Tätigkeit im Labor konzentrierte sich an der Medizinischen Hochschule Hannover zunächst auf Untersuchungen zur Übergerinnbarkeit und zum Plasma-Fibronectin bei akuten Leukämien und soliden Tumoren. Am 10.2.1988 Habilitation mit dem Thema: "Fibronectin, Glycoprotein der vielfältigen Interaktion".

Danach Arbeiten zur zellbiologischen Bedeutung von Zytokinen. Etablierung verschiedener permanenter Zelllinien von Patienten mit myeloischen und lymphatischen Neoplasien. Untersuchungen zur Modulation des Proliferationsverhaltens hämatopoetischer und lymphoider Zellen durch Zytokine mit Hilfe von Stammzellassays, Suspensions-Langzeitkulturen und mit Hilfe der Durchflußzytometrie.

1989 Organisation der 34. Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie (1000 Teilnehmer), des ersten bis dritten "International Symposium on Cytokines in Hemopoiesis, Oncology, and Immunology" in den Jahren 1989 bis 1993 mit 450 bis 650 Teilnehmern.

Mit Übernahme der Abteilung für Hämatologie und Onkologie 1994 zunächst wissenschaftliche Schwerpunktbildung im Bereich der Hochdosistherapie und der autologen peripheren Blutstammzelltransplantation. Dabei Durchführung von Studien im Bereich von Patienten mit rezidierten hochmalignen Non-Hodgkin-Lymphomen, mit chronisch myeloischer Leukämie und rezidivierter akuter lymphatischer Leukämie. Untersuchungen zu neuen Methoden zur Stammzellmobilisierung mit hochdosiertem Etoposid.

Ab 1998 mit Hilfe der Deutschen Krebshilfe Aufbau der allogenen Knochenmark- und Blutstammzelltransplantation an der Universität Rostock. Im Rahmen eines Programms zur Entwicklung neuer Konditionierungsschemata am 1.3.1999 erste allogene Transplantation mit Gabe von hochdosiertem Treosulfan weltweit. In der Folge multizentrische Phase I/II-Studien und erfolgreiche internationale Etablierung des neuen Konditionierungsverfahrens bis 2006.

Ab 1999 Aufbau einer Arbeitsgruppe für Experimentelle Knochenmark- und Blutstammzelltransplantation. In diesem Rahmen Etablierung von Groß- und Kleintiermodellen ab 2001.

Ab 2001 Beginn eines interdisziplinären Programms zur kardialen Regeneration unter dem Einfluß von Knochenmarkstammzellpräparationen zusammen mit der Klinik für Herzchirurgie der Universität Rostock und der Abteilung für Kardiologie der Klinik und Poliklinik für Innere Medizin.

1997 bis 2005 Initiative zur Errichtung des Biomedizinischen Forschungszentrums Rostock in Kooperation mit dem Institut für Immunologie und den Institut für Biochemie der Universität Rostock sowie der Hansestadt Rostock. Einweihung des Biomedizinischen Forschungszentrums Rostock am 6.12.2005. 2003 bis 2006 Initiative zur Schaffung eines Reinraumzentrums für Stammzelltechnologie im Rahmen des Biomedizinischen Forschungszentrums in Kooperation mit der Firma GST – Gesellschaft für Stammzelltechnologie Rostock GmbH.

Präsident der Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie in Hannover 2005 mit 3.000 Teilnehmern.

Aktuelle Forschungsaktivitäten im Bereich von lymphatischen myeloische Neoplasien, allogene Knochenmark und Blutstammzelltransplantation sowie im Bereich der regenerativen Medizin.

LEHRTÄTIGKEIT

Regelmäßiger Studentenunterricht einschließlich der Untersuchungskurse am Krankenbett, Vorlesungstätigkeit, sowie Leitung des Kurses der hämatologischen Zytologie an der Medizinischen Hochschule Hannover von Sommersemester 1983 bis 1994.

An der Universität Rostock seit Oktober 1994 regelmäßige Wahrnehmung der Lehre im Rahmen der Hauptvorlesung und der Untersuchungskurse. Anleitung zur klinischen Strategiefindung in der Hämatologie und Onkologie im Rahmen der regelmäßigen Abteilungskonferenzen und Problemvisiten. Durchführung eines freiwilligen hämatologisch-zytologischen Kurses für Studenten und angehende Ärzte, eines hämatologischen Blockpraktikums und POL-Kleingruppenunterricht.

Durchführung des jährlichen Austauschprogrammes "Hanseatic Students' Days of Science" für Studenten aus Ostseeraum und Baltikumzwischen 1996 und 2003.

UNTERNEHMERISCHE TÄTIGKEIT

Gründer der folgenden Firmen:
M.D. Medical Development GmbH Rostock 1996
GST - Gesellschaft für Stammzelltechnologie Rostock GmbH 2002
2008 umfirmiert in Seracell Stammzelltechnologie GmbH
Seracell AG 2007; hier Vorsitzender des Aufsichtsrats
Medical Development in Immunology GmbH Rostock 2009
Institut für Integrative Medizin Rostock gGmbH 2010

MITGLIEDSCHAFTEN UND FUNKTIONEN

American Society for Clinical Oncology
American Society for Hematology
Biotechnologie, Biomedizin und Biomedizintechnik Mecklenburg Vorpommern e.V.
Vorsitzender 1997 – 2000, stellv. Vorsitzender ab 2001, erneut Vorsitzender ab 2004
Deutsche Arbeitsgemeinschaft für Knochenmarktransplantation e.V.
Deutsche Arbeitsgemeinschaft für Gentherapie e.V.
Deutsche Gesellschaft für Hämatologie und Onkologie ,
Gewähltes Mitglied des Beirats der Gesellschaft 1990 bis 1996
Sekretär und Schatzmeister der DGHO 1996 bis 2014
Vertreter der Gesellschaft im Sektor Sektorkomitee 5 der Zentralstelle der Länder für den Gesundheitsschutz bei Medizinprodukten (ZLG)
Deutsche Gesellschaft für Innere Medizin e.V.
Mitglied des Ausschusses 2002 bis 2005
Deutsche Hämophiliegesellschaft zur Bekämpfung von Blutungskrankheiten
Deutscher Hochschulverband e.V.
Deutsche Krebsgesellschaft e.V.
Arbeitsgemeinschaft für Internistische Onkologie der Deutschen

Krebsgesellschaft e.V.
Hämophilie 2000 e.V.
Krebsgesellschaft Mecklenburg-Vorpommern e.V., Mitglied der Deutschen
Krebsgesellschaft
Gewählter 1. Vorsitzender des Landesverbandes seit 1996
Gesellschaft für Fortschritte in der Inneren Medizin e.V.
Tumorzentrum Rostock e.V.
Ostdeutsche Studiengruppe Hämatologie und Onkologie e.V. (OSHO)
Gewählter 2. Vorsitzender seit 1998 bis 2000, 1. Vorsitzender ab 2001 bis 2005
Mitglied der Leitkommission ab 2006
Gesellschaft der Internisten Mecklenburg-Vorpommerns e.V.
Medizinische Gesellschaft zu Rostock e.V.
Studienstiftung des Deutschen Volkes

VERÖFFENTLICHUNGEN

291 Zeitschriftenartikel
88 Buchbeiträge
24 Bücher und Supplemente
678 Abstrakts

B. VERÖFFENTLICHUNGEN

I. ARTIKEL

1. Ostendorf P, Freund M, Hiller E, Mittermayer C. Röntgenologischer Thoraxbefund im Schock. Vergleichende Untersuchung röntgenologischer, klinischer und pathologisch - anatomischer Veränderungen. Fortbildung in Thoraxkrankheiten 1978; 8: 221-229.
2. Freund M, Ostendorf P, Waller HD. Meningeosis carcinomatosa bei Patientinnen mit Mammakarzinom. Onkologie 1979; 2: 243-248.
3. Ostendorf P, Zimmermann R, Freund M, Wilms K, Benöhr HC, Waller HD. Maligne Zweiterkrankungen bei Morbus Hodgkin, Plasmozytom und chronischer myeloischer Leukämie nach Strahlen- und zytostatischer Therapie. Verh Dtsch Ges Inn Med 1980; 86: 1076-1079.
4. Ostendorf P, Freund M, Benöhr HC. Orale Antikoagulantien und Plättchenaggregationshemmer. Zur Pathophysiologie und Reinfarktprophylaxe nach überstandem Herzinfarkt. Der Krankenhausarzt 1981; 54: 661-676.
5. Freund M, Ostendorf P. Lungenembolie: Differentialtherapie mit Antikoagulantien, Fibrinolyse oder Operation. Der Krankenhausarzt 1981; 54: 681-690.
6. Ostendorf P, Freund M. Pneumokokkenvakzine nach Splenektomie? Der Internist 1981; 22: 171-174.
7. Freund M, Ostendorf P, Gärtner VH, Tidow S. OPSI -Ein Fall foudroyant verlaufender Sepsis. Der Internist 1981; 22: 175-179.
8. Freund M, Ostendorf P, Wilms K. Ungewöhnlicher Verlauf bei zwei Patienten mit Hoden - Teratom unter Vinblastin - Cyclophosphamid - Chemotherapie. Onkologie 1981; 4: 150-154.
9. Freund M, Ostendorf P. Clostridieninfektionen in der inneren Medizin. Der Internist 1981; 22: 508-513.
10. Freund M, Ostendorf P, Hiller E. Ein Fall von Clostridienbakteriämie mit Verbrauchskoagulopathie. Der Internist 1981; 22: 514-517.
11. Ostendorf P, Freund M. Systemische Candida - Mykosen. Der Internist 1981; 22: 479-488.
12. Freund M, Ostendorf P, Gärtner VH, Waller HD. CNS -manifestations in Non-Hodgkin Lymphomas (NHL). Klinische Wochenschrift 1983; 61: 903-909.
13. Freund M, Barthels M, Poliwoda H. Fibronectin determinations in patients with disseminated malignoma. Verh Dtsch KrebsGes 1984; 5: 115.
14. Freund M, Schmoll H-J. CNS - involvement in testicular cancer. Verh Dtsch KrebsGes 1984; 5: 246.
15. LeBlanc S, Schmoll H-J, Poliwoda H, Schmidt FW, Diehl V, Pfreundschuh M, Freund M. High dose folinic acid and 5-FU treatment in advanced colorectal, gastric and pancreatic adenocarcinomas. Verh Dtsch KrebsGes 1984; 5: 420.
16. Bartsch HH, Schuff-Werner P, Schreml W, Nagel GA, Seeber S, Queisser W, Freund M. Recombinant alpha- leucocyte interferon for the treatment of patients with soft tissue sarcomas. Verh Dtsch KrebsGes 1984; 5: 835.
17. Freund M, Poliwoda H, Bodenstein H, Eisert R. Treatment of acute myelocytic leukemia with a daunorubicin - cytarabine - 6-thioguanine regimen without maintenance therapy. Onkologie 1985; 8: 150-152.
18. Freund M, Barthels M, Poliwoda H. Medikamentöse Reinfarktprophylaxe. Der Quickwert muss exakt stimmen! Ärztliche Praxis 1985; 37: 2995-2998.
19. Freund M, Eisert R, Anagnou J, Poliwoda H. Zwei Fälle von chronisch myeloischer Leukämie (CML) mit Hydrazin-Exposition. Zbl Arbeitsmed 1985; 35: 375-377.
20. Kovacs G, Freund M, Georgii A. Trisomy 1q and deletion of 11q in acute myelofibrosis. Acta Haemat 1985; 73: 179-180.
21. Blazek-Kemnitz J, Helmke M, Freund M, Vykopil KF, Georgii A. Über die Heterogenität des Phänotyps von Blasten bei akuten Leukämien und Blastenkrisen. Verh Dtsch Ges Path 1985; 69: 560.
22. Helmke M, Blazek-Kemnitz J, Freund M, Georgii A, Choritz H. Zur Frage der zellulären Immunität bei akuten Leukämien und Blastenkrisen der chronischen Leukämien. Verh Dtsch Ges Path 1985; 69: 561.
23. Kovacs G, Freund M, Poliwoda H, Leithäuser H, Thiel E. Homogeneously staining chromosomal region in a case of erythroleukemia. Scand J Hematol 1986; 36: 232-237.
24. Kurrle E, Ehninger G, Freund M, Heil G, Hoelzer D, Link H, Mitrou PS. Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia. Onkologie 1986; 9: 141-143.
25. Ho AD, Lipp T, Ehninger G, Meyer P, Freund M, Hunstein W. Combination therapy with mitoxantrone and VP-16 in refractory acute myelogenous leukemia. Cancer Treat Rep 1986; 70: 1025-1027.
26. Kemnitz J, Freund M, Helmke M, Cullen P. Phenotype of leukemic cells (letter). Hum Pathol 1986; 17: 640-641.
27. Barthels M, Freund M. Hämophilie und andere Koagulopathien. Med Welt 1986; 37: 38-41.

28. Kemnitz J, Helmke M, Freund M, Buhr T, Dominis M, Georgii A. Onkogen-NS-hybridisierung "in situ" und immunenzymhistochemische Untersuchungen der Onkogen-produkte bei akuten Leukämien und Blastenkrisen der chronischen Leukämien. *Verh Dtsch Ges Path* 1986; 70: 594.
29. Helmke M, Kemnitz J, Freund M, Diedrich H, Dominis M, Choritz H, Poliwoda. Frühe Megakaryopoese im Knochenmark bei akuten und chronischen Leukämien. *Verh Dtsch Ges Path* 1986; 70: 515.
30. Kemnitz J, Helmke M, Freund M, Diedrich H, Dominis M, Choritz H, Poliwoda H. Immunzytochemische Diagnostik der unterschiedlichen Typen des Phänotyps leukämischer Zellen. *Verh Dtsch Ges Path* 1986; 70: 513.
31. Freund M. Akute myeloische Leukämie. Gibt es etwas Neues in Diagnostik und Therapie? *Münch Med Wschr* 1987; 129: 122-125.
32. Hoelzer D, Thiel E, Löffler H, Ganser A, Heimpel H, Büchner T, Urbanitz D, Koch P, Freund M, Diedrich H, Engelhard R, Müller U, Wendt FC, Maschmeyer G, Rühl H, Ludwig WD, Kaboth W, Lipp T, Busch FW, Heil G, Gassmann W, Vaupel HA, Nowrouslan RM, Fischer J, Aul C, Kuchler R, Braumann D, v. Paleske A, Weh JH, Gerecke D, Kress M, Bartels H, Harms F, Weiss A, Burkert M, Bodenstein H, Emmerich B, Kolb H, Huber H, Mitrou PS, Fülle HH, Lunsken C, Zurborn KH, Ho AH, Pralle H, Glöckner W, Bonfert B, Görg C, Löffler B, Schlimok G, König H, Zwingers T, Messerer D. Risk groups in adult acute lymphoblastic leukemia. *Haematol Blood Transfus* 1987; 30: 104-110.
33. Von Wussow P, Duehlmann J, Grethlein T, Hirschmann WD, Huegl E, Koch O, Martin WR, Pees HW, Urbanitz W, Freund M. IFN-beta-Therapie bei der Haarzelleukaemie. *Klin Wochenschr* 1987; 65: 688-690.
34. Von Wussow P, Freund M, Block B, Diedrich H, Schmoll H, Poliwoda H, Deicher H. Niedrigdosierte Interferon-alpha- Therapie der Haarzelleukaemie. *Klin Wochenschr* 1987; 65: 681- 684.
35. Von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. *Lancet* 1987; ii: 635-636.
36. Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A, Heil G, Kurrle E, Heimpel H, Koch P, Lipp T, Kaboth W, Kuse R, Kuchler R, Sodomann H, Maschmeyer G, Freund M, Diedrich H, von Paleske A, Weh J, Kolb H, Müller U, Bross K, Fuhr G, Gassmann W, Gerecke D, Kress M, Busch FW, Nowrouslan RM, Schneider W, Aul C, Rühl H, Bartels H, Harms F, Weiss A, Löffler B, Glöckner W, Fülle H, Pralle H, Ho AD, Bonfert B, Emmerich B, Braumann D, Brenner-Serke M, Planker M, Straif K, Meyer P, Greil R, Petsch S, Görk C, Grüneisen A, Vaupel HA, Bodenstein H, Overkamp F, Schlimock G, Augener W, Öhl S, Nowicki L, Raeth U, Zurborn KH, Neiss A, Messerer D. Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia. *Semin Oncol* 1987; 14: 92-97.
37. Kemnitz J, Helmke M, Freund M, Buhr T, Dominis M, Choritz H. Heterogenetiy of the phenotype of leukemic cells. I. Different types of the heterophenotype with respect to myeloid and erythroid markers of leukemic cells in acute leukemias and blast crises of chronic myeloproliferative disorders. *Tumor Diagnostik und Therapie* 1987; 8: 237-245.
38. Kemnitz J, Freund M, Helmke M, Dominis M. Annotations concerning the correlation of the immunophenotypes of leukaemic cells in acute myeloid leukemia with the FAB classification. *Br J Haematol* 1987; 66: 120-121.
39. Ho AD, Lipp T, Ehninger G, Meyer P, Freund M, Illiger HJ, Körbling M. Mitoxantrone and VP-16 in refractory acute myelogenous leukemia. *Haematol Bluttransfus* 1987; 30: 339-342.
40. Bernhards J, Döhler U, Freund M, Emmerich B, Georgii A. Die Bedeutung der Histopathologie des Knochenmarks für die Lebenserwartung von Patienten mit chronisch lymphatischer Leukämie. *Verh Dtsch Ges Path* 1987; 71: 478-478.
41. Wang MC, Freund M, Poliwoda H. The inhibitory effect of 3',5'-cCMP on T-lymphoblastic cell line JM. *Chinese Journal of Pathophysiology* 1987; 3: 206-210.
42. Kemnitz J, Helmke M, Cohnert TR, Buhr T, Freund M. In situ hybridization in the analysis of abl and sis oncogenes in myeloproliferative disorders. *Hum Pathol* 1987; 18: 1302-1303.
43. Link H, Freund M, Diedrich H, Wilke H, Austein J, Poliwoda H. Mitoxantron in Kombination mit Cytosin-Ara-binosid und VP-16 (MAV) in der Rezidiv- und Primärtherapie der akuten myeloischen Leukämie - erste Ergebnisse. *FAC* 1987; 6-9: 1491-1499.
44. Ho AD, Lipp Th, Ehninger G, Illiger HJ, Meyer P, Freund M. Mitoxantron in Kombination mit Etoposid (NOVE) bei refraktären akuten myeloischen Leukämien. *FAC* 1987; 6-9:1501-1503.
45. Von Wussow P, Hartmann F, Freund M, Poliwoda H, Deicher H. Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha-2b. *Lancet* 1988; i: 882-883.
46. Kurrle E, Ehninger G, Freund M, Heil G, Hoelzer D, Link H, Mitrou PS, Öhl S, Queisser W. Induktions- und intensivierte Konsolidationstherapie der akuten myeloischen Leukämie des Erwachsenen. *Onkologie* 1988; 11: 5-9.
47. Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Rühl H, Maschmeyer G, Lipp T, Nowrouslan MR, Burkert M, Gerecke D, Pralle H, Müller U, Lunsken C, Fülle H, Ho AD, Kuchler R, Busch FW, Schneider W, Görg C, Emmerich B, Braumann D, Vaupel HA, von Paleske A, Bartels H, Neiss A, Messerer D. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. *Blood* 1988; 71: 123-131.
48. Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W. Combination of Mitoxantrone and Etoposide in refractory acute myelogenous leukemia - an active and well-tolerated regimen. *J Clin Oncol* 1988; 6: 213-217.

49. Link H, Freund M, Kirchner H, Stoll M, Schmid H, Bucsky P, Seidel J, Schulz G, Schmidt RE, Riehm H, Poliwoda H, Welte K. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) after bone marrow transplantation. *Behring Inst Mitt* 1988; 83:313-319.
50. Von Wussow P, Freund M, Dahle S, Jakschies D, Poliwode H, Deicher H. Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. *N Engl J Med* 1988; 319:1226-1227.
51. Freund M, Von Wussow P, Knüver-Hopf J, Mohr H, Pohl U, Exeriede G, Link H, Wilke HJ, Poliwoda H. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b. *Blut* 1988; 57:311-315.
52. Kurrle E, Ehninger G, Freund M, Heil G, Hoelzer D, Link H, Mitrou PS, Öhl S, Queisser W, Schlimok G, Wandt G. A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukemia. *Blut* 1988; 56:233-236.
53. Bernhards J, Döhler U, Freund M, Rastetter J, Georgii A. Die Bedeutung der Histopathologie des Knochenmarks für die Lebenserwartung von Patienten mit chronischer lymphatischer Leukämie. *Med Klin* 1988; 83:637-642.
54. Wilke H, Schmoll HJ, Preusser P, Fink U, Stahl M, Schober C, Link H, Freund M, Hanauske A, Meyer HJ, et al. Folinic acid (CF)/5-fluorouracil (FUra) combinations in advanced gastrointestinal carcinomas. *Adv Exp Med Biol* 1988; 244:233-243.
55. Wilke H, Schmoll H-J, Schöber C, Stahl M, Preusser P, Freund M, Poliwoda H. Folinic acid (FA) plus 5-Fluorouracil (FU) in progressive advanced colorectal cancer. *Biomed Pharmacother* 1988; 42:373-380
56. Kemnitz J, Freund M, Dominis M. Heterogeneity of the phenotype of leukemia cells. *Tumor Diagnostik & Therapie* 1989; 10:21-26
57. Kemnitz J, Freund M, Cohnert TR, Georgii A. MDR+ Zellen (multidrug resistant cells) in Populationen leukämischer Zellen vor der Therapie. *Verh Dtsch Ges Path* 1988; 79:607-607.
58. Wagner C, Dati F, Barthels M, Egbring R, Freund M, Norfolk D, Seitz R, Tatra G. Detection of hypercoagulability associated with malignancies - by detection of thrombin/antithrombin III complexes. *J Clin Chem Clin Biochem* 1988; 26:777-778.
59. Hoelzer D, Thiel E, Loeffler H, Buechner T, Ganser A, Heil G, Kurrle E, Heimpel H, Koch P, Lipp T, Kaboth W, Kuse R, Küchler R, Sodomann H, Maschmeyer G, Freund M, Diedrich H, von Paleske A, Weh J, Kolb H, Müller U, Bross K, Fuhr G, Gassmann W, Gerecke D, Kress M, Busch FW, Nowrousian RM, Schneider W, Aul C, Rühl H, Bartels H, Harms F, Weiss A, Löffler B, Glöckner W, Fülle H, Pralle H, Ho AD, Bonfert B, Emmerich B, Braumann D, Brenner-Serke M, Planker M, Straiff K, Meyer P, Greil R, Petsch S, Görg C, Grüneisen A, Vaupel HA, Bodenstein H, Overkamp F, Schlimock G, Augener W, Öhl S, Nowicki L, Raeth U, Zurborn KH, Neiss A, Messerer D. Intensivierte Konsolidierungstherapie für ALL-Hochrisikopatienten (Intensive combined therapy for high-risk ALL patients). *Onkologie* 1988; 11:18-24.
60. Raude E, Oellerich M, Weinel P, Freund M, Schrappe M, Riehm H, Poliwoda H. High-dose methotrexate: pharmacokinetics in children and young adults. *Int J Clin Pharmacol Ther Toxicol* 1988; 26:364-370
61. Freund M. Diagnostik der akuten Leukämien. *MTA* 1989; 4:493-501.
62. Freund M. Zweifel an TNF. *Dtsch Aerztebl* 1989; 86:B-1931-1931.
63. Haase D, Fonatsch C, Bodenstein H, Diedrich H, Freund M, Zankovich R, Zippel R. Myelodysplastische Syndrome. Bedeutung der Chromosomenanalyse für Prognose und Therapie. *Muench Med Wschr* 1989; 131:475-479.
64. Kemnitz J, Freund M, Dominis M, Cohnert FR, Uysal A, Georgii A. Detection of cells with multidrug resistant phenotype in myeloproliferative disorders before therapy. *Hematologic Pathology* 1989; 3:73-78.
65. Freund M, Von Wussow P, Diedrich H, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, Poliwoda H. Recombinant human Interferon (IFN) alpha 2-b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-Interferon antibodies. *Br J Haematol* 1989; 72:350-356.
66. Von Wussow P, Jakschies D, Freund M, Deicher H. Humoral response to recombinant interferon- α 2b in patients receiving recombinant interferon- α 2b therapy. *J Interferon Res* 1989; 9 (Suppl. 1):25-31.
67. Hiddemann W, Maschmeyer G, Pfreundschuh M, Ludwig WD, Pflüger KH, Schmitz N, Schumacher K, Lengfelder E, Planker M, Freund M, Ho AD, Donhuijsen-Ant R, Wagner Th, Büchner Th. Hochdosis Cytosin-Arabinosid und Mitoxantron (HAM) in der Therapie bei refraktären akuten Leukämien und Morbus Hodgkin: Eine Übersicht über vier multizentrische Phase-II-Studien. *Beitr Onkol* 1989; 36:72-79.
68. Freund M. Cytokine - Aufbruch in eine neue Dimension (Teil 1). *Pharmaz Zeitg* 1989; 134:2145-2151.
69. Freund M. Cytokine - Aufbruch in eine neue Dimension (Teil 2). *Pharmaz Zeitg* 1989; 134:2512-2516.
70. Freund M, Link H, Welte K. Neue Perspektiven. Erster Internationaler Zytokin-Kongress in Hannover. *Dtsch Aerzteblatt* 1989; 86:B-2460-2461.
71. Freund M. Der GM-CSF: Erfahrungen, Möglichkeiten und Perspektiven. *Sandorama* 1989; 4:16-19.
72. Buhr Th, Freund M, Nafe R, Georgii A. Histologische Befunde bei Interferon-Therapie der CML. *Verh Dtsch Ges Path* 1989; 73:585.
73. Freund M. GM-CSF: Experience, opportunities and prospects. *Sandorama (International)* 1990; 2:5-8.

74. Kemnitz J, Freund M, Dominis M, Cohnert T, Uysal A, Georgii A. Cells with multidrug-resistant phenotype in myeloproliferative disorders before therapy. *Hematol Transfuziol (Moscow)* 1990; 35:15-18.
75. Kleine HD, Birnbach A, Exeriede G, Link H, Poliwoda H, Freund M. Results and prognosis of acute non-lymphocytic leukemia in adults. A retrospective study of 319 patients between 1977-1987. *Onkologie* 1990; 13:280-284.
76. Freund MRF, Luft S, Schöber C, Heussner P, Schrezenmaier H, Porzsolt F, Welte K. Differential effect of GM-CSF and G-CSF in cyclic neutropenia. *Lancet* 1990; ii:313.
77. Kemnitz J, Helmke M, Freund M, Buhr T, Dominis M, Choritz H. Heterogeneity of leukemia cell phenotype I. Different variants of heterophenotype with respect to myeloid and erythroid markers of leukemic cells in acute leukemias and blast crisis of chronic myeloproliferative diseases. *Hematol Transfuziol (Moscow)* 1990; 35:9-14.
78. Kemnitz J, Freund M, Dominis M. Heterogeneity of leukemia cell phenotype II. Different variants of heterophenotype with respect to myeloid and megakaryocyte markers of leukemic cells in acute leukemias and blast crisis of chronic myeloproliferative disease. *Hematol Transfuziol (Moscow)* 1990; 35:15-18.
79. Hanauske AR, Trijssenaar J, Hanauske HM, Szamel MM, Depenbrock H, Freund M, Poliwoda H. Differential effects of anthracyclines on growth factor binding to breast cancer cells. *J Cell Pharmacol* 1990; 1:86-94.
80. Link H, Seidel J, Stoll M, Kirchner H, Linderkamp C, Freund M, Bucsky P, Welte K, Riehm H, Burdach S, et al. Regeneration of granulopoiesis with recombinant human granulocyte-macrophage colony-stimulating factor after bone marrow transplantation. *Hematol Bluttransfus* 1990; 33:741-746.
81. Link H, Freund M, Diedrich H, Wilke H, Austein J, Henke M, Wandt H, Fackler Schwalbe E, Schlimok G, Hoffmann R, Calavrezos A, Poliwoda H. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. *Hamatol Bluttransfus* 1990; 33:322-325.
82. Ehninger G, Fackler Schwalbe E, Freund M, Heil G, Henke M, Hoelzer D, Hoffmann R, Kurrle E, Link H, Löscher A, Mitrou PS, Queißer W, Schlimok G, Wandt H. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. *Hamatol Bluttransfus* 1990; 33:316-317.
83. Freund M, De Boben M, Diedrich H, Ganser A, Heil G, Heyll A, Henke M, Hiddemann W, Knauf U, Koch P, Körbling M, Kuchler R, Link H, Maschmeyer G, Planker M, Renner D, Schadeck-Gressel C, Schmitz N, von Verschuer U, Wilhelm S, and Hoelzer D. Treatment of relapsed acute lymphocytic leukemia in adults. *Hamatol Bluttransfus* 1990; 33:432-436.
84. Ludwig WD, Thiel E, Bartram CR, Kranz BR, Raghavachar A, Löffler H, Ganser A, Buchner T, Hiddemann W, Heil G, Freund M, Maschmeyer G, Reiter A, Messerer D, Riehm H, Hoelzer D. Clinical importance of T-ALL subclassification according to thymic or prethymic maturation stage. *Hamatol Bluttransfus* 1990; 33:419-27.
85. Stoll M, Freund M, Schmid H, Deicher H, Riehm H, Poliwoda H, Link H. Allogeneic bone marrow transplantation for Langerhans' cell histiocytosis: report of a case. *Cancer* 1990; 66:284-288.
86. Joraschkewitz M, Depenbrock H, Freund M, Erdmann G, Meyer HJ, De Riese W, Neukam D, Hanauske U, Krumwieg M, Poliwoda H, Hanauske AR. Effects of cytokines on in vitro colony formation of primary human tumour specimens. *Eur J Cancer* 1990; 26:1070-1074.
87. Freund M, Hanauske A-R. Interferon alpha in der Therapie der Non-Hodgkin-Lymphome. *Onkologie* 1990; 13:424-428.
88. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, Freund M, Meusers P, Salama A, Heimpel H. A prospective trial of antilymphocyte globulin and methylprednisolone with or without cyclosporin A for treatment of aplastic anemia. *N Engl J Med* 1991; 324:1297-1304.
89. Von Wussow P, Jakschies D, Freund M, Heilmann H, Brockhaus F, Hochkeppel H, Horisberger M, Deicher H. Treatment of anti rIFN-alpha 2 antibody positive CML patients with natural interferon alpha. *Br J Haematol* 1991; 78:210-216.
90. Freund M, Von Wussow P. Anti-interferon antibodies in alpha interferon treated patients with chronic myeloid leukaemia - reply. *Br J Haematol* 1991; 78:466-467.
91. Hild F, Freund M, Fonatsch C. Chromosome aberrations during interferon therapy for chronic myeloid leukemia. *N Engl J Med* 1991; 325:132.
92. Rieder H, Fonatsch C, Freund M. Abnormalities of the short arm of chromosome 9. A nonrandom secondary aberration in Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). *Cancer Genet Cytogenet* 1991; 53:139-142.
93. Horowitz MM, Messerer D, Hoelzer D, Gale RP, Atkinson K, Barrett AJ, Büchner Th, Freund M, Heil G, Hiddemann W, Kolb H-J, Löffler H, Marmont AM, Maschmeyer G, Rimm AA, Rozman C, Sobocinski KA, Speck B, Thiel E, Weisdorf DJ, Zwaan FE, Bortin MM. Comparison of chemotherapy and bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. *Ann Intern Med* 1991; 115:13-18.
94. Hiddemann W, Rottmann R, Wörmann B, Thiel E, Essinck M, Ottensweiler C, Freund M, Büchner T, van de Loo J. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study. *Ann Hematol* 1991; 63:1-4.

95. Freund M, Giller S, Hinrichs F, Baars A, Meran J, Körfer A, Link H, Poliwoda H. Five day m-AMSA and intermediate-dose araC in high risk relapsing or refractory AML. *J Cancer Res Clin Oncol* 1991; 117:489-492
96. Harstrick A, Schmoll H-J, Wilke H, Köhne-Wömpner C-H, Stahl M, Schöber C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, Bergmann L, Lammers U, Freund M, Poliwoda H. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. *J Clin Oncol* 1991; 9:1549-1555
97. Freund M, Link H, Diedrich H, LeBlanc S, Wilke H, Poliwoda H. High-dose ara-C and etoposide in refractory or relapsing acute leukemia. *Cancer Chemother Pharmacol* 1991; 28:487-490
98. Schubert J, Alvarado M, Uciechowski P, Zielinska-Skowronek M, Freund M, Vogt H, Schmidt RE. Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) using immunophenotyping of peripheral blood cells. *Br J Haematol* 1991; 79: 487-492
99. Kleine H-D, Wagner U, Poliwoda H, Freund M. Effects of TNF α on bone marrow aspirates of patients with AML determined by flow cytometric cell-cycle analysis. *J Cancer Res Clin Oncol* 1991; 118: 56-60
100. Freund M. Infektionsrisiken bei alten und immungeschwächten Patienten. *Krh -Hyg +Inf Verh* 1991; 13:130-137.
101. Freund M, Diedrich H, Ganser A, Gramatzki M, Heil G, Heyll A, Henke M, Hiddemann W, Haas R, Kuse R, Koch P, Link H, Maschmeyer G, Planker M, Queißer W, Schadeck-Gressel C, Schmitz N, von Verschuer U, Wilhelm S, Hoelzer D. Treatment of relapsed or refractory adult acute lymphocytic leukemia. *Cancer* 1992; 69: 709-716
102. Fonatsch C, Haase D, Freund M, Bartels H, Tesch H. Partial trisomy 1q - a new nonrandom primary chromosomal abnormality in myelodysplastic syndromes? *Cancer Genet Cytogenet* 1991; 56:243-253.
103. Freund M. Ärztliche Kooperation per Videokonferenz. *Dt Aerztebl* 1992; 89:A1-852.
104. Freund M, Wunsch-Zeddies S, Schäfers M, Wysk J, Seidel I, Hiddemann W, Hanauske A-R, Link H, Schmoll H-J, Poliwoda H. Prednimustine and mitoxantrone (PmM) in patients with low grade malignant non-Hodgkin's lymphomas (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL). *Ann. Hematol.* 1992; 64:83-87
105. Hanauske AR, De Riese W, Joraschkewitz M, Freund M, Poliwoda H. Effects of cytokines on clonogenic growth of primary renal cancer cells: an in vitro phase II study. *Onkologie* 1992; 15:147-150.
106. Donhuijsen K, Haedicke C, Hattenberger S, Hauswaldt C, Freund MRF. GM-CSF related eosinophilia and Loeffler's endocarditis. *Blood* 1992; 79:2798.
107. Steinke B, Manegold Ch, Freund M, Reinold H-M, Fischer H-J, Arnold H, Lengfelder E, Lutz M, Zwingers Th, Münz A, Hecht Th. G-CSF for treatment intensification in high-grade malignant Non-Hodgkin's lymphomas. *Onkologie* 1992; 15:46-50.
108. Maschek H, Kaloutsi V, Werner M, Bandekar K, Kressel M-G, Choritz H, Freund M, Hufnagl D, Georgii A. Myelofibrosis in primary myelodysplastic syndromes. A retrospective study of 352 patients. *Eur J Haematol* 1992; 48:208-214.
109. Freund M, Kleine H-D, Wilke H, Link H, Poliwoda H. Immunmodulatoren und Cytokine. *Inn Med* 1992; 19:79-87.
110. Bauer E, Danhauser-Riedl S, De Riese W, Raab H-R, Sandner S, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. Effects of recombinant human erythropoietin on clonogenic growth of primary human tumor specimens in vitro. *Onkologie* 1992; 15:254-258.
111. Avenarius HJ, Freund M, Deinhardt J, Poliwoda H. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on circulating platelets. *Ann Hematol* 1992; 65:6-9.
112. Haase D, Fonatsch C, Freund M. Karyotype instability in myelodysplastic syndromes - a specific step in pathogenesis preceding clonal chromosome abnormalities. *Leukemia and Lymphoma* 1992; 8:221-228
113. Bokemeyer C, Freund M, Rieder H, Fonatsch C. Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumor. *Ann Oncol* 1992; 3:772
114. Freund M, Kleine H-D. The role of GM-CSF in infection. *Infection* 1992; 20 (Suppl. 2): S84-92
115. Kleine HD, Scheinichen D, Lux E, Poliwoda H, Freund M. A constant flux system using the "magnetic cell separator" (MACS) for highly efficient T-cell depletion. *Anal Cell Pathol* 1992; 5:125-128
116. Hoelzer D, Thiel E, Ludwig WD, Löffler H, Büchner T, Freund M, Heil G, Hiddemann W, Maschmeyer G, Völkers B, et al . The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group. *Leukemia* 1992; 6 Suppl 2:175-177.
117. Freund M. Therapie der chronischen myeloischen Leukämie. *Internist* 1993; 34:542-549
118. Bokemeyer C, Lürer M, Schmoll H-J, Freund M, Poliwoda H. Secondary cancer following Hodgkin's disease. *Ann Oncol* 1993; 4:520-521.
119. Avenarius HJ, Freund M, Kleine H-D, Heußner P, Poliwoda H. Granulocyte colony-stimulating factor enhances the expression of CD62 on platelets in vivo. *Int J Hematol* 1993; 58:189-196.

120. Link H, Brune T, Hübner G, Diedrich H, Freund M, Stoll M, Peest D, Ebell W, Bettoni C, Oster W, Nicolay U, Heinrichs H. Effect of recombinant human erythropoietin after allogeneic bone marrow transplantation. *Ann Hematol* 1993; 67:169-173.
121. Grauer ME, Bokemeyer C, Welte T, Freund M, Link H. Successful treatment of Mucor pneumonia in a patient with relapsed lymphoblastic leukemia after bone marrow transplantation. *Bone Marrow Transplantation* 1993; 12:421.
122. Freund M, Huber Ch. Interferon has become a standard in the treatment of chronic myelogenous leukemia. *Semin Hematol* 1993; 30 (Suppl. 3):1-5
123. Freund M, Hild F, Grote-Metke A, Nowak R, Otremba B, Wörmann B, Koch O, Dohmen M, Kleine H-D, Link H, Hiddemann W, Hinrichs F, Balleisen L, Fonatsch C, Poliwoda H. Combination of chemotherapy and interferon α -2b in the treatment of chronic myelogenous leukemia. *Semin Hematol* 1993; 30 (Suppl. 3):11-13
124. Hoelzer D, Thiel E, Ludwig WD, Löffler H, Buchner T, Freund M, Heil G, Hiddemann W, Maschmeyer G, Völkers B, Gokbuget N, Aydemir Ü. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). *German Adult ALL Study Group. Leukemia* 1993; 7 Suppl 2:S130-S134.
125. Ottmann OG, Ganser A, Freund M, Heil G, Hiddemann W, Heit W, Gracien E, Hoelzer D. Simultaneous administration of granulocyte colony-stimulating factor (Filgrastim) and induction chemotherapy in acute lymphoblastic leukemia. A pilot study. *Ann Hematol* 1993; 67:161-167.
126. Hiddemann W, Unterhalt M, Pott C, Wörmann B, Sandford D, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert M, Hellriegel K, Knauf B, Emmerich B, Kanz L, Koch P. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German low-grade non-Hodgkin's lymphoma study group. *Semin Oncol* 1993; 20:28-31.
127. Petersen D, Demertzis S, Freund M, Schumann G, Oellerich M. Individualization of 5-fluorocytosine therapy. *Chemotherapy* 1994; 40:149-156.
128. Schöffski P, Luttmann A, Petersen D, Schumann G, Rapp-Bernhardt U, Freund M. Amphotericin B - neue Darreichungsform eines bewährten Antikmykotikums. *Arzneimitteltherapie* 1993;10:319-29". *Arzneimitteltherapie* 1994; 12:115-117.
129. Steinke B, Münz A, Manegold Ch, Freund M, Reinold H-M, Fischer JTh, Arnold H, Lengfelder E, Lutz M, Hecht Th, Zwingers Th. Treatment intensification with r-metHuG-CSF in high-grade malignant non-Hodgkin's lymphomas. *Onkologie* 1994; 17:248-253.
130. Hassan HT, Grell S, Borrmann-Danso U, Freund M. Interleukin-4 inhibits proliferation of human leukaemic megakaryoblast cell line MHH 225. *Hematological Oncology* 1994; 12:61-66.
131. Schubert J, Vogt HG, Zielinska-Skowronek M, Freund M, Kaltwasser JP, Hoelzer D, Schmidt RE. Development of the glycosylphosphatidylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. *Blood* 1994; 83:2323-2328
132. Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig W-D, Thiel E, Freund M, Bodenstein H, Schwieder G, Grüneisen A, Aul C, Schnittger S, Rieder H, Haase D, Hild F. Correlation of cytogenetic findings with clinical features in 18 patients with paracentric inversion in 3q or translocation t(3;3)(q21;q26). *Leukemia* 1994; 8:1318-1326
133. Mouthon MA, Freund M, Titeux M, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis. *Blood* 1994; 84:1085-1097
134. Grauer ME, Bokemeyer C, Bautsch W, Freund M, Link H. Successful treatment of a trichosporon beigeliee septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor. *Infection* 1994; 22:283-286.
135. Spiekermann K, Emmendoerffer A, Elsner J, Raeder E, Lohmann-Matthes M-L, Prahst A, Link H, Freund M, Welte K. Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. *Br J Haematol* 1994; 87:31-38.
136. Hassan HT, Grell S, Borrmann-Danso U, Freund M. Effect of recombinant human interferons in inducing differentiation of acute megakaryoblastic leukaemia blast cells. *Leuk Lymphoma* 1995; 16:329-333.
137. Freund M. Möglichkeiten und Grenzen der Therapieintensivierung bei Non-Hodgkin-Lymphomen unter Einsatz peripherer Blutstammzellen. *Onkologie* 1995; 18:79-81.
138. Haase D, Fonatsch C, Freund M, Wörmann B, Bodenstein H, Bartels H, Stollmann-Gibbels B, Lengfelder E. Cytogenetic findings in 179 patients with myelodysplastic syndromes. *Ann Hematol* 1995; 70:171-187.
139. Schoch C, Rieder H, Freund M, Hoelzer D, Riehm H, Fonatsch C. Twenty-three cases of acute lymphoblastic leukemia with translocation t(4;11)(q21;q23): the implication of additional chromosomal aberrations. *Ann Hematol* 1995; 70:195-201.
140. Schoch C, Rieder H, Stollmann-Gibbels B, Freund M, Tischler H-J, Silling-Engelhardt G, Fonatsch C. 17p Anomalies in lymphoid malignancies: diagnostic and prognostic implications. *Leuk Lymphoma* 1995; 17:271-279.
141. Anders O, Burstein Ch, Bitter S, Kundt M, Freund M. Aktivierungs- und Umsatzmarker der Hämostase im Verlauf der akuten tiefen Beinvenenthrombose. *Hämostaseologie* 1995; 51:87-91.

142. Hassan HT, Petershofen E, Lux E, Fonatsch C, Heil G, Freund M. Establishment and characterization of a novel CD34-positive human myeloid leukemia cell line: MHH225 growing in serum-free culture. *Ann Hematol* 1995; 71: 111-117.
143. Hassan HT, Freund M. Review of megakaryoblastic cell lines. Characteristic biological features of human megakaryoblastic leukaemia cell lines. *Leukemia Research* 1995; 19: 589-594.
144. Hassan HT, Hanauske A-R, Lux E, Kleine H-D, Freund M. A new fibroblast growth stimulating activity from the human megakaryoblastic leukaemia cell line ELF-153: in vitro and in vivo findings. *Int J Exp Path* 1995; 76: 361-367.
145. Heil G, Mitrou PS, Hoelzer D, Freund M, Link H, Ehninger G, Steinke B, Öhl S, Wandt H, Fackler-Schwalbe E, Schlimock G, Löscher A, Queisser W, Löffler B, Gaus W, Högel J, Heimpel H, Kurrle E. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial. *Ann Hematol* 1995; 71:219-225.
146. Heußner P, Haase D, Kanz L, Fonatsch C, Welte K, Freund M. G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. *Int J Hematol* 1995; 62: 225-234.
147. Zhang MJ, Hoelzer D, Horowitz MM, Gale RP, Messerer D, Neiss A, Atkinson K, Barrett AJ, Büchner T, Freund M, Heil G, Hiddemann W, Klein JP, Kolb H, Löffler H, Marmont AM, Maschmeyer G, Rozman C, Sobocinski KA, Speck B, Thiel E, Weisdorf D, Zwaan FE, Bortin MM. Long-term follow-up of chemotherapy versus bone-marrow transplantants in adults with acute lymphoblastic leukemia in first remission. *Ann Intern Med* 1995; 123:428-431
148. Hassan HT, Freund M. Human stem cell factor protects CD34 positive human myeloid leukaemia cells from chemotherapy-induced apoptosis. *Eur J Cancer* 1995; 31A:1883-1884.
149. Creutzig A, Freund M. Severe Raynaud's syndrome associated with interferon therapy. A case report. *Angiology* 1996; 47:185-187.
150. Hoelzer D, Ludwig W-D, Thiel E, Gabmann W, Löffler H, Fonatsch C, Rieder H, Heil G, Heinze B, Arnold R, Hossfeld D, Büchner T, Koch P, Freund M, Hiddemann W, Maschmeyer G, Heyll A, Aul C, Faak T, Kuse R, Ittel T, Gramatzki M, Diedrich H, Kolbe K, Fuhr H-G, Fischer K, Schadeck-Gressel C, Weiss A, Strohscheer I, Metzner B, Fabry U, Völker B, Gökbuğut N, Messerer D. Improved outcome in adult B-cell acute lymphoblastic leukemia. *Blood* 1996; 87:495-508.
151. Freund M, Heussner P, Hild F, Nowak R, Grote-Metke A, Diedrich H, Koch O, Otremba B, Von Wussow P, Kleine H-D, Meran J, Link H, Hinrichs F, Balleisen L, Fonatsch C, Poliwoda H. Therapie der chronischen myeloischen Leukämie mit Interferon alpha. Erfahrungen aus einem Jahrzehnt. *Med Klin* 1996; 91:18-25.
152. Hübner G, Link H, Schönrock-Nabulsi P, Wandt H, Gramatzki M, Löffler B, Fackler-Schwalbe I, Queiber W, Brack N, Geer T, Raab M, Öhl S, Schneider B, Schneider C, Freund M, Poliwoda H, Ehninger G. Intensive Postremissionstherapie bei akuter myeloischer Leukämie. Ergebnisse einer prospektiv vergleichenden Studie der Süddeutschen Hämoblastosegruppe (SHG). *Med Klin* 1996; 91:26-32.
153. Link H, Diedrich H, Arseniev L, Stoll M, Ebell W, Freund M, Tischler J, Casper J, Schöffski P, Diehl S, Goes A, Jacobs R, Kadar J, Stangel W, Müller R, Rittmann K-L, Wildfang I, Bucsky P, Bettoni C, Schmidt RE, Riehm H, Poliwoda H. Zehn Jahre Transplantation von Knochenmark und hämatopoetischen Stammzellen bei Erwachsenen an der Medizinischen Hochschule Hannover. *Med Klin* 1996; 91:3-17.
154. Freund M, Casper J. Standort und Perspektiven der hämatopoetischen Stammzelltransplantation. *J Lab Med* 1996; 20:207-209
155. Kleine H-D, Freund M. Monoklonale Antikörper und Immunmarkierung. *Infusionsther Transfusionsmed* 1996; 23:109-110.
156. Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H, Trümper L, Nahler M, Reuss-Borst M, Tirier C, Neubauer A, Freund M, Kreuser E-D, Dietzfelbinger H, Bodenstein H, Engert A, Stauder R, Eimermacher H, Landys K, Hiddemann W, for the German Low Grade Lymphoma Study Group. Prednimustine, mitoxantrone (PmM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low grade non Hodgkin's Lymphoma. *Leukemia* 1996; 10:836-843
157. Haase D, Freund M, Heußner P, Fonatsch C. Cytogenetic follow-up of 13 patients with myelodysplastic syndromes (MDS) treated with granulocyte-macrophage colony-stimulating factor (GM-CSF). *Tumordiagn u Ther* 1996; 17:74-81
158. Steiner M, Reincke J, Krammer-Steiner B, Freund M. Decreased serum tetranectin in multiple myeloma - relation to disease stage. *Fibrinolysis* 1996; 10 (Suppl. 2):105-107
159. Creutzig A, Caspary L, Freund M. The Raynaud phenomenon and interferon therapy. *Ann Int Med* 1996; 125:423
160. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, Löffler H, Büchner T, Fonatsch C. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukemia with translocation t(15;17)(q22;q21): a report on fifty patients. *Br J Haematol* 1996; 94:493-500.
161. Anders O, Barz D, Reinhardt KM, Freund M. Therapieergebnisse der chronischen Autoimmunthrombozytopenie bei Erwachsenen. *Hämostaseologie* 1996; 16:188-193.
162. Schoch C, Haase D, Gudat H, Büchner T, Freund M, Link H, Lengfelder E, Wandt H, Sauerland MC, Haferlach T, Löffler H, Fonatsch C. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. *Leukemia* 1996; 10:1288-1295.

163. Hoelzer D, Gökbuget N, Arnold R, Büchner T, Freund M, Gaßmann W, Heil G, Hiddemann W, Löffler H, Lipp T, Ludwig WD, Maschmeyer G, Thiel E, Messerer D, Protokollkommission für die Studiengruppe "Multizentrische intensivierte Therapiestudie der ALL des Erwachsenen 05/93". Akute lymphatische Leukämie des Erwachsenen. Diagnostik, Risikogruppen und Therapie. *Internist* 1996; 37:994-1007.
164. Raghavachar A, Ganser A, Freund M, Heimpel H, Herrmann F, Schrezenmeier H. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia. *Cytokines and Molecular Therapy* 1996; 2:215-223.
165. Kleine H-D, Buthmann U, Freund M. Fluoreszenz aktivierte Zellsortierung (FACS) auf Einzelzellebene für PCR und FISH. *J Lab Med* 1997; 21:610-611.
166. Feldman E, Ahmed T, Lutton JD, Farley T, Tani K, Freund M, Asano S, Abraham NG. Adenovirus mediated alpha interferon (IFN-alpha) gene transfer into CD34+ cells and CML mononuclear cells. *Stem Cells* 1997; 15:386-395.
167. Jaeger K, André M, Scheinichen D, Heine J, Kleine H-D, Leuwer M, Piepenbrock S. Einfluss von Remifentanyl auf den Respiratory Burst humaner neutrophiler Granulozyten in vitro. *Anaesthesiol Reanimat* 1997; 22:121-124.
168. Mischke R, Freund M. Verbrauchskoagulopathie infolge akuter Monozytenleukämie bei einem Hund. *Wien Tierärztl Mschr* 1997; 85:164-168.
169. Mischke R, Freund M, Leinemann-Fink T, Eisenberger B, Casper J, Nolte I. Veränderungen der Hämostase bei Hunden mit akuter Lymphoblastenleukämie. *Berl Münch Tierärztl Wschr* 1998; 111:53-59.
170. Hiddemann W, Unterhalt M, Hermann R, Wöltjen H-H, Kreuser E-D, Trümper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, Kaiser U, Hanrath R-D, Middeke H, Helm G, Freund M, Stein H, Tiemann M, Pawaresch R. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. *J Clin Oncol* 1998; 16:1922-1930.
171. Lestin F, Lestin H-G, Burstein C, Anders O, Freund M. Provisional experience with procalcitonin, c-reactive protein, neopterin, selected cytokines, and hemostatic parameters in patients with malignant hematological diseases and febrile neutropenia induced by cytostatic treatment. *Clin Lab* 1998; 44:451-61
172. Wilhelm S, Junghanß C, Leuhäuser M, Krammer-Steiner B, Heußner P, Casper J, Freund M. Behandlungsmöglichkeiten der chronischen myeloischen Leukämie in der chronischen Phase. *Arzteblatt Mecklenburg-Vorpommern* 1999; 9:11-17.
173. Gökbuget N, Arnold R, Büchner T, Freund M, Gassmann W, Heil G, Hiddemann W, Löffler H, Lipp T, Ludwig WD, Maschmeyer G, Thiel E, Messerer D, Hoelzer D. Akute lymphatische Leukämie des Erwachsenen. *Praxis* 1999; 88:407-420.
174. Junghanß C, Petershofen E, Wilhelm S, Decker S, Lakner V, Freund M. Eine invasive Aspergillus-Infektion des Larynx eines Patienten mit akuter myeloischer Leukämie. *Tumordiagn Ther* 1999; 20:45-48.
175. Löhr M, Bago ZT, Bergmeister H, Ceijna M, Freund M, Gelbmann W, Günzburg WH, Jesnowski R, Hain J, Hauenstein K, Henniger W, Hoffmeyer A, Karle P, Kröger J-C, Kundt G, Liebe S, Losert U, Müller P, Probst A, Püschel K, Renner M, Renz R, Saller R, Salmons B, Schuh M, Schwendenwein I, von Rombs K, Wagner T, Walter I. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced stage pancreatic carcinoma: a phase I/II study. *J Mol Med* 1999; 77:393-398.
176. Raab N, Heller T, Holle A, Kröger J, Freund M, Nizze H, Rolfs A, Liebe S, Löhr M. Intestinales Lymphom. Ein langer diagnostischer Weg. *Med Klin* 1999; 94:345-352.
177. Engert A, Höffken K, Freund M, Diehl V. Hämatologie und Internistische Onkologie. *Internist* 1999; 40:356-368
178. Gahn B, Brittinger G, Dölken G, Döhner H, Emmerich B, Franke A, Freund M, Huber C, Kuse R, Scholten T, Hiddemann W. Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia. *Leuk Lymphoma* 2000; 37:169-173.
179. Herold M, Ströhl J, Assmann M, Eschenburg H, Franke A, Freund M, von Grünhagen U, Hahnfeld S, Hoffmann FA, Huhn D, Klinkenstein C, Knauf W, Pasold R, Hurtz H-J, Steglich J, Wolf H, for the 'ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO). Acute toxicity of mitoxantrone, chlorambucil and prednisolone (MCP) versus MCP plus rituximab in low-grade non-Hodgkin's lymphoma - interim results of a phase III trial. *Onkologie* 2000; 23:164-166.
180. Huebner G, Karthaus M, Pethig K, Freund M, Ganser A. Myelodysplastic syndrome and acute myelogenous leukemia secondary to heart transplantation. *Transplantation* 2000; 70:688-690.
181. Gökbuget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M, Ganser A, Kneba M, Langer W, Lipp T, Ludwig WD, Maschmeyer G, Rieder H, Thiel E, Weiss A, Messerer D. Treatment of adult ALL according to the protocols of the German Multicenter Study Group for Adult ALL (GMALL). *Hematology/Oncology Clinics of North America* 2000; 14:17-1-17-19.
182. Junghanss C, Leithauser M, Wilhelm S, Kleine HD, Knopp A, Decker S, Alscher A, Casper J, Kohne CH, Freund M. High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize. *Annals of Hematology* 2001;80:96-102.
183. Kunz M, Wilhelm S, Freund M, Zimmermann R, Gross G. Treatment of severe erythrodermic acute graft-versus-host disease with photochemotherapy. *Br.J.Dermatol.* 2001;144:901-22.

184. Löhr M, Hoffmeyer, A., Kröger J-C, Freund M, Hain J, Holle A, Karle P, Knöfel WT, Liebe S, Müller P, Nizze H, Renner M, Saller RM, Wagner T, Hauenstein K, Günzburg WH, Salomons B. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. *The Lancet* 2001;357:1591-2.
185. Hallek M, Schmitt B, Wilhelm M, Busch R, Kröber A, Fostitisch HP, Sezer O, Herold M, Knauf U, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Döhner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. *British Journal of Haematology* 2001;114:342-8.
186. Freund M. Klinische Relevanz der Anämiebehandlung mit Erythropoietin bei Tumorpatienten unter chemotherapeutischer Behandlung. *Onkologie* 2001;24 (Suppl. 3):3.
187. Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. *Br.J.Cancer* 2002;87:1341-53.
188. Kahl C, Leithäuser M, Freund M. Rationale Therapie mit hämatopoetischen Wachstumsfaktoren (G-CSF, GM-CSF) bei Neutropenie. *DMW* 2002;127:1473-8.
189. Kahl C, Leithäuser M, Wolff D, Steiner B, Hartung G, Casper J, Freund M. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. *Ann.Hematol* 2002;81:646-50.
190. Hoelzer D, Arnold R, Bartram CR, Bohme A, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, Maschmeyer G, Rieder H, Thiel E, Messerer D, Weiss A, Gökbüget N. Akute lymphatische Leukämie des Erwachsenen. Diagnostik, Risikogruppen und Therapie. *Internist (Berl)* 2002;43:1212-24.
191. Freund M. Erythropoietin: ein Hormon der Blutbildung lenkt den Blick in viele Richtungen. *Focus MUL* 2002;19:188-91.
192. Freund M. Qualitätsmanagement und Zertifizierung in der Onkologie. Die Sicht der Krankenhäuser. *Onkologie* 2002;25 (Beilage zu Heft 1):5-7.
193. Steiner B, Riebold D, Wolff D, Freund M, Reisinger E. Eggs of *Strongyloides stercoralis* in an urthral smear after bone marrow transplantation. *Clinical Infectious Diseases* 2002;34:1280-1.
194. Wolff D, Krammer-Steiner B, Lakner V, Casper J, Richter I, Dölken G, Freund M. Allogene hämatopoetische Stammzelltransplantationen in Mecklenburg-Vorpommern von 1991-2000. *Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz* 2002;45:446-50.
195. Wolff D, Reichenberger F, Steiner B, Kahl C, Leithäuser M, Skibbe T, Friedrich T, Terpe H, Helbig W, Freund M. Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease. *Bone Marrow Transplantation* 2002;29:357-60.
196. Steiner M, Schuff-Werner P, Freund M, Köhne CH. Combined chemotherapy trials require combined pharmacogenetic approaches. *Journal of Clinical Oncology* 2002;20:1425-6.
197. Freund M. Patienten mit Krebs - Alternativmedizin und die Aufgabe des Arztes. *Ärzteblatt Mecklenburg-Vorpommern* 2003;13:374-9.
198. Freund M, Höffken K, Hossfeld D, Niederle N, Overkamp F, Schmitz S, Schmoll H-J, Seeber S. Zu zukünftigen Strukturen der Versorgung von Krebskranken in Deutschland - die Sicht der Internistischen Onkologie. *InFoOnkologie* 2003;6:145.
199. Herold M, Dolken G, Fiedler F, Franke A, Freund M, Helbig W, Pasold R. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. *Annals of Hematology* 2003;82:77-9.
200. Kahl C, Knopp A, Steiner B, Leithäuser M, Wilhelm S, Kleine HD, Wolff D, Casper J, Freund M. Rare coincidence of hypertriploid chromosome number and aberrant coexpression of the lymphoid-associated antigen CD5 in acute myeloid Leukaemia FAB M0. *Leukemia* 2003;17:1188-9.
201. Kahl C, Fetscher S, Grau G, Freund M. Rezidivierende Querschnittssymptomatik bei einem Patienten mit idiopathischer Myelofibrose. *Med.Klin.(Munich)* 2003;98:591-2.
202. Kittner Ch, Steiner B, Kahl C, Wolff D, Putzar H, Rösler K, Hauenstein K-H, Freund M, Schümichen C. Behandlungsversuch einer Meningeosis leukaemica durch intrathekale Applikation von 90Y-Silikat und 90Y-Zitrat-Kolloid bei chronisch myeloischer Leukämie. *Nuklearmedizin* 2003;N72-N75.
203. Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schafer-Eckart K, Wittkowsky G, Schmitz N, Kruger W, Zabelina T, Renges H, Ayuk F, Krull A, Zander A. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). *Bone Marrow Transplantation* 2003;31:973-9.
204. Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, De Wasch G, Vercaemmen E, Schuette W, Wils J, Freund M. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. *Hematol Oncol.* 2003;21:169-80.

205. Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, Coutre PP, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Dynamics of BCR-ABL mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinib or interferon α /ara-C. *Leukemia* 2003;17:2392-400.
206. Sezer O, Jakob C, Zavrski I, Heider U, Fleissner C, Freund M. Bisphosphonates in early multiple myeloma. *Eur.J.Haematol.* 2003;71:231-2.
207. Stamm C, Westphal B, Kleine H-D, Petzsch M, Kittner C, Klinge H, Schümichen C, Nienaber CA, Freund M, Steinhoff G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. *The Lancet* 2003;361:45-6.
208. Steiner B, Wolff D, Leithäuser M, Hartung G, Freund M. Lymphoma-associated haemophagocytic syndrome with jaundice and generalized skin involvement. *Eur.J.Haematol.* 2003;70:193-4.
209. Aapro M, Bajetta E, Freund M, Littlewood TJ, Nortier JWR, Rapoport B, for the Epoetin alfa study group. Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy? *Eur.J.Cancer* 2004;Supplement Vol. 2:20-8.
210. Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, Heimpel H, Fonatsch C, Heinze B, Pfirrmann M, Holgado S, Schmeil A, Tobler A, Hasford J, Buhr Th, Kreipe H-H. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response – meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia. *Leukemia* 2004;18:1460-7.
211. Bugat R, Freund M, Nortier JWR, Vaupel P. Introduction: Of oxygen, hemoglobin, and tumor treatment. *Eur.J.Cancer* 2004;(Supplement 2):1-2.
212. Casper J, Freund M. Treosulfan-based conditioning for autologous and allogeneic hematopoietic stem cell transplantation. *Int.J.Clin.Pharmacol.Ther.* 2004;42:661-2.
213. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, Wegener R, Kleine H-D, Wilhelm S, Knopp A, Hartung G, Dölken G, Freund M. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. *Blood* 2004;103:725-31.
214. Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, Schafer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander A, Kroger N, Doelken G, Freund M. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. *Ann.Hematol* 2004;83 Suppl 1:S70-S71.
215. Freund M. Hämatologische Erkrankungen in der Schwangerschaft. *Der Gynäkologe* 2004;37:392-400.
216. Koenigsmann M, Mohren M, Jentsch-Ullrich K, Franke A, Becker E, Heim M, Freund M, Casper J. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. *Bone Marrow Transplantation* 2004;34:477-83.
217. Lenz G, Dreyling M, Schiegnitz E, Forstpointer R, Wandt H, Freund M, Huber C, Truemper L, Diehl V, Berdel W, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma -results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). *Blood* 2004;104:2667-774.
218. Stamm C, Kleine HD, Westphal B, Petzsch M, Kittner C, Nienaber CA, Freund M, Steinhoff G. CABG and bone marrow stem cell transplantation after myocardial infarction. *Thorac.Cardiovasc.Surg.* 2004;52:152-8.
219. Wolff D, Steiner B, Stilgenbauer S, Kahl C, Junghanß C, Leithäuser M, Wilhelm S, Kleine HD, Zimmermann R, Hartung G, Casper J, Freund M. Treatment with Campath-1H for relapse of CLL after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD. *Eur.J.Haematol.* 2004;72:145-8.
220. Beelen DW, Trensche R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J, Pichlmeier U, Hahn JR, Holler E. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. *Bone Marrow Transplantation* 2005;35:233-41.
221. Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hahling D, Hartung G, Hilgendorf I, Luck A, Junghans C, Kahl C, Baumgart J, Pichlmeier U, Freund M. Allogene Blutstammzelltransplantation von Risikopatienten nach Treosulfan und Fludarabin. [Allogeneic blood stem cell transplantation of high-risk patients after conditioning with treosulfan and fludarabine]. *Dtsch.Med Wochenschr.* 2005;130:2125-9.
222. Freund M. Was können wir für die Wertschätzung klinisch - onkologischer Forschung in Deutschland tun? [What can we do to improve the appreciation of clinical-oncological research in Germany?]. *Dtsch.Med Wochenschr.* 2005;130:2123-4.
223. Herold M, Schulze A, Niederwieser D, Franke A, Fricke H-J, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann B, Klinkenstein C, Schulze M, Arzberger A, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller C, for the East German Study Group Hematology and Oncology (OSHO). Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO #19). *J Cancer Res Clin Oncol* 2005;132:105-12.

-
224. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer Th, Berdel W, Reis H-E, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German Low Grade lymphoma Study Group (GLSG). *Blood* 2005;106:3725-32.
 225. Hilgendorf I, Weirich V, Zeng L, Koppitz E, Wegener R, Freund M, Junghans C. Canine hematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism. *Veterinary Research Communications* 2005;29:103-10.
 226. Ince H, Petzsch M, Kleine HD, Schmidt H, Rehders T, Korber T, Schumichen C, Freund M, Nienaber CA. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). *Circulation* 2005;112:3097-106.
 227. Ince H, Petzsch M, Kleine HD, Eckard H, Rehders T, Burska D, Kische S, Freund M, Nienaber CA. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. *Circulation* 2005;112:173-180.
 228. Jenke A, Freiberg-Richter J, Wilhelm S, Freund M, Renner UD, Bornhauser M, Schleyer E, Ehninger G, Schuler U. Accidental busulfan overdose during conditioning for stem cell transplantation. *Bone Marrow Transplantation* 2005;35:125-8.
 229. Junghans C, Waak M, Knopp A, Kleine H-D, Kundt G, Leithäuser M, Hilgendorff I, Wolff D, Casper J, Freund M. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression. *Neoplasma* 2005;52:402-10.
 230. Kahl C, Freund M. Differentialdiagnose einer makrozytären, hyperchromen Anämie bei Alkoholabusus und gleichzeitiger Triamteren- und Cotrimoxazoltherapie. [Differentialdiagnosis of a macrocytic, hyperchromic anemia following alcohol abuse and simultaneous therapy with triamteren and cotrimoxacol.]. *Dtsch.Med Wochenschr.* 2005;130:2139-41.
 231. Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, Breitsprecher R, Schmits R, Freund M, Fietkau R, Ketterer P, Freitag EM, Hinkelbein M, Heinecke A, Parwaresch R, Tiemann M. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). *J Clin.Oncol.* 2005;23:7050-9.
 232. Loebermann M, Kahl C, Steiner B, Kunst D, Hartung G, Freund M. Accidental intrathecal administration of bleomycin: favorable outcome after pneumo-encephalus and cerebrospinal fluid exchange: a case report. *Leukemia and Lymphoma* 2005;46:943.
 233. Steiner B, Lenz JH, Gundlach KK, Freund M. Kieferosteonekrosen unter Bisphosphonattherapie: Diagnostik und Therapie. [Osteonecrosis of the jaws during treatment with bisphosphonates: diagnosis and therapeutic options]. *Dtsch.Med Wochenschr.* 2005;130:2142-5.
 234. Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH, Schuff-Werner P. 5-Fluorouracil/irinotecan-induced lethal toxicity due to a combined pharmacogenetic syndrome: report of a case. *Journal of Clinical Pathology* 2005;58:553-5.
 235. Steiner M, Steiner B, Rolfs A, Wangnick M, Burstein C, Freund M, Schuff-Werner P. Antithrombin gene mutation 5356-5364*delCTT with type I deficiency and early-onset thrombophilia and a brief review of the antithrombin alpha-helix D molecular pathology. *Annals of Hematology* 2005;84:56-8.
 236. Wilhelm S, Freund M. Steven-Johnson-Syndrom/Toxic epidermal necrolysis. *Dtsch.Med Wochenschr.* 2005;130:2137-8.
 237. Wolff D, Knopp A, Weirich V, Steiner B, Kleine HD, Casper J, Freund M. Loss of the GVL-effect by loss of the Y-chromosome as mechanism of immune escape in ALL. *Bone Marrow Transplantation* 2005;35:101-2.
 238. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, Leithaeuser M, Hofmeister N, Junghans C, Casper J, Hartung G, Holler E, Freund M. Treatment of steroid resistant acute graft-versus-host disease with daclizumab and etanercept. *Bone Marrow Transplantation* 2005;35:1003-10.
 239. Herold M, Schulze A, Niederwieser D, Franke A, Fricke H-J, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann B, Klinkenstein C, Schulze M, Arzberger A, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller C, for the East German Study Group Hematology and Oncology (OSHO). Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO #19). *J Cancer Res Clin Oncol* 2005;132:105-12.
 240. Nienaber CA, Petzsch M, Kleine HD, Eckard H, Freund M, Ince H. Effects of granulocyte-colony-stimulating factor on mobilization of bone-marrow-derived stem cells after myocardial infarction in humans. *Nat.Clin.Pract.Cardiovasc.Med.* 2006;3 Suppl 1:S73-S77.
 241. Hilgendorf I, Wolff D, Wilhelm S, Steiner B, Kiefel V, Hickstein H, Junghans C, Freund M, Casper C. T-cell-depleted stem cell boost for the treatment of autoimmune haemolytic anaemia after T-cell-depleted allogeneic bone marrow transplantation complicated by adenovirus infection. *Bone Marrow Transplantation* 2006.

242. Wolff D, Frei E, Hofmeister N, Steiner B, Kleine H-D, Junghanss C, Sievert K, Terpe H, Schrenk HH, Freund M, Hartung G. Methotrexate-albumin and aminopterin-albumin effectively prevent experimental acute graft-versus-host disease. *Transplantation* 2006;82:527-33.
243. Wolff D, Wilhelm S, Jahn H, Gentilini C, Hilgendorf I, Steiner B, Kahl C, Junghanss C, Hartung G, Casper J, Uharek L, Holler E, Freund M. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy (TAM) or renal insufficiency associated with graft-versus-host disease. *Bone Marrow Transplantation* 2006;38:445-51.
244. Herold M, Schulze A, Niederwieser D, Franke A, Fricke H-J, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann B, Klinkenstein C, Schulze M, Arzberger A, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller C, for the East German Study Group Hematology and Oncology (OSHO). Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO #19). *J Cancer Res Clin Oncol* 2006;132:105-12.
245. Hilgendorf I, Wilhelm S, Prall F, Junghanss C, Steiner B, Wolff D, Freund M, Casper J. Headache after haematopoietic stem cell transplantation: Being aware of chronic bilateral subdural haematoma. *Leukemia and Lymphoma* 2006;47:2247-9.
246. Pönisch W, Mitrou PS, Merkle Kh, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze M, Subert R, Harksel B, Grobe N, Stelzer E, Schulze A, Bittrich B, Freund M, Pasold R, Friedrich Th, Helbig W, Niederwieser D. Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone - a randomised phase III study of the East German Study Group of Hematology and Oncology (OSHO). *Journal of Cancer Research and Clinical Oncology* 2006;132:205-12.
247. Nickenig C, Dreyling M, Hoster E, Ludwig WD, Dorken B, Freund M, Huber C, Ganser A, Trumper L, Forstpointner R, Unterhalt M, Hiddemann W. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. *Ann Oncol.* 2007;18:136-42.
248. Hilgendorf I, Casper J, Sviland L, Prall F, Junghanss C, Freund M, Wolff D. Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplantation* 2007;39:245-6.
249. Schmidt-Hieber M, Blau IW, Trensche R, Andreesen R, Stuhler G, Einsele H, Kanz L, Keilholz U, Marinets O, Beelen DW, Fauser AA, Volin L, Ruutu T, Uharek L, Fietz T, Knauf W, Hopfenmuller W, Thiel E, Freund M, Casper J. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. *Bone Marrow Transplantation* 2007;39:389-96.
250. Lange S, Mueller SC, Altmann S, Dahlhaus M, Drewelow B, Freund M, Junghanss C. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after non-myeloablative allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation* 2007;Dec 17 [Epub ahead of print].
251. Höinghaus R, von Wasielewski R, Hewicker-Trautwein M, Freund M, Mischke R. Immunocytological detection of lymph node metastases in dogs with malignant epithelial tumours. *J.Comp Pathol.* 2007;137:1-8.
252. Herold M, Haas A, Srock S, Nesper S, Al Ali KH, Neubauer A, Dolken G, Naumann R, Knauf W, Freund M, Rohrberg R, Hoffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grunhagen U. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. *Journal of Clinical Oncology* 2007;25:1986-92.
253. Dreyling M, Trumper L, von Schilling C, Rummel M, Holtkamp U, Waldmann A, Wehmeyer J, Freund M. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy. *Ann Hematol.* 2007;86:81-7.
254. Stamm C, Kleine HD, Choi Y-H, Dunkelmann S, Lauffs J-A, Lorenzen B, David A, Liebold A, Nienaber C, Freund M, Steinhoff G. Intramyocardial delivery of CD133+ bone marrow cells and CABG surgery for chronic ischemic heart disease: safety and efficacy studies. *J.Thorac.Cardiovasc.Surg.* 2007;133:717-25.
255. Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A, Freund M, Casper J. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. *Br.J Haematol.* 2008;142:284-92.
256. Fietz T, Knauf WU, Hanel M, Franke A, Freund M, Thiel E. Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate. *Annals of Hematology* 2008;2008 Oct 14. [Epub ahead of print].
257. Lange S, Mueller SC, Altmann S, Dahlhaus M, Drewelow B, Freund M, Junghanss C. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation* 2008;41:667-74.
258. Altmann S, Lange S, Pommerencke J, Murua EH, Bullerdiek J, Nolte I, Freund M, Junghanss C. High Mobility Group Box 1-Protein expression in canine haematopoietic cells and influence on canine peripheral blood mononuclear cell proliferative activity. *Vet.Immunol.Immunopathol.* 2008;126:367-72.
259. Kahl C, Hilgendorf I, Freund M, Casper J. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma. *Onkologie* 2008;31:485.

260. Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, Casper J, Freund M. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. *Annals of Hematology* 2008;87:1009-12.
261. Wolff D, Andree H, Hilgendorf I, Casper J, Freund M, Junghanss C. Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation - timing and conditioning regimen may be crucial. *Biology of Blood and Marrow Transplantation* 2008;14:942-3.
262. Andree H, Hilgendorf I, Leithäuser M, Junghanss C, Holzhüter S, Loddenkemper C, Steiner B, Freund M, Wolff D. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. *Bone Marrow Transplantation* 2008;42:541-2.
263. Freund M. Leserbrief zum Fall Lucentis. *Dt.Ärztebl.* 2008;105.
264. Ruck S, Hilgendorff I, Müller-Hilke B, Kiefel V, Junghanss C, Freund M, Greinix H, Wolff D. Autoantibody mediated agranulocytosis in association with chronic GvHD. *Bone Marrow Transplantation* 2008;42:359-60.
265. Hilgendorf I, Aepinus C, Wolff D, Leithaeuser M, Junghanss C, Casper J, Freund M. Visual deterioration after gram-negative sepsis in neutropenia. *Ann Hematol.* 2008;87:155-7.
266. Jost K, Leithäuser M, Große-Thie C, Bartholomäus A, Hilgendorf I, Andree H, Casper J, Freund M, Junghanss C. Perforation of the superior vena cava - a rare complication of central venous catheters. *Onkologie* 2008;31:262-4.
267. Casalegno-Garduno R, Schmitt A, Yao J, Wang X, Xu X, Freund M, Schmitt M. Multimer technologies for detection and adoptive transfer of antigen-specific T cells. *Cancer Immunol.Immunother.* 2009.
268. Leithäuser M, Kahl C, Aepinus C, Prall F, Maruschke M, Riemer H, Wolff D, Jost K, Hilgendorf I, Freund M, Junghanss C. Invasive zygomycosis in patients with graft-versus-host disease after allogeneic stem cell transplantation. *Transpl.Infect.Dis.* 2009;[Epub ahead of print].
269. Fietz T, Knauf WU, Hanel M, Franke A, Freund M, Thiel E. Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate. *Annals of Hematology* 2009;88:433-9.
270. Kahl C, Leithäuser M, Junghanss C, Prall F, Freund M. [Pancytopenia and lymph node swelling. Cardinal symptoms of an unusual differential diagnosis]. *Internist (Berl).* 2009;50:734-9.
271. Al Ali H, Cross M, Lange T, Freund M, Dolken G, Niederwieser D. Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia. *Curr.Opin.Oncol.* 2009;21 Suppl 1:S17-22.:S17-S22.
272. Sender V, Hofmeister-Mielke N, Sievert K, Teifke JP, Vogel H, Baumgart J, Pichlmeier U, Freund M, Casper J, Wolff D. Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats. *Immunopharmacol.Immunotoxicol.* 2009.
273. Lange S, Altmann S, Brandt B, Adam C, Riebau F, Vogel H, Weirich V, Hilgendorf I, Storb R, Freund M, Junghanss C. Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. *Exp.Hematol.* 2009;37:143-50.
274. Knueppel A, Killian D, Lange S, Vogel H, Lindner I, Dunkelmann S, Prall F, Freund M, Knuebel G, Sekora A, Junghanss C. Intra-Bone Marrow Transplantation of CD34+ Enriched Grafts Following a Non-Myeloablative Conditioning Allows Successful Engraftment In DLA-Identical Canine Litters. *ASH Annual Meeting Abstracts* 2010;116:3711.
275. Hilgendorf I, Loebermann M, Borchert K, Junghanss C, Freund M, Schmitt M. Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD. *Bone Marrow Transplantation* 2010;Epub ahead of print.
276. Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hubel K, Silling G, Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger G, Grimminger W, Engert A, Schlimok G, Scheid C, Hellmann P, Heinisch H, Einsele H, Hinke A, Emmerich B. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. *Blood* 2010;21163927.
277. Schneidawind D, Schmitt A, Wiesneth M, Mertens T, Bunjes D, Freund M, Schmitt M. Polyomavirus BK-specific CD8+ T cell responses in patients after allogeneic stem cell transplant. *Leuk.Lymphoma.* 2010;51:1055-62.
278. Herzberg PY, Heussner P, Mumm FH, Horak M, Hilgendorf I, von Harsdorf S, Hemmati P, Rieger K, Greinix H, Freund M, Lee SJ, Holler E, Wolff D. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. *Biol.Blood Marrow Transplant.* 2010;16:1707-17.
279. Schult C, Dahlhaus M, Ruck S, Sawitzky M, Amoroso F, Lange S, Etro D, Glass A, Fuellen G, Boldt S, Wolkenhauer O, Neri LM, Freund M, Junghanss C. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. *BMC Cancer.* 2010;10:560.
280. Freund M. Correspondence (letter to the editor): National foundation. *Dtsch.Arztebl.Int.* 2010;107:671-4.

-
281. Leithauser M, Kahl C, Aepinus C, Prall F, Maruschke M, Riemer H, Wolff D, Jost K, Hilgendorf I, Freund M, Junghanss C. Invasive zygomycosis in patients with graft-versus-host disease after allogeneic stem cell transplantation. *Transpl.Infect.Dis.* 2010;12:251-7.
 282. Glass B, Ziepert M, Reiser M, Freund M, Trumper L, Metzner B, Feller A, Loeffler M, Pfreundschuh M, Schmitz N. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. *Annals of Oncology* 2010;21:2255-61.
 283. Wang X, Schmitt A, Chen B, Xu X, Mani J, Linnebacher M, Freund M, Schmitt M. Streptamer-based selection of WT1-specific CD8(+) T cells for specific donor lymphocyte infusions. *Exp.Hematol.* 2010.
 284. Kahl C, Hirt C, Decker S, Glaser D, Rohde S, Jost K, Hilgendorf I, Respondek-Dryba E, Leithauser M, Junghanss C, Freund M. Multimodal therapy for localized spinal epidural follicular lymphoma. *Onkologie* 2010;33:381-4.
 285. Hilgendorf I, Wolff D, Gromke T, Trenchel R, Elmaagacli AH, Pichlmeier U, Junghanss C, Freund M, Beelen DW, Casper J. Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. *Bone Marrow Transplantation* 2010;Epub ahead of print.
 286. Kahl C, Freund M. Peripheral blood alterations in a patient with infectious mononucleosis. *Br.J Haematol.* 2010;150:2.
 287. Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schafer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kroger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. *J Clin Oncol.* 2010;28:3344-51.
 288. Casalegno-Garduno R, Schmitt A, Yao J, Wang X, Xu X, Freund M, Schmitt M. Multimer technologies for detection and adoptive transfer of antigen-specific T cells. *Cancer Immunol.Immunother.* 2010;59:195-202.
 289. Gerber B, Freund M, Reimer T. Rezidiertes Mammakarzinom: Therapiekonzepte zum Erhalt der Lebensqualität. *Dt.Ärztebl.* 2010;107:85-91.
 290. Hilgendorf I, Freund M, Kropp P, Hartmann S, Krogmann D, Daunke A, Klasen J, Klöcking S, Zettl H, Classen CF. Onkologische Erkrankungen bei Jugendlichen und jungen Erwachsenen - Zahlen aus dem Klinischen Krebsregister Rostock als Arbeitsgrundlage für eine interdisziplinäre Herausforderung. *Tumordiagnostik und Therapie* 2011;32:85-92.
 291. Stubert J, Hilgendorf I, Stengel B, Krammer-Steiner B, Freund M, Gerber B. Bilateral breast enlargement and reddish skin macules as first signs of acute lymphoblastic T cell leukemia. *Onkologie* 2011;34:384-7.

II. BUCHBEITRÄGE

1. Ostendorf P, Freund M, Walter E, Wolf KJ. Veränderungen der Blutgerinnung durch Katheterangiographie und Injektion von Megluminamidotrizoat (Angiographin R 65%) und Metrizamid (Amipaque R). In: Frommhold W, Hacker H, Schmitt HE, Vogelsang H, eds. Amipaque Workshop. Amsterdam, Oxford: Elsevier, 1978; 151-160.
2. Ostendorf PC, Freund M. Platelets and coronary heart disease. In: Mason DT, Collins JJ, eds. Myocardial revascularization. Medical and surgical advances in coronary disease., New York: Yorke Medical Books, 1981; 366-388.
3. Ostendorf P, Freund M. Thrombozytenaggregation und Plättchenlebenszeitbestimmung bei Patienten mit aorto-femoralen Gefäßprothesen und diabetischer Mikroangiopathie vor und unter Therapie mit Aggregationshemmern. In: Schreiber R, ed. München: Müller und Steinicke, 1981; 66-75.
4. Ostendorf P, Freund M, Mittermayer C. Schocklunge durch Thrombin - induzierte Verbrauchskoagulopathie beim Hund. In: Marx R, Thies HA, eds. Lunge, Blutgerinnung und Hämostase. Basel, Grenzach-Wyhlen: Editiones Roche, 1981; 187-208.
5. Freund M, Schmoll HJ, Poliwoda H. ZNS - Manifestation maligner Hodentumoren. In: Von Heyden HW, Krauseneck P, eds. Hirnmetastasen. Pathophysiologie, Diagnostik und Therapie. München, Bern, Wien: W. Zuckschwerdt, 1984; 271-275.
6. Freund M, Barthels M, Poliwoda H. Erste Behandlung eines Patienten mit schwerer Hämophilie A und Hemmkörper mit einem hochgereinigten Faktor VIII - Präparat vom Schwein. In: Landbeck G, Marx R, eds. 14. Hämophilie Symposium, Hamburg 1983. Stuttgart, New York: Schattauer Verlag, 1986; 418-426.
7. Barthels M, Sens B, Freund M. Hemosteological management of hemophiliacs. In: Döhring S, Schulz KP, eds. Orthopedic problems in hemophilia. München, Bern, Wien: W. Zuckschwerdt Verlag, 1985; 63-69.
8. Freund M. Knochenmarkaspiration und Knochenmarkbiopsie. In: Schmoll H-J, Peters H-D, Fink U, eds. Kompendium Internistische Onkologie. Berlin, Heidelberg: Springer Verlag, 1986; 455-470.
9. Wilke H, Schmoll HJ, Preusser P, Fink U, Stahl M, Schöber C, Link H, Freund M, Hanauske A, Meyer HJ, Achterrath W, Poliwoda H. Folinic acid/5-fluorouracil-combinations in advanced gastrointestinal carcinomas. In: Rustum YM, McGuire J, eds. The expanding role of folates and fluoropyrimidines in cancer chemotherapy. New York: Plenum Press, 1988
10. Wilke H, Schmoll HJ, Preusser P, Stahl M, Schöber C, Link H, Freund M, Fink U, Meyer HJ, Poliwoda H. Ambulante Therapie am Beispiel gastrointestinaler Tumoren. In: Nagel GA, Sauer R, Schreiber HW, eds. Aktuelle Onkologie. München: Zuckschwerdt Verlag, 1988
11. Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A, Heil G, Kurrle E, Heimpel H, Koch P, Lipp T, Kaboth W, Kuse R, Küchler R, Sodomann H, Maschmeyer G, Freund M, Diedrich H, von Paleske A, Weh J, Kolb J, Müller U, Bross K, Fuhr G, Gassmann W, Gerecke D, Kress M, Busch FW, Nowrousian RM, Schneider W, Aul C, Rühl H, Bartels H, Harms F, Weiss A, Löffler B, Glöckner W, Fülle H, Pralle H, Ho AD, Bonfert B, Emmerich B, Braumann D, Brenner, Serke M, Planker M, Straif K, Meyer P, Greil R, Petsch S, Görg C, Grüneisen A, Vaupel HA, Bodenstein H, Overkamp F, Schlimock G, Augener W, Öhl S, Nowicki L, Raeth U, Zurborn KH, Neiss A, Messerer D. Therapie der ALL/AUL des Erwachsenen: Vergleich der Ergebnisse der Therapiestudien 01/81 und 02/84. In: Lutz D, Heinz R, Nowotny H, Stacher A, eds. Leukämien und Lymphome Fortschritte und Hoffnungen. München: Urban & Schwarzenberg, 1988, p. 18-23.
12. Link H, Freund M, Kirchner H, Stoll M, Schmid H, Bucsky P, Seidel J, Schulz G, Schmidt RE, Riehm H, Poliwoda H, Welte K. Enhancement of autologous bone marrow engraftment with recombinant human granulocyte colony stimulating factor (rhGM-CSF). In: Beger, HG, ed. Cancer therapy. Berlin-Heidelberg: Springer-Verlag, 1989, p. 96-102
13. Freund M, Wilke H, Link H, Poliwoda H. Wirkungen und Wechselwirkungen von BRM-Substanzen bei hämatologischen Neoplasien. In: Dönhardt A, ed. Nordwestdeutsche Gesellschaft für Innere Medizin. Kongressbericht. 111. Tagung. Hamburg, 19. bis 21. Januar 1989. Lübeck: Hansisches Verlagskontor, 1989, p. 14-15.
14. Von Wussow P, Freund M, Hartmann F, Diedrich H, Poliwoda H, Deicher H. Clinical significance of neutralizing antibodies in patients with chronic myelogenous leukemia. In: Huhn D, Hellriegel KP, Niederle N, eds. Chronic myelocytic leukemia and interferon. Berlin-Heidelberg: Springer-Verlag, 1988, p. 91-101.
15. Wilke H, Preusser P, Fink U, Stahl M, Schöber C, Freund M, Achterrath W, Lenaz L, Meyer HJ, Wegener G, Schmoll HJ. Etoposide /high-dose folinic acid/5-fluorouracil (ELF) - a well tolerable, effective combination in advanced gastric carcinoma. In: Gastric Cancer Symposium, Tokyo: Bristol-Myers K.K., 1989, p. 42-45.
16. Barthels M, Freund M, Poliwoda H. Hämostasestörungen bei myeloproliferativen Syndromen. In: Heimburger N, ed. Gerinnung und Fibrinolyse. Diagnostik aktuell. Marburg: Medizinische Verlagsgesellschaft mbH, 1989, p. 102-108.
17. Freund M, Wunsch S, Schäfers M, Diedrich H, Link H, Wilke H, Schmoll HJ, Poliwoda H Pilot study of prednimustine and mitoxantrone (PmM) in patients with chronic lymphocytic leukemia (CLL), Ip-immunocytoma (IC) and centrocytic/centroblastic NHL. In: Second Nordic Novantrone Symposium. November 17, 1988, Oslo, Norway, Hoeganaes, Sweden: Bra Boecker Pulishing Corp., 1989, p. 56-61.

18. Kurrle E, Ehninger G, Fackler-Schwalbe E, Freund M, Heil G, Hoelzer D, Link H, Löffler B, Lösch A, Mitrou PS, Öhl S, Queißer W, Schlimok G, Wandt H. Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J, eds. *Hematol. Bluttransfus. Acute Leukemias II*. Berlin Heidelberg: Springer Verlag, 1990, p. 254-260.
19. Hoelzer D, Thiel E, Löffler H, Büchner T, Freund M, Ganser A, Heil G, Hiddemann W, Maschmeyer G, Aul C, Wendt FC, Bross K, Pralle H, Küchler R, Diedrich H, Metternich M, Lindemann A, Lipp T, Kaboth W, Nowrousian MR, Koch P, Busch FW, Heimpel H, Götz G, Weiss A, Kolb H, Messerer D. Intensified chemotherapy and mediastinal irradiation in adult T-cell acute lymphoblastic leukemia. In: Gale RP, Hoelzer D, eds. *Acute lymphoblastic leukemia*. New York: Alan R. Liss Inc. 1990, p. 221-229.
20. Depenbrock H, Trijssenaar J, Neukam D, Meyer H-J, Freund M, Poliwoda H, Hanauske A-R. Growth factor-dependent stimulation of primary human tumor cells. In: Freund M, Link H, Welte K, eds. *Cytokines in Hemopoiesis, Oncology, and AIDS*. Berlin Heidelberg: Springer-Verlag, 1990, p. 173-180.
21. Joraschkewitz M, Trijssenaar J, Freund M, Neukam D, Krumwieg D, Meyer H-J, Poliwoda H, Hanauske A-R. Effects of recombinant cytokines on clonogenic cells from primary human tumors. In: Freund M, Link H, Welte K, eds. *Cytokines in Hemopoiesis, Oncology, and AIDS*. Berlin Heidelberg: Springer-Verlag, 1990, p. 189-195.
22. Link H, Burdach S, Seidel J, Diedrich H, Kirchner H, Freund M, Ebell W, Bucsky P, Riehm H, Welte K, Schmitz N, Schulz G, Poliwoda H. Recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation. In: Freund M, Link H, Welte K, eds. *Cytokines in Hemopoiesis, Oncology, and AIDS*. Berlin Heidelberg: Springer-Verlag, 1990, p. 409-416.
23. Link H, Sens B, Diedrich H, Bucsky P, Ebell W, Seidel J, Stoll M, Freund M, Tischler J, Brune Th, Riehm H, Poliwoda H. Use of recombinant human erythropoietin after bone marrow transplantation. In: Freund M, Link H, Welte K, eds. *Cytokines in Hemopoiesis, Oncology, and AIDS*. Berlin Heidelberg: Springer Verlag, 1990, p. 481-486.
24. Freund M, Von Wussow P, Hild F, Buchholz F, Buhr Th, Tischler J, Eisert R, Koch O, LeBlanc S, Blessmann B, Stiller S, Kleine HD, Exeriede G, Hiddemann W, Link H, Wilke H, Fonatsch C, Poliwoda H. Interferon α -2b in chronic myelogenous leukemia. Experiences with two treatment regimens. In: Freund M, Link H, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS*. Berlin Heidelberg: Springer-Verlag, 1990, p. 513-522.
25. Exeriede G, Doering G, Lux E, Poliwoda H, Freund M. Influence of busulfan or interferon alfa treatment on CFU-C from bone marrow and peripheral blood in patients with CML in chronic phase. In: Freund M, Link H, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS*. Berlin Heidelberg: Springer-Verlag, 1990, p. 537-540.
26. Tischler H-J, Freund M, Harstrick A, Schöber Ch, Poliwoda H, Schmoll H-J. Recombinant interferon alfa-2b in patients with advanced osteosarcoma after aggressive chemotherapy. In: Freund M, Link H, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS*. Berlin Heidelberg: Springer Verlag, 1990, p. 623-628.
27. Link H, Freund M, Sens B, Hoffmann A, Atzpodien J, Kirchner H, Stahl M, Schöber C, Schmoll H-J, Andres J, Volgmann Th, Mohr H, Pohl U, Poliwoda H. Natural interleukin-2 (nIL-2) plus lymphokine-activated killer (LAK) cells in patients with advanced malignancy. In: Freund M, Link H, Welte K, eds. *Cytokines in Hemopoiesis, Oncology, and AIDS*. Berlin Heidelberg: Springer-Verlag, 1990, p. 727-732.
28. Freund M. Infektionsrisiken bei alten und immungeschwächten Patienten. In: Sander J, Sander U, eds. *Praxis der Krankenhaushygiene: Einfluß von Pflege und Technik. Referate vom 4. Fortbildungskongress Hannover 15. - 17.10.90*. Osnabrück: Monika Schliehe Verlag, 1990, p. 239-254.
29. Freund M, Hoelzer D. Akute lymphatische Leukämie. In: Ostendorf PC, ed. *Innere Medizin der Gegenwart. Band 8. Hämatologie*. München - Wien - Baltimore: Urban & Schwarzenberg, 1991, p. 438-451.
30. Freund M, Queißer W. Knochenmark. In: Ostendorf PC, ed. *Innere Medizin der Gegenwart. Band 8. Hämatologie*. München - Wien - Baltimore: Urban & Schwarzenberg, 1991, p. 107-124.
31. Heil G, Freund M, Link H, Mitrou P, Hoelzer D, Wandt H, Ehninger G, Fackler-Schwalbe E, Schlimock G, Lösch A, Queißer W, Löffler B, Kurrle E. Acute myeloid leukemia: an update of treatment results with high-dose Ara-C consolidation therapy. In: Hiddemann W, Büchner T, Plunkett W, Keating M, Wörmann B, Andreeff M, eds. *Haematology and Blood Transfusion Vol. 34. Acute leukemias. Pharmacokinetics and management of relapsed and refractory disease*. Berlin Heidelberg: Springer Verlag, 1992, p. 425-429.
32. Freund M, Giller S, Hinrichs F, Baars A, Meran J, Körfner A, Link H, Poliwoda H. Treatment of high risk relapsing or refractory AML with m-AMSA and Id-AraC. In: Hiddemann W, Büchner T, Plunkett W, Keating M, Wörmann B, Andreeff M, eds. *Haematology and Blood Transfusion Vol. 34. Acute leukemias. Pharmacokinetics and management of relapsed and refractory disease*. Berlin Heidelberg: Springer-Verlag, 1992, p. 450-457.
33. Freund M, Diedrich H, Ganser A, Heil G, Heyll A, Henke M, Hiddemann W, Haas R, Kuse R, Koch P, Link H, Maschmeyer G, Planker M, Queißer W, Schadeck-Gressel C, Schmitz N, von Verschuer U, Wilhelm S, Hoelzer D. Treatment of relapsed or refractory adult acute lymphocytic leukemia. In: Hiddemann W, Büchner T, Plunkett W, Keating M, Wörmann B, Andreeff M, eds. *Haematology and Blood Transfusion Vol. 34. Acute leukemias. Pharmacokinetics and management of relapsed and refractory disease*. Berlin Heidelberg: Springer-Verlag, 1992, p. 472-480.

34. Link H, Freund M, Diedrich H, Arseniev L, Wilke H, Austein J, Poliwoda H. Mitoxantrone, cytosine arabinoside and VP-16 (MAV) for de novo acute myeloid leukemia: a pilot study. In: Hiddemann W, Büchner T, Plunkett W, Keating M, Wörmann B, Andreeff M, eds. *Haematology and Blood Transfusion Vol. 34. Acute leukemias. Pharmacokinetics and management of relapsed and refractory disease.* Berlin Heidelberg: Springer-Verlag, 1992, p. 653-655.
35. Bauer E, Danhauser-Riedl S, De Riese W, Raab H-R, Sandner S, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. Effects of recombinant human erythropoietin on clonogenic growth of primary human tumor specimens in vitro. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 115-125.
36. Donné S, De Riese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. Growth modulating effects of interleukin-1 α , interleukin-1 β , and macrophage colony-stimulating factor in clonogenic tumor cells in vitro. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 127-134.
37. Oelke M, De Riese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. Effects of interleukin-4, interleukin-5, and interleukin-7 on clonogenic growth of primary human tumors in vitro. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 135-143.
38. Bauer E, Danhauser-Riedl S, Welte K, De Riese W, Raab H-R, Sandner S, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. Effects of Interleukin-6 on soft agar colony formation of primary solid tumor specimens. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 145-151.
39. Kleine HD, Wagner U, Poliwoda H, Freund M. Effects of tumor necrosis factor- α on acute myeloid leukemia cells measured by flow cytometric detection of bromodeoxyuridine incorporation. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 163-170.
40. Haase D, Fonatsch C, Freund M, Bodenstein H, Bartels H. Differential response of cytogenetically abnormal cell clones in myelodysplastic syndromes to cytokines in vitro. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 185-193.
41. Freund M, Diedrich H, Ebell W, Peest D, Kempeni J, Müller A, Link H. Tumor necrosis factor α in the course of allogeneic and autologous bone marrow transplantation. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 449-456.
42. Raghavachar A, Hinterberger W, Kaltwasser JP, Höffken K, Herrmann F, Freund M, Platzer E, Frisch J, Heimpel H, Frickhofen N. Recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia: a phase I/II trial with emphasis on very severe neutropenia and active infection. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 555-563.
43. Freund M, Hild F, Von Wussow P, Nowak R, Hiddemann W, Wörmann B, Koch O, Balleisen L, Grote-Metke A, Steiner M, Dohmen M, Stiller S, Kleine HD, Meran J, Link H, Fonatsch C, Poliwoda H. Interferon α -2b in the treatment of chronic myeloid leukemia. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 647-660.
44. Hild F, Rieder H, Freund M, Fonatsch C. Complex karyotype evolution influenced by interferon therapy in a case of Ph-positive chronic myeloid leukemia. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 667-672.
45. Freund M, Steinmeier O, Kleine H-D, Exeriede G, Link H, Kempeni J, Schlick E, Barthels M, Poliwoda H. Treatment with human recombinant tumor necrosis factor- α of patients with acute myeloid leukemia and chronic myeloid leukemia in its accelerated or blastic phase. In: Freund M, Link H, Schmidt RE, Welte K, eds. *Cytokines in hemopoiesis, oncology, and AIDS II.* Berlin Heidelberg New York: Springer Verlag, 1992, p. 693-706.
46. Freund M. Interferons in hematology. In: Lechner K, Gadner H, eds. *Haematology Trends '93. Proceedings of the educational programme of the XIIth meeting of the International Society of Haematology (European and African Division), Vienna, August 28 - September 3, 1993.* Stuttgart New York: Schattauer, 1993, p. 120-143.
47. Freund M, Heußner P. Non-Hodgkin-Lymphome. In: Seeber S, Schütte J, eds. *Therapiekonzepte Onkologie.* Berlin Heidelberg New York: Springer Verlag, 1993, p. 58-111.
48. Freund M, Kleine H-D, Heußner P, Poliwoda H. Clinical significance of interferons in the treatment of malignant lymphomas. In: *Cytokines in cancer therapy.* Eds. Bermann L, Mitrou PS. *Contrib. Oncol. Vol. 46.* Basel: Karger Verlag, 1994, p. 53-70.
49. Freund M. Polycythaemie und Polyglobulie. In: *Klinik der Gegenwart*, edited by Gerok, W., Hartmann, F., Pfreundshuh, M., Philipp, T., Schuster, H.-P. and Sybrecht, G.W. München Wien Baltimore: Urban & Schwarzenberg, 1994.

50. Spiekermann, K., Roesler, J., Elsner, J., Link, H., Freund, M., Welte, K., Lohmann-Matthes, M.-L. and Emmendoerffer, A. Kinetics of human neutrophil surface marker expression and chemotaxis during G-CSF treatment. In: *Cytokines in Hematology, Oncology, and Immunology III*, edited by Freund, M., Link, H., Schmidt, R.E. and Welte, K. Berlin Heidelberg New York: Springer Verlag, 1994, p. 103-113.
51. Avenarius, H.-J., Freund, M., Deinhardt, J., Heußner, P., Kleine, H.-D. and Poliwoda, H. Treatment with rhG-CSF increases the CD62-expression on the surface of thrombocytes. In: *Cytokines in Hematology, Oncology, and Immunology III*, edited by Freund, M., Link, H., Schmidt, R.E. and Welte, K. Berlin Heidelberg New York: Springer Verlag, 1994, p. 115-127.
52. Könneke, A., Arseniev, L., Andres, J., Battmer, K., Südmeyer, I., Bokemeyer, C., Freund, M. and Link, H. Peripheral blood progenitor cells and immunohematopoietic reconstitution after multiple consecutive courses of intensive chemotherapy. In: *Cytokines in Hematology, Oncology, and Immunology III*, edited by Freund, M., Link, H., Schmidt, R.E. and Welte, K. Berlin Heidelberg New York: Springer Verlag, 1994, p. 173-179.
53. Heußner, P., Haase, D., Ottmann, O.G., Kanz, L., Fonatsch, C., Welte, K. and Freund, M. G-CSF in the treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. In: *Cytokines in Hematology, Oncology, and Immunology III*, edited by Freund, M., Link, H., Schmidt, R.E. and Welte, K. Berlin Heidelberg New York: Springer Verlag, 1994, p. 235-247.
54. Haase, D., Freund, M., Welte, K., Zabel, B. and Fonatsch, C. Association of monosomy 7 and leukemic response to myeloid growth factors? In: *Cytokines in Hematology, Oncology, and Immunology III*, edited by Freund, M., Link, H., Schmidt, R.E. and Welte, K. Berlin Heidelberg New York: Springer Verlag, 1994, p. 253-260.
55. Junghanß, C., Hinrichs, H.-F., Petershofen, E.K., Kleine, H.-D., Poliwoda, H. and Freund, M. Effects of IL-2 and IL-4 and its combination on B-CLL cells in vitro. In: *Cytokines in Hematology, Oncology, and Immunology III*, edited by Freund, M., Link, H., Schmidt, R.E. and Welte, K. Berlin Heidelberg New York: Springer Verlag, 1994, p. 349-354.
56. Hinrichs, H.-F., Petershofen, E.K., Scheinichen, D., Junghanß, C., Kleine, H.-D., Poliwoda, H. and Freund, M. Cytokines in chronic lymphocytic leukemia - effects of TNF α , IFN α , and SCF on B-cells in vitro. In: *Cytokines in Hematology, Oncology, and Immunology III*, edited by Freund, M., Link, H., Schmidt, R.E. and Welte, K. Berlin Heidelberg New York: Springer Verlag, 1994, p. 355-360.
57. Heußner, P., Petershofen, E.K., Kleine, H.-D., Tischler, J. and Freund, M. Phase II study of IFN α -2b in refractory acute leukemia. In: *Cytokines in Hematology, Oncology, and Immunology III*, edited by Freund, M., Link, H. and Welte, K. Berlin Heidelberg New York: Springer Verlag, 1994, p. 580-585.
58. Freund, M., Kahrs, M., Heußner, P., Petershofen, E.K., Schöffski, P., Andres, J., Arseniev, L., Link, H. and Poliwoda, H. Hochdosis-Chemotherapie mit anschließender Reinfusion autologer peripherer Stammzellen: Salvage-Maßnahme oder Alternative zur Knochenmarktransplantation? In: *Morbus Hodgkin und Non-Hodgkin-Lymphome*, edited by Diehl, V., Schlag, R. and Thiel, E. Basel: Karger, 1995, p. 117-125.
59. Freund, M., Heußner, P. Non-Hodgkin-Lymphome niedriger Malignität In: Seeber S, Schütte J, eds. *Therapiekonzepte Onkologie*. 2. Aufl. Berlin Heidelberg New York: Springer Verlag, 1995, p. 189-268.
60. Freund, M., Heil, G., Pompe, K., Arnold, R., Bartram, C., Büchner, T., Diedrich, H., Fonatsch, C., Ganser, A., Hiddemann, W., Koch, P., Kolbe, K., Link, H., Löffler, H., Ludwig, W.D., Maschmeyer, G., Schmitz, N., Schwonzen, M., Thiel, E., Hoelzer, D. on behalf of the German Relapsing Acute Lymphocytic Leukemia Study Group (GRALLSG). Salvage therapy of adult ALL. In: *Acute Leukemias V: Experimental approaches and management of refractory disease*, edited by Hiddemann, W. Berlin Heidelberg: Springer Verlag, 1996, p. 229-234.
61. Anders, O., Burstein, C., Bauer, I. and Freund, M. Untersuchungen zur Resistenz gegenüber aktiviertem Protein C (APC-Resistenz) bei Patienten mit tiefer Beinvenenthrombose. In: *Gerinnungsstörungen. Diagnostik und Behandlung*, edited by Anders, O. and Jacob, J. Schriesheim: Weller Verlag, 1996, p. 53-58.
62. Freund, M. and Lohrmann, H.-P. Blutbild und Knochenmark. In: *Hämatologie, Onkologie*, edited by Ostendorf, P. and Seeber, S. München, Wien, Baltimore: Urban & Schwarzenberg, 1997, p. 75-89.
63. Freund, M. and Hoelzer, D. Akute lymphatische Leukämie. In: *Hämatologie, Onkologie*, edited by Ostendorf, P. and Seeber, S. München, Wien, Baltimore: Urban & Schwarzenberg, 1997, p. 522-533.
64. Hiddemann, W., Unterhalt, M., Herrmann, R., Tiemann, M., Parwaresch, R., Stein, H., Trümper, L., Nahler, M., Reuss-Borst, M., Tirier, C., Neubauer, A., Freund, M., Kreuser, E.-D., Dietzfelbinger, H., Bodenstein, H., Engert, A., Stauder, R., Eimermacher, H. and Landys, K. Therapie der zentroblastischen und zentrozytischen Lymphome in fortgeschrittenen Stadien - Ergebnisse der Deutschen Studiengruppe zur Behandlung niedrigmaligner Lymphome. In: *Maligne Lymphome. Biologie, Klassifikation und Klinik*, edited by Höffkes, H.G. and Uppenkamp, M. Berlin, Heidelberg, New York: Springer Verlag, 1997, p. 177-125.
65. Hoelzer, D., Gökbüget, N., Ludwig, W.D., Thiel, E., Gassmann, W., Löffler, H., Fonatsch, C., Rieder, H., Heil, G., Heinze, B., Arnold, R., Hossfeld, D., Büchner, T., Koch, P., Freund, M., Hiddemann, W., Maschmeyer, G., Heyll, A., Aul, C., Faak, T., Kuse, R., Ittel, T.H., Gramatzki, M., Diedrich, H., Kolbe, K., Fuhr, H.G., Fischer, K., Schadeck-Gressel, C., Weiss, A., Strohscheer, I., Metzner, B., Fabry, U., Völkers, B. and Messerer, D. Therapie der B-ALL und lymphoblastischer B-NHL in den multizentrischen ALL-Studien des Erwachsenen. In: *Maligne Lymphome. Biologie, Klassifikation und Klinik*, edited by Höffkes, H.-G. and Uppenkamp, M. Berlin, Heidelberg, New York: Springer Verlag, 1997, p. 177-187.

66. Freund, M. and Hoelzer, D. Akute lymphatische Leukämie (ALL). In: Kompendium Internistische Onkologie, edited by Schmoll, H.-J., Höffken, K. and Possinger, K. Berlin Heidelberg New York: Springer Verlag, 1997, p. 33-66
67. Freund, M., Diem, H., Engel, H. and Gassmann, W. Checkliste Klinische Chemie und Hämatologie - Hämatologie. In: Handbuch für die Akkreditierung medizinischer Laboratorien, edited by Arbeitsgemeinschaft Medizinische Laboratoriumsdiagnostik (AML) and Zentralstelle der Länder für Gesundheitsschutz bei Medizinprodukten (ZLG). Berlin: Bernd-Michael Paschke Verlag, 1997
68. Heußner P, Willemze R, Ganser A, Hanauske A, Amadori S, Heil G, Schleyer E, Hiddemann W, Selbach J, Schüßler M, Freund M. YNK01, an oral cytosine arabinoside derivative in acute myeloid leukemia and chronic myeloid leukemia. In: Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig U., eds. Acute Leukemias VI. Prognostic factors and treatment strategies. Berlin, Heidelberg, New York: Springer-Verlag, 1997: 882-5.
69. Freund, M., Heußner, P., Hild, F., Nowak, R., Grote-Metke, A., Diedrich, H., Koch, O., Otremba, B., Kleine, H.-D., Meran, J., Link, H., Hinrichs, H.F., Balleisen, L., Fonatsch, C. and Poliwoda, H. Interferon-alpha in Kombination oder Sequenz mit Chemotherapeutika zur Therapie der chronischen myeloischen Leukämie. In: Therapie der Leukämien und Lymphome - Schwerpunkt Zytokine, edited by Fleischer, J., Hiddemann, W. and Hoelzer, D. Freiburg: Karger Verlag, 1998, p. 120-129.
70. Freund, M. and Heußner, P. Non-Hodgkin-Lymphome niedriger Malignität. In: Therapiekonzepte Onkologie, edited by Seeber, S. and Schütte, J. Berlin, Heidelberg, New York: Springer Verlag, 1998, p. 257-332.
71. Freund M, Hoelzer D. Akute lymphatischer Leukämie (ALL). In: Schmoll H-J, Höffken K, Possinger K., eds. Kompendium Internistische Onkologie. Berlin, Heidelberg, New York: Springer Verlag, 1999: 36-70.
72. Freund M, Hoelzer D. Akute lymphatische Leukämie (ALL). In: Schmoll H-J, Höffken K, Possinger K., eds. Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Indikationen und Therapiekonzepte. Kurzversion. Berlin, Heidelberg, New York: Springer Verlag, 1999: 15-36.
73. Anders O, Freund M. Blutgerinnung. In: Pfreundschuh M, Schölmerich J., eds. Pathophysiologie Pathobiochemie. München, Jena: Urban & Fischer, 1999: 69-77.
74. Freund M. Hämatologie / Internistische Onkologie (Auswahl). In: Alexander K, Daniel WG, Diener H-C, Freund M, Köhler H, Matern S, Maurer HH, Michel BA, Nowak D, Risler T, Schaffner A, Scherbaum WA, Sybrecht GW, Wolfram G, Zeitz M., eds. Thiems Innere Medizin (TIM). Stuttgart, New York: Georg Thieme Verlag, 1999: 810-1029.
75. Anders, O. and Freund, M. Blutgerinnung. In: Pathophysiologie, Pathobiochemie, edited by Pfreundschuh, M. and Schölmerich, J. München, Jena: Urban & Fischer, 2000, p. 69-77.
76. Steiner B, Freund M. Amphotericin B - Antimykotikum des Jahres. In: Janata O, Reisinger E. Infektiologie. Aktuelle Aspekte. Jahrbuch 2001/2002. Wien New York: Springer Verlag, 2001:11-7.
77. Mischke R, Freund M. Leukämien, akute (Hund und Katze). In: Wiesner E. Handlexikon der Tierärztlichen Praxis. Stuttgart: Encke Verlag, 2001:514g-m.
78. Casper J, Knauf W, Hammer U, Wegener H, Steiner B, Wolff D, Knopp A, Kleine H-D, Freund M. Reduced toxicity on conditioning with treosulfan and fludarabine. In: Schultze W. High-dose therapy and transplantation of Haematopoietic stem cells (2001), 1 ed. Berlin: Blackwell Verlag GmbH, 2002:42-6.
79. Casper J, Knauf W, Hammer U, Wegener H, Steiner B, Wolff D, Knopp A, Kleine H-D, Freund M. Reduced Toxicity on Conditioning with Treosulfan and Fludarabine. In: Schultze W. High-dose therapy and transplantation of haematopoietic stem cells (2001). London: Blackwell Publishing Ltd, 2002:42-6.
80. Kleine H-D. Selection and purification of stem cells. In: Steinhoff G, Freund M, Jansson V, Rolfs A. Stem cells in tissue regeneration. Lengerich: Pabst Science Publishers, 2003:54-64.
81. Leithäuser M, Freund M. Non-Hodgkin-Lymphome niedriger Malignität. In: Seeber S, Schütte J. Therapiekonzepte Onkologie, 4 ed. Berlin, Heidelberg, New York: Springer Verlag, 2003:364-438.
82. Kleine H-D. Selection and purification of stem cells. In: Steinhoff G, Freund M, Jansson V, Rolfs A. Stem cells in tissue regeneration. Lengerich: Pabst Science Publishers, 2003:54-64.
83. Hartung G, Wolff D. Klinische Erfahrung zur Linezolid-induzierten Thrombozytopenie sowie zur hepatischen und renalen Toxizität von Linezolid. In: von Eiff C, Becker K. Linezolid: neue Daten nach Einführung in die Klinik. Wessobrunn: Sozio-medico Verlag GmbH, 2004:175-87.
84. Freund M. Hämatologische Erkrankungen. In: Rath W, Friese K. Erkrankungen in der Schwangerschaft. Stuttgart - New York: Georg Thieme Verlag, 2005:221-46.
85. Freund M, Hoelzer D. Akute lymphatische Leukämie (ALL). In: Schmoll H-J, Höffken K, Possinger K. Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Therapiekonzepte maligner Tumoren, vol. 2, 4 ed. Berlin, Heidelberg, New York: Springer Verlag, 2006.
86. Leithäuser M, Freund M. Non-Hodgkin-Lymphome niedriger Malignität. In: Seeber S, Schütte J. Therapiekonzepte Onkologie. Heidelberg: Springer Medizin Verlag, 2007:342-84.
87. Junghanss C, Freund M. Rezidivtherapie der ALL. In: Gökbüget N. Akute lymphatische Leukämie. Bremen, London, Boston: Uni-Med Verlag AG, 2007:112-5.
88. Schmitt M, Freund M. Blood. In: Steinhoff G. Regenerative Medicine. Heidelberg: Springer Verlag, 2011.

III. BÜCHER UND SUPPLEMENTE

1. Freund M, Link H, Welte K. Cytokines in hemopoiesis, oncology, and AIDS. Berlin Heidelberg New York: Springer Verlag, 1990
2. International Cancer Update: Focus on interferon alfa-2B edited by Freund, M., and Salmon, S.E. Eur.J.Cancer, Vol. 27, Suppl 4, 1991
3. Freund M, Link H, Schmidt RE, Welte K. Cytokines in hemopoiesis, oncology, and AIDS II. Berlin Heidelberg New York: Springer Verlag, 1992
4. Freund M, Link H, Schmidt RE, Welte K. Cytokines in hematology, oncology, and immunology III. Berlin Heidelberg New York: Springer Verlag, 1994
5. Heckner F, Freund M. Praktikum der mikroskopischen Hämatologie. 9. neubearbeitete und erweiterte Auflage. München Wien Baltimore: Urban & Schwarzenberg Verlag, 1997
6. Heckner F, Freund M. Atlas de Hematologia. Madrid: Marban Libros, 1997
7. Clinical results of topotecan (Hycamtin R). Associated symposium at the 23rd National Cancer Congress of the German Cancer Society. Berlin, June 9, 1998. Kreienberg R and Freund M.(eds.) Basel Freiburg: Karger Verlag, 1998
8. Heckner F, Freund M. Atlas Hematologi. Praktikum Hematologi dengan Mikroskop. Suwono WJ ed. 9th edition. Jakarta: EGC Medical Publisher, 1999
9. Heckner F, Freund M. Praktikum der mikroskopischen Hämatologie. 10. neubearbeitete und erweiterte Auflage. München Wien Baltimore: Urban & Schwarzenberg Verlag, 2001, 136 S.
10. Steinhoff G, Freund M, Jansson V, Rolfs A. (eds). Stem cells in tissue regeneration. Lengerich: Pabst Science Publishing, 2003.
11. Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Hannover, 1.-5. Oktober 2005. Abstracts, vol. Supplement 3, Band 28 Onkologie. Basel: Karger Verlag, 2005:1-290.
12. Ehninger G, Overkamp F, Freund M, Schmitz S, Nerl C, Wilhelm M et al. Hämatologie und Onkologie 2007. Berlin: 2007. 95 Seiten
13. Petrasch S. Update Hämatologie/Onkologie 2007. Eds: Ehninger,G.; Freund,M.; Overkamp,F. München: Lukon Verlag, 2007. 376 Seiten
14. Update Hämatologie / Onkologie 2008, vol. 6. Eds: Petrasch,S.; Ehninger,G. Series eds: Ehninger,G.; Freund,M.; Overkamp,F. München: Lukon Verlag, 2008. 428 Seiten.
15. Freund M. Praktikum der mikroskopischen Hämatologie, 11 ed. München, Jena: Urban & Fischer, 2008. 142 Seiten.
16. Ehninger G. Colloquium Onkologie 5. Dresdner Symposium Hämatologie und Onkologie 2007. Eds: Ehninger,G.; Freund,M.; Overkamp,F. München: Lukon Verlagsgesellschaft mbH, 2008. 128 Seiten.
17. Ehninger G. Colloquium Onkologie 5. Dresdner Symposium Hämatologie und Onkologie 2007 Eds: Ehninger, G., Freund, M., and Overkamp, F. München: Lukon Verlagsgesellschaft mbH, 2008. ISBN: 978-3-933012-10-4. 128 Seiten.
18. Freund M. Praktikum der mikroskopischen Hämatologie, 11 ed. München, Jena: Urban & Fischer, 2008. ISBN: 978-3-437-450-39-6. 142 Seiten.
19. Update Hämatologie / Onkologie 2008, vol. 6 Eds: Petrasch, S. and Ehninger, G. In: Colloquium Onkologie. Edited by: Ehninger, G., Freund, M., and Overkamp, F. München: Lukon Verlag, 2008. 428 Seiten.
20. Dresdner Symposium Hämatologie und Onkologie 2008, Ed: Ehninger, G. In: Colloquium Onkologie Vol. 7. Edited by: Ehninger, G., Freund, M., and Overkamp, F. München: Lukon Verlag, 2009. ISBN-10: 3933012120; ISBN-13: 978-3933012128; 119 Seiten.
21. Update Hämatologie / Onkologie 2009, Eds: Petrasch, S. and Ehninger, G. In: Colloquium Onkologie Vol. 8. Edited by: Ehninger, G., Freund, M., and Overkamp, F. München: Lukon Verlag, 2009. ISBN-10: 3933012139; ISBN-13: 978-3933012135; 466 Seiten.
22. Dresdner Symposium Hämatologie und Onkologie 2009, Ed: Ehninger, G. In: Colloquium Onkologie Vol. 9. Edited by: Ehninger, G., Freund, M., and Overkamp, F. München: Lukon Verlag, 2009. ISBN 978-3-933012-14-2
23. Update Hämatologie / Onkologie 2010, Eds: Petrasch, S. and Ehninger, G. In: Colloquium Onkologie Vol. 8. Edited by: Ehninger, G., Freund, M., and Overkamp, F. München: Lukon Verlag, 2010. IISBN: 978-3-933012-16-6
24. Freund M. Heckner - Atlas Hematologi, 11 ed. Jakarta: Penerbit Buku Kedokteran, 2011.

IV. ABSTRAKTS

1. Ostendorf P, Freund M, Stunkat R, Sebold H, Bustamante J. Der Einfluss von Gefäßprothesen auf die Thrombozytenüberlebenszeit ohne und unter Therapie mit Plättchenaggregationshemmern. Thoraxchirurgie, vaskuläre Chirurgie (Sonderheft 1) 1978; 26: 18.
2. Freund M, Barthels M, Poliwoda H. Determination of plasmafibronektin by lasernephelometry and by electroimmunoassay (Abstr.). Thrombos Hemostas 1983; 50: 267.
3. Freund M, Barthels M, Poliwoda H. Fibronectin determinations in patients with disseminated malignoma. J Cancer Res Clin Oncol (Suppl) 1984; 107: 100.
4. Freund M, Schmoll HJ. CNS - involvement in testicular cancer. J Cancer Res Clin Oncol (Suppl) 1984; 107: 39.
5. LeBlanc S, Schmoll HJ, Poliwoda H, Schmidt FW, Diehl V, Pfreundschuh M, Freund M. High dose folinic acid and 5- FU treatment in advanced colorectal, gastric and pancreatic adenocarcinomas. J Cancer Res Clin Oncol (Suppl) 1984; 107: 50.
6. Bartsch HH, Schuff-Werner P, Schreml W, Nagel GA, Seeber S, Queisser W, Freund M. Recombinant alpha- leucocyte interferon for the treatment of patients with soft tissue sarcomas. J Cancer Res Clin Oncol (Suppl) 1984; 107: 3.
7. Von Roemeling R, Sohr J, Schmoll H-J, Peter HH, Freund M, Vykopil KF, Poliwoda H. Angioimmunoblasticlymphadenopathy: Clinical course, immunological characteristics and treatment results in 24 patients (Abstr 99). In: Second international conference on malignant lymphoma, Lugano, 1984.
8. Freund M, Plaumann L, von Roemeling R, Casper J, Metzner B, LeBlanc S, Schilling B, Schmoll E. Chemotherapy of relapsing or refractory high grade malignant NHL with CCNU, etoposide, vindesine, high dose methotrexate and dexamethasone: Toxicity and preliminary results (Abstract T84). In: Second international conference on malignant lymphoma, Lugano, 1984.
9. Freund M, Kemnitz J, Poliwoda H, Helmke M, Georgii A. Detection of glycoprotein IIb-IIIa complex on leukemia and lymphoma cells by the monoclonal antibody Hu P1-m1 (Abstr). In: XIIth Symposium for comparative research on leukemia and related diseases Hamburg 1985.
10. Freund M, Diedrich H, Poliwoda H. Treatment of relapsing or refractory acute leukemia with high dose AraC and VP16. Blut 1985; 51: 211.
11. Diedrich H, Freund M, Poliwoda H. Treatment of relapsing or refractory acute leukemia with M-Amsa and VP16. Blut 1985; 51: 211.
12. Metzner B, Freund M, Diedrich H, Casper J, Poliwoda H. Treatment of aplastic anemia with antilymphocyte - serum (ALS). Blut 1985; 51: 178.
13. Kemnitz J, Freund M, Helmke M, Poliwoda H, Georgii A. Detection of glycoprotein IIb-IIIc complex on leukemia and lymphoma cells by the monoclonal antibody Hu P1m1. Blut 1985; 51: 216.
14. Kirchner HH, Freund M, Diedrich H, Poliwoda H. Continuous infusion therapy with low doses of cytarabine. Blut 1985; 51: 163.
15. Freund M, Plaumann L, Casper J, Metzner B, LeBlanc S, Schmoll E, Poliwoda H, Schmoll HJ. Chemotherapy of relapsing or refractory malignant lymphomas with CCNU, VP16, vindesine, high dose methotrexate and dexamethasone. Blut 1985; 51: 148.
16. Von Wussow P, Freund M, Schmoll HJ, Anagnou J, Deicher H, Poliwoda H. Low dose interferon-alpha-therapy of hairy cell leukemia. Blut 1985; 51: 239.
17. Freund M, Link H, H Diedrich, Poliwoda H. High dose Ara-C and VP16 in treatment of refractory or relapsing acute leukemia. J Cancer Res Clin Oncol (Suppl) 1986; 111: 107.
18. Wang MC, Freund M, Poliwoda H. The effect of 3',5'-C-AMP, 3',5'-C-GMP and 3',5'-C-CMP on cell growth of the T-lymphoblastic JM cell line. An in vitro study on parasynchronized cells by flow cytometry. J Cancer Res Clin Oncol (Suppl) 1986; 111: 106.
19. Bock K, Freund M, Poliwoda H. Detection of insolublefibronectin in lymphoma-cell-lines. J Cancer Res Clin Oncol (Suppl) 1986; 111: 106.
20. Exeriede G, Freund M, Birk G, Delorme S, Poliwoda H. Effects of cytotoxic drugs on the lymphoma cell line JM. An in vitro study by flow cytometry. J Cancer Res Clin Oncol (Suppl) 1986; 111: 106.
21. Freund M, Barthels M, Poliwoda H. Serial determination of fibronectin and hemostatic parameters in acute leukemia. J Cancer Res Clin Oncol (Suppl) 1986; 111: 106.
22. Diedrich H, von Wussow P, Freund M, LeBlanc S, Link H, Wilke HJ, Poliwoda H. Treatment of chronic myelogenous leukemia (CML) with recombinant interferon alpha 2. Blut 1986; 53: 236.
23. Freund M, Barthels M, Lux E, Wang MC, Gust R, Poliwoda H. Serial determinations of fibronectin and coagulation parameters in patients with acute myelogenous leukemia. Blut 1986; 53: 180.
24. Freund M, Link H, Bodenstein H, Poliwoda H. Long-term results in acute myeloid leukemia treated with conventional DA and TAD polychemotherapy. Blut 1986; 53: 241.
25. Wang MC, Freund M, Poliwoda H. Effect of harringtonine on the parasynchronized T-lymphoblastic cell line JM. A study by flow cytometry. Blut 1986; 53: 255.

26. Metzner B, Freund M, Casper J, Gust R, von Wussow P, Schmoll H-J, Poliwoda H. Treatment of adult patients with disseminated high grade lymphomas of B-type. *Blut* 1986; 53: 221.
27. Von Wussow P, Hill W, Diedrich H, Freund M, Poliwoda H, Deicher H. Low dose interferon-alpha-therapy of hairy cell leukemia. *Blut* 1986; 53: 214-215.
28. Diedrich H, Freund M, von Wussow P, LeBlanc S, Link H, Wilke HJ, Schmoll H-J, Poliwoda H. Treatment of chronic myelogenous leukemia (CML) with recombinant interferon alpha-2. *Cancer Chemother Pharmacol (Suppl. 1)* 1986; 18: A23.
29. Freund M, Link H, Diedrich H, Schmoll H-J, Poli-woda H. High dose Ara-C and VP16 in treatment of refractory or relapsing acute leukemia. *Cancer Chemother Pharmacol (Suppl. 1)* 1986; 18: A29.
30. Von Wussow P, Hill W, Diedrich H, Freund M, Poliwoda H, Deicher H. Low dose interferon-alpha therapy of hairy cell leukemia. *Cancer Chemother Pharmacol (Suppl.1)* 1986; 18: A76.
31. Kemnitz J, Buhr T, Freund M, Helmke M, Dominis M, Georgii A. The heterogeneous phenotype of leukaemic cells in acute leukaemias and blast crises of CMPD (in the system of MY 7: GP IIb-IIa). *Blut* 1987; 55: 234.
32. Helmke M, Kemnitz J, Buhr T, Freund M, Dominis M, Georgii A. Correlation of oncogen expression with the manifestation of different types of the immunophenotype of leukaemic cells. *Blut* 1987; 55: 208.
33. Freund M, Kemnitz J, Menzel B, Link H, Diedrich H, Wilke HJ, Poliwoda H. Prognostic significance of surface markers in AML. *Blut* 1987; 55: 293.
34. Diedrich H, Freund M, von Wussow P, Eisert R, Metzner B, Link H, Wilke HJ, Schmoll HJ. and H Poliwoda. Treatment of chronic myelogenous leukemia (CML) with low doses of recombinant interferon alpha 2 b. *Blut* 1987; 55: 280.
35. Freund M, Link H, Diedrich H, Wilke HJ, Schmoll HJ, Poliwoda H. High dose Ara-C and etoposide in the treatment of refractory or relapsing acute leukemia. *Blut* 1987; 55: 215.
36. Freund M, Barthels M, Link H, Diedrich H, Wilke HJ, Lux E, Poliwoda H. Plasmatic coagulation and fibronectin during treatment of AML with intensive chemotherapy. *Blut* 1987; 55: 286.
37. Link H, Kayser W, Gassmann W, Rister M, Stoll M, Schmid HJ, Freund M, etal. Autologous and allogeneic bone marrow transplantation in advanced Hodgkin's disease. *Blut* 1987; 55: 274.
38. Link H, Freund M, Diedrich H, Wilke H, Henke M, Hecht T, Wandt H, etal. Combination chemotherapy for adult acute myeloid leukemia with mitoxantrone, cytosine arabinoside and VP-16. *Blut* 1987; 55: 214.
39. Schmoll HJ, Knoblauch T, Wilke HJ, Freund M, Poliwoda H. Salvage chemotherapy in disseminated testicular cancer. In: Biennial conference on chemotherapy of infectious diseases and malignancies, Munich: Futuramed Verlagsgesellschaft mbH, 1987; Abstr. 87.
40. Mitrou PS, Freund M, Kurrle E, Heil G, Link H, Ehninger G, Schlimok G, Hoelzer D. Aclarubicin (ACM) and cytosine-arabioside (Ara-C) in the treatment of acute myeloid leukemia (AML). In: Biennial conference on chemotherapy of infectious diseases and malignancies, Munich: Futuramed Verlagsgesellschaft mbH, 1987; Abstr. 222.
41. Ho AD, Lipp T, Ehninger G, Meyer P, Freund M, Illiger HJ. Mitoxantrone and VP-16 (Nove) - a highly effective and well tolerated regimen for refractory acute myeloid leukemia. In: Biennial conference on chemotherapy of infectious diseases and malignancies., Munich: Futuramed Verlagsgesellschaft mbH, 1987; Abstr. 356.
42. Von Wussow P, Freund M, Hartmann F, Diedrich H, Poliwoda H, Deicher H. Clinical significance of interferon antibodies. *Blut* 1987; 55: 256.
43. Schoeber C, Stahl M, Schmoll HJ, Poliwoda H, Freund M, Fink U, Schick H, Preusser P. and H. Wilke. A three day schedule of high dose leucovorin (L) plus 5- fluorouracil(F) in untreated patients with progressive and advanced colorectal cancer - phase I/II study. *Blut* 1987; 55: 264.
44. Stahl M, Schoeber C, Kirchner HH, Diedrich H, Gust R, Schmoll HJ, Freund M, Poliwoda H. and H. Wilke. Hormone therapy of progressive and metastatic renal cell carcinoma (RCC) with high dose - tamoxifen (HD-TAM). *Blut* 1987; 55: 277.
45. Diedrich H, Freund M, Schmoll HJ, Wilke H, von Wussow P. Phase II - trial of a combination therapy with vinblastin (VBL), alpha - human - leukocyte interferon (hu IFN alpha) and tamoxifen in advanced renal cell carcinoma (RCC). *Proc 4th Europ Conf Clin Oncol* 1987; 4: 61.
46. Wilke H, Stahl M, Schoeber C, Kirchner H, Diedrich H, Freund M, Poliwoda H, Schmoll HJ. Increased response rates in progressive and metastatic renal cell carcinoma using high dose (HD) tamoxifen. *Proc 4th Europ Conf Clin Oncol* 1987; 4: 68.
47. Wilke H, Fink U, Preusser P, Schoeber C, Stahl M, Freund M, Schick H, Poliwoda H. HJ Schmoll. Phase I/II study of high dose folinic acid (FA) plus 5-fluorouracil in progressive advanced colorectal cancer - a three day schedule. *Proc 4th Europ Conf Clin Oncol* 1987; 4: 83.
48. Freund M, von Wussow P, Diedrich H, LeBlanc L, Link H, Poliwoda H. Treatment of chronic myelogenous leukemia (CML) with interferon alpha 2 b. *Proc 4th Europ Conf Clin Oncol* 1987; 4: 172.
49. Link H, Freund M, Diedrich H, Wilke H, Austein J, Poliwoda H. Mitoxantrone, cytosine-arabioside and VP-16 for therapy of refractory, relapsed and untreated acute myeloid leukemia. *Proc 4th Europ Conf Clin Oncol* 1987; 4: 174.

50. Link H, Freund M, Stoll M, Schmid H, Bucsky P, Schulz G, Schmidt R, Riehm H, Poliwoda H, Welte K. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF): preliminary results in patients following bone marrow transplantation. *Blood* 1987; 70 (Suppl.1): 310-310. (Abstract)
51. Valleé D, von Pawel J, Freund M, Schmoll HJ, Wilke H. Phase-II-study with etoposide (E) / vincristine (V) in extensive disease small cell lung cancer (SCLC). *J Cancer Res Clin Oncol* 1988; 114 (Suppl.):8-8.
52. Anagnou J, Avenarius HJ, Diedrich H, Eisert R, Freund M, Kirchner H, LeBlanc S, Metzner B, Poliwoda H. Bone marrow biopsy (Jamshidi needle) revisited. II.: Complications on the basis of 7000 biopsies. *J Cancer Res Clin Oncol* 1988; 114 (Suppl.):49-49.
53. Anagnou J, Avenarius HJ, Diedrich H, Eisert R, Freund M, Kirchner H, LeBlanc S, Metzner B, Poliwoda H. Bone marrow biopsy (Jamshidi) revisited. I: Indications, success rate, quality of trephine specimens and other characteristics on the basis of 7000 biopsies. *J Cancer Res Clin Oncol* 1988; 114 (Suppl.):49-49. (Abstr)
54. Exeriede G, Freund M, Eisert R, Von Wussow P, Pohl U, Poliwoda H. Natural interferon α (nIFN α) in a patient with CML and antibodies to rIFN α 2b. *J Cancer Res Clin Oncol* 1988; 114 (Suppl.):110-110. (Abstr)
55. Link H, Kirchner H, Freund M, Stoll M, Seidel J, Schmid H, Schmidt RE, Bucsky P, Schulz G, Riehm H, Poliwoda H, Welte K. Recombinant human granulocyte-macrophage colony stimulating factor (rh-GM-CSF) for hematological reconstitution after bone marrow transplantation: first clinical results. *J Cancer Res Clin Oncol* 1988; 114 (Suppl.):115-115. (Abstr)
56. Diedrich H, Freund M, Von Wussow P, Eisert R, Metzner B, Poliwoda H. Low dose recombinant interferon α 2b in chronic myelogenous leukemia: results and questions. *J Cancer Res Clin Oncol* 1988; 114 (Suppl.):146-146. (Abstr)
57. Freund M, Calvrezos A, De Boben M, Diedrich H, Ganser A, Heil G, Heyll A, Henke M, Hiddemann W, Hoelzer D, Koch P, Link H, Planker M, Renner D, Schmitz N. Treatment of relapsing acute lymphocytic leukemia in adults. *J Cancer Res Clin Oncol* 1988; 114 (Suppl.):174-174. (Abstr)
58. Metzner B, Möllers M, Schildmann I, Freund M, Kirchner HH, Schmoll HJ, Poliwoda H. Late toxicity in patients with high-grade Non-Hodgkin-Lymphoma. *J Cancer Res Clin Oncol* 1988; 114 (Suppl.):176-176. (Abstr)
59. Wilke H, Achterrath W, Gunzer U, Fink U, Preusser P, Schmoll HJ, Mayr AC. Etoposide (VP-16) and split dose Cisplatin (DDP) for NSCLC. *Proc Am Soc Clin Oncol* 1987; 6:180-180.(Abstr)
60. Wilke H, Behre W, Brömsen J, Reile D, Hemelt H, Harstrick A, Freund M, Meyer HJ, Poliwoda H, Schmoll HJ. Comparison of different schedules of anthracyclines in human gastric cancer (GC) xenografts. 13th Congr Europ Soc Med Oncol 1988; 13:105-105.(Abstr)
61. Kemnitz J, Freund M, Dominis M, Georgii A. The heterogeneous phenotype of leukaemic cells in adult acute lymphoblastic leukaemias (in the system of CD-10: CD-13). *Blut* 1988; 57:188-188.(Abstr)
62. Freund M, Bleßmann B, Buchholz F, Eisert R, Tischler J, Metzner B, Von Wussow P, Poliwoda H. Recombinant interferon alpha-2b maintenance after busulfan-induction in chronic myelogenous leukemia (CML). *Blut* 1988; 57:195-195.(Abstr)
63. Freund M, Dierich M, Metzner B, Link H, Schmoll HJ, Poliwoda H. Combination of ID MTX, Ara-C, and VM26 in heavily pretreated patients with relapsing of refractory non-Hodgkin's lymphoma (NHL). *Blut* 1988; 57:196-196.(Abstr)
64. Metzner B, Freund M, Casper J, Diedrich H, Engert A, Kirchner HH, Tischler HJ, Von Wussow P, Schmoll HJ, Poliwoda H. Treatment of adult patients with disseminated high-grade lymphomas of the B-type. *Blut* 1988; 57:197-197.(Abstr)
65. Kirchner H, Stoll M, Schmid HJ, Bucski P, Seidel J, Atzpodien J, Poliwoda H, Link H. Allogeneic and autologous bone marrow transplantation (BMT) after high dose busulfan and cyclophosphamide treatment. *Blut* 1988; 57:198-198.(Abstr)
66. Körfer A, Kirchner H, Atzpodien J, Freund M, Poliwoda H. Expression of p145 in normal and malignant bone marrow. *Blut* 1988; 57:212-212.(Abstr)
67. Link H, Seidel J, Kirchner H, Freund M, Schulz G, Stoll M, Schmidt RE, Bucski P, Riehm H, Poliwoda H, Welte K. Influence of recombinant human granulocyte-macrophage colony stimulating factor (rh-GM-CSF) on hematological reconstitution after autologous and allogeneic bone marrow transplantation. *Blut* 1988; 57:217-217.(Abstr)
68. Von Wussow P, Hartmann F, Freund M, Poliwoda H, Deicher H. Natural IFN-alpha therapy in rIFN-alpha 2b resistant patients. *Blut* 1988; 57:223-223.(Abstr)
69. Tischler HJ, Deinhardt J, Freund M, Poliwoda H. Platelet function in patients with chronic myeloid leukemia (CML) and chronic myeloproliferative disease (CMPD). Variations with Interferon alpha 2 therapy. *Blut* 1988; 57:242.(Abstr)
70. Marschal O, Freund M, Link H, Wilke HJ, Engert A, Kirchner HH, Poliwoda H. High dose intravenous immunoglobulins (IG) in patients refractory to platelet transfusions. *Blut* 1988; 57:244-244.(Abstr)
71. Freund M, De Boben M, Diedrich H, Ganser A, Heil G, Heyll A, Henke M, Hiddemann W, Hoelzer D, Koch P, Küchler R, Link H, Planker M, Renner D, Schmitz N. Treatment of relapse acute lymphocytic leukemia in adults. *Blut* 1988; 57:248-248.(Abstr)

72. Link H, Atzpodien J, Kirchner H, Stahl M, Volgmann T, Mohr H, Pohl U, Freund M, Schmoll HJ, Poliwoda H. Phase I/II trial of natural interleukin-2 (nIL-2) plus lymphokine-activated killer (LAK) cells in patients with advanced and/or metastatic cancer. *Blut* 1988; 57:249-249.(Abstr)
73. Von Wussow P, Freund M, Block B, Diedrich H, Schmoll HJ, Poliwoda H, Deicher H. Continuous low dose IFN alpha-2b therapy: a four year follow-up study. *Blut* 1988; 57:256-256.(Abstr)
74. Freund M, Wunsch S, Schäfers M, Diedrich H, Hiddemann W, Kienast J, Koch O, Koch P, Link H, Schmoll HJ, Poliwoda H. Pilot study of prednimustine and mitoxantrone (PmM) in patients with chronic lymphocytic leukemia (CLL) and Ip-immunocytoma (IC). *Blut* 1988; 57: 264-264.(Abstr)
75. Stoll M, Freund M, Schmid H, Riehm H, Deicher H, Poliwoda H, Link H. Chemotherapy-resistant Langerhans' cell histiocytosis (LCH) and allogeneic bone marrow transplantation. *Blut* 1988; 57:198-198.(Abstr)
76. Freund M, Diedrich H, Von Wussow P, Eisert R, Link H, Poliwoda H. Treatment of chronic myelogenous leukemia (CML) with low doses of recombinant interferon (IFN) alfa-2b. *Proc XXII Cong Internat Soc Hematol* 1988; 337-337.(Abstr)
77. Hoelzer D, Thiel E, Löffler H, Ganser A, Völkers B, Büchner T, Freund M, Heil G, Hiddemann W, Maschmeyer G, Messerer D. Results of the german multicentre trial for treatment of adult acute lymphoblastic leukemia (ALL). *Proc XXII Cong Internat Soc Hematol* 1988; 48-48.(Abstr)
78. Kurrle E, Ehninger G, Fackler-Schwalbe E, Freund M, Heil G, Hoelzer D, Link H, Löffler B, Löscher A, Mitrou PS, Öhl S, Queißer W, Schlimok G, Wandt H. Consolidation therapy with high-dose cytosine arabinoside in acute myeloid leukaemia. Experiences of a prospective study. *Acute leukemias. Prognostic factors and treatment strategies* 1989; 2:6-6.(Abstr)
79. Ehninger G, Fackler-Schwalbe E, Freund M, Heil G, Henke M, Hoelzer D, Hoffmann R, Kurrle E, Link H, Löscher A, Mitrou PS, Queißer W, Schlimok G, Wandt H. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. *Acute leukemias. Prognostic factors and treatment strategies* 1989; 2:18-18.(Abstr)
80. Link H, Freund M, Diedrich H, Wilke H, Austein J, Henke M, Wandt H, Fackler-Schwalbe E, Schlimok G, Hoffmann R, Calavrezos A, Poliwoda H. Mitoxantrone, cytosine-arabinoside and VP-16 (MAV) in 36 patients with relapsed and refractory acute myeloid leukemia. *Acute leukemias. Prognostic factors and treatment strategies* 1989; 2:19-19.(Abstr)
81. Hoelzer D, Thiel E, Löffler H, Büchner T, Freund M, Ganser A, Heil G, Hiddemann W, Maschmeyer G, Völkers B, Messerer D, Aydemir U. Treatment of adult ALL in the German multicenter trials. *Acute leukemias Prognostic factors and treatment strategies* 1989; 2:23-23.(Abstr)
82. Thiel E, Bartram CR, Kranz BR, Rhagavachar A, Ludwig WD, Ganser A, Büchner T, Heil G, Hiddemann W, Freund M, Maschmeyer G, Messerer D, Hoelzer D. Clinical importance of T-ALL subclassification according to thymic or prethymic maturation degree. *Acute leukemias Prognostic factors and treatment strategies* 1989; 2: 23-23.(Abstr)
83. Link H, Maschmeyer G, Wendt F, Freund M, Scharf RE, Wolf HH, Böhme A, Hoelzer D, Meyer P, Wilms K, Dunker D, De Boben K, Ho AD, Lathan B, Sauer S, Hartlapp JH, Höffken G, Hiddemann W, Essinck M, Hallen M, Letzel H, Helmerking M, Schmitt J, Stille W, Adam D. Empiric antimicrobial therapy in neutropenic patients with fever: The prospective randomized trial of the Paul Ehrlich Society for Chemotherapy. *Acute leukemias.Prognostic factors and treatment strategies* 1989; 2:25-25.(Abstr)
84. Freund M, De Boben M, Diedrich H, Ganser A, Heil G, Heyll A, Henke M, Hiddemann W, Hoelzer D, Koch P, Küchler R, Link H, Maschmeyer G, Planker M, Renner D, Schmitz N. Treatment of relapsed acute lymphocytic leukemia in adults. *Acute leukemias Prognostic factors and treatment strategies* 1989; 2:31-31.(Abstr)
85. Link H, Seidel J, Bucsky P, Freund M, Stoll M, Kirchner H, Linderkamp C, Schulz G, Gassmann W, Schmitz N, Welte K, Riehm H, Poliwoda H. Regeneration of granulopoiesis with recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation. *Acute leukemias Prognostic factors and treatment strategies* 1989; 2:41-41.(Abstr)
86. Joraschkewitz M, Trijssenaar J, Krumwieg D, Neukam D, Meyer HJ, Freund M, Poliwoda H, Hanauske A-R. Effects of recombinant cytokines on clonogenic cells from primary human tumors. *Molecular Biotherapy* 1989; 1 (Suppl.):A26. (Abstr)
87. Depenbrock H, Trijssenaar J, Neukam D, Meyer H-J, Freund M, Poliwoda H, Hanauske A-R. Growth factor-dependent stimulation of primary human tumor cells. *Molecular Biotherapy* 1989; 1 (Suppl.):A130. (Abstr)
88. Freund M, Fonatsch C, Blessmann B, Tischler J, Eisert R, Von Wussow P, Exeriede G, Hiddemann W, Link H, Wilke H, Buhr Th, Poliwoda H. Interferon α -2b in CML. Experiences with two treatment regimen. *Molecular Biotherapy* 1989; 1 (Suppl.):A78.(Abstr)
89. Link H, Burdach S, Seidel J, Stoll M, Kirchner H, Linderkamp C, Freund M, Ebell W, Bucsky P, Welte K, Riehm H, Hauch M, Schmitz N, Gassmann W, Harabacz I, Schulz G, Poliwoda H. Recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation. *Molecular Biotherapy* 1989; 1 (Suppl.):A23.(Abstr)
90. Link H, Ebell W, Diedrich H, Seidel J, Bucsky P, Stoll M, Freund M, Sens B, Kirchner H, Schmid H, Riehm H, Poliwoda H. High dose VP16 and total body irradiation as conditioning for allogeneic and autologous bone marrow transplantation in acute lymphoblastic leukemia and Non-Hodgkin's lymphoma. *Molecular Biotherapy* 1989; 1 (Suppl.):A155.(Abstr)

91. Engert A, Exeriede G, Steinmeier O, Barthels M, Poliwoda H, Freund M. Recombinant human tumor necrosis factor (rhTNF) administered as a 24h infusion in CML blastic phase (CML-BC) or AML and its effects on WBC and coagulation. *Molecular Biotherapy* 1989; 1 (Suppl.):A126.(Abstr)
92. Exeriede G, Doering G, Lux E, Poliwoda H, Freund M. Influence of busulfan or interferon alfa treatment on cluster forming cells from bone marrow and peripheral blood in patients with CML in chronic phase. *Molecular Biotherapy* 1989; 1 (Suppl.):A95.(Abstr)
93. Tischler H-J, Harstrick A, Schöber Ch, Freund M, Schmoll H-J, Poliwoda H. Recombinant interferon alfa-2b in patients with advanced osteosarcoma after aggressive chemotherapy. *Molecular Biotherapy* 1989; 1 (Suppl.):A99.(Abstr)
94. Ebell W, Bucsky P, Diedrich H, Seidel J, Stoll M, Freund M, Sens B, Tischler J, Brune H, Riehm H, Poliwoda H, Link H. Use of recombinant human erythropoietin after bone marrow transplantation. *Molecular Biotherapy* 1989; 1 (Suppl.):A53.(Abstr)
95. Link H, Freund M, Sens B, Hoffmann A, Atzpodien J, Kirchner H, Stahl M, Schöber C, Volgmann Th, Mohr H, Andres J, Pohl U, Schmoll H-J, Poliwoda H. Natural interleukin-2 (nIL-2) plus lymphokine-activated killer (LAK) cells in patients with advanced malignancy. *Molecular Biotherapy* 1989; 1 (Suppl.):A118.(Abstr)
96. Wilke H, Preusser P, Fink U, Köhne-Wömpner Ch, Achterrath W, Stahl M, Geerlings H, Lenaz L, Harstrick A, Meyer HJ, Meyer J, Wegener G, Freund M, Schmoll H-J. Prognostic factors relating to effective chemotherapy in advanced gastric carcinoma. *Proc ECCO* 1989; 5:O-0635.(Abstr)
97. Freund M, Fonatsch C, Von Wussow P, Wilke H, Poliwoda H. Interferon alpha-2b in CML. Comparison of two treatment regimen. *Proc ECCO* 1989; 5:O-0720.(Abstr)
98. Freund M, Wunsch S, Link H, Wilke H, Schäfers M, Poliwoda H. Prednimustine and Mitoxantrone (PmM) in patients with CLL, immunocytoma (IC), and centrocytic/ centroblastic NHL. *Proc ECCO* 1989; 5:P-0399.(Abstr)
99. Wilke H, Preusser P, Stahl M, Fink U, Schöber C, Achterrath W, Lenaz L, Harstrick A, Meyer HJ, Meyer J, Freund M, Schmoll H-J. Leucovorin (L), etoposide (E), 5-FU (F), Cisplatin (P) = FLEP - a pilot study in advanced gastric (GC) and esophageal (EC) carcinoma. *Proc ECCO* 1989; 5:P-0694.(Abstr)
100. Freund M, Koch P, Maschmeyer G. Treatment of relapsed acute lymphocytic and undifferentiated leukaemia in adults. *Proc ECCO* 1989; 5:P-0778.(Abstr)
101. Exeriede G, Lux E, Doehring G, Engert A, Poliwoda H, Freund M. Cluster and colony formation from bone marrow (BM) and peripheral blood during different stages of CML. *Proc ECCO* 1989; 5:P-0779.(Abstr)
102. Harstrick A, Wilke H, LeBlanc S, Stahl M, Freund M, Schmoll E, Bergmann L, Klee M, Scherpe M, Bartels H, Poliwoda H, Schmoll H-J. Cisplatin (P), etoposide (E) and ifosfamide (I) (PEI) salvage in relapsing of refractory nonseminomatous germ cell cancer (NSGCC). *Proc ECCO* 1989; 5:P-0843.(Abstr)
103. Engert A, Exeriede G, Rössler M, Poliwoda H, Freund M. Treatment with interferon gamma in a patient with chronic granulomatous disease (CGD). *Blut* 1989; 59: 330-330.(Abstr)
104. Exeriede G, Lux E, Doehring G, Poliwoda H, Freund M. Cluster and colony formation from bone marrow (BM) and peripheral blood (PB) during different stages of CML. *Blut* 1989; 59:267-267.(Abstr)
105. Exeriede G, Diedrich H, Link H, Kempeni J, Möller A, Poliwoda H, Freund M. Tumor necrosis factor alpha (TNF-alpha) serum levels in patients after autologous and allogeneic bone marrow transplantation (BMT). *Blut* 1989; 59:329-329.(Abstr)
106. Kleine HD, Birnbach A, Exeriede G, Poliwoda H, Freund M. Results and prognosis of acute non-lymphocytic leukemia in adults: non-selective retrospective study from 319 patients in the years 1977 - 1987. *Blut* 1989; 59:270-270.(Abstr)
107. Heuer A, Trijssenaar J, Freund M, Meyer H-J, Poliwoda H, Hanauske A-R. Value of enzymatic tissue disintegration for culture of primary human tumor specimens. *Blut* 1989; 59:278-278.(Abstr)
108. Depenbrock H, Trijssenaar J, Neukam D, Meyer H-J, Freund M, Poliwoda H, Hanauske A-R. Stimulation of primary tumor cells by EGF, insulin and transferrin: a head to-head comparison. *Blut* 1989; 59:336-336.(Abstr)
109. Joraschkewitz M, Trijssenaar J, Freund M, Krumwieg D, Poliwoda H, Hanauske A-R. Recombinant G-CSF, and IL-3 stimulate clonogenic growth fo human breast cancer cells. *Blut* 1989; 59:337-337.(Abstr)
110. Link H, Diedrich H, Freund M, Ebell W, Bucsky P, Stoll M, Burdach S, Schmitz N, Schulz G, Poliwoda H. Use of hematopoietic growth factors after bone marrow transplantation. *Blut* 1989; 59:292-292.(Abstr)
111. Joraschkewitz M, Trijssenaar J, Freund M, Neukam D, Krumwieg D, Meyer H-J, Poliwoda H, Hanauske A-R. GM-CSF, G-CSF, and IL-3 stimulate anchorageindependent growth of primary tumor cells. *Blut* 1989; 59:294-294. (Abstr)
112. Kemnitz J, Freund M, Dominis M, Cohnert TR, Uysal A, Schmoll H-J, Stangel W, Georgii A. Detection of cells with multidrug-resistant phenotype in myeloproliferative disorders before therapy. *Blut* 1989; 59:296-296. (Abstr)
113. Nafe R, Buhr Th, Freund M, Georgii A. Effects of different therapy regimens on megakaryopoiesis in CML - a comparison of bone marrow histology in busulfan- and interferon-treated patients. *Blut* 1989; 59:296-296. (Abstr)

114. Maschek H, Freund M, Fritsch RS, Buhr Th, Georgii A. Megakaryoblastic leukemia as outcome of myelodysplastic syndrome with myelofibrosis. *Blut* 1989; 59:268-268.(Abstr)
115. Tischler H-J, Freund M, Harstrick A, Schöber C, Poliwoda H, Schmoll H-J. Recombinant interferon alfa-2b in patients with advanced osteosarcoma after aggressive chemotherapy. *Blut* 1989; 59:322-322.(Abstr)
116. Tischler H-J, Eisert R, Fonatsch C, Avenarius HJ, Poliwoda H, Freund M. Recombinant interferon alfa-2b in the treatment of essential thrombocythemia. *Blut* 1989; 59:251-251.(Abstr)
117. Freund M, Fonatsch C, Bleßmann B, Stiller S, Buchholz F, Von Wussow P, Link H, Wilke H, Poliwoda H. Interferon alpha-2b in CML. Comparison of two treatment regimen. *Blut* 1989; 59:295-295.(Abstr)
118. Freund M, Wunsch S, Link H, Wilke H, Schäfers M, Poliwoda H. Prednimustine and mitoxantrone (PmM) in patients with CLL, immunocytoma (IC) and centrocytic/ centroblastic NHL. *Blut* 1989; 59:345-345.(Abstr)
119. Freund M, De Boben M, Diedrich H, Ganser A, Heil G, Heyll A, Henke M, Hiddemann W, Hoelzer D, Knauf W, Koch P, Körbling M, Küchler R, Link H, Maschmeyer G, Planker M, Renner D, Schadeck-Gressel C, Schmitz N, von Verschuer U, Wilhelm S. Treatment of relapsed acute lymphocytic and undifferentiated leukemia in adults. *Blut* 1989; 59:302-302.(Abstr)
120. Möllers M, Schmoll H-J, Metzner B, Freund M, Wilke H, Poliwoda H. Late toxicity in patients with high-grade Non-Hodgkin's-lymphoma. *Blut* 1989; 59:315-315.(Abstr)
121. Wilke H, Preusser P, Stahl M, Fink U, Achterrath W, Harstrick A, Lenaz L, Meyer H-J, Meyer J, Freund M, Poliwoda H, Schmoll H-J. Pilot study with 5-fluoro-uracil (F), leucovorin (L), etoposide (E), cisplatin (P) (FLEP) in advanced upper gastrointestinal carcinomas. *Blut* 1989; 59:316-316.(Abstr)
122. Harstrick A, Wilke H, LeBlanc S, Stahl M, Freund M, Schmoll E, Bergmann L, Klee M, Lammers U, Scherpe, Poliwoda H, Schmoll H-J. Cisplatin (P), etoposide (E) and ifosfamide (I) (PEI) salvage in relapsing or refractory nonseminomatous germ cell cancer (NSGCC). *Blut* 1989; 59:304-304.(Abstr)
123. Wilke H, Preusser P, Fink U, Köhne-Wömpner CH, Achterrath W, Stahl M, Geerlings H, Lenaz L, Harstrick A, Meyer H-J, Meyer J, Wegener G, Freund M, Link H, Schmoll H-J. Factors predictive for response and survival in chemotherapeutically treated patients with gastric carcinoma (GC) - results of a multivariate analysis. *Blut* 1989; 59:257-257.(Abstr)
124. Von Wussow P, Pralle H, Jakschies D, Freund M, Deicher H. Development of clinical resistance to cytokines. *Blut* 1989; 59:294-294.(Abstr)
125. Freund M, Engert A, Exeriede G, Steinmeier O, Barthels M, Schmoll H-J, Poliwoda H. Recombinant human Tumor Necrosis Factor (rhTNF) administered as a 24h infusion in CML blastic phase (CML-BC) or AML and its effect on WBC and coagulation. *Blut* 1989; 59:329-329.(Abstr).
126. Schubert J, Kolanus W, Uciechowski P, Freund M, Schmidt RE. The CD16 (Fc gamma RIII) defect in patients with paroxysmal nocturnal hemoglobinuria. XV Annual Meeting of the EBMT 1989; 15:155-155.(Abstr)
127. Wilke H, Preusser P, Fink U, Köhne-Wömpner Ch, Achterrath W, Stahl M, Meyer H-J, Lenaz L, Freund M, Schmoll H-J. Clinical outcome and prognostic factors in 145 patients with advanced gastric cancer treated with EAP. EORTC Symposium on advances in gastrointestinal tract cancer research and treatment 1989; 1:43-43.(Abstr)
128. Freund M. Alpha-Interferone in der Therapie der Non-Hodgkin-Lymphome (NHL). *Onkologie* 1989; 12:302-303.(Abstr)
129. Freund M, Wunsch S, Link H, Wilke H, Wysk J, Schäfers M, Poliwoda H. Prednimustine and mitoxantrone (PmM) in patients with CLL, PLL, immunocytoma (IC) and centrocytic/centroblastic NHL. Fourth International Conference on Malignant Lymphoma, Lugano 1990; T53 (Abstr)
130. Freund M, Ganser A, Heil G, Heyll A, Hiddemann W, Knauf U, Koch P, Link H, Maschmeyer G, Planker M, Schadeck-Gressel C, Schmitz N, v. Verschuer U, Wilhelm S, Hoelzer D. Treatment of adult acute lymphocytic (ALL) and undifferentiated leukemia (AUL) in relapse. Fourth International Conference on Malignant Lymphoma, Lugano 1990; T104 (Abstr)
131. Joraschkewitz M, Depenbrock H, De Riese W, Krumwieg D, Freund M, Poliwoda H, Hanauske A-R. Effects of GM-CSF, G-CSF, and IL-3 on clonogenic growth of primary renal cancer cells in vitro. *J Cancer Res Clin Oncol* 1990; 116 (Suppl.):280.(Abstr)
132. Freund M, Fonatsch C, LeBlanc S, Stiller S, Von Wussow P, Link H, Wilke H, Poliwoda H. Interferon (IFN) α -2b in CML. Comparison of two treatment regimen. *J Cancer Res Clin Oncol* 1990; 116 (Suppl.):305.(Abstr)
133. Kleine HD, Radde P, Poliwoda H, Freund M. A method detecting effects of cytokines on bone marrow aspirates from patients with acute myeloic leukemia and myelodysplastic syndrome. *J Cancer Res Clin Oncol* 1990; 116 (Suppl.):274.(Abstr)
134. Exeriede G, Ganser A, Heil G, Heyll A, Hiddemann W, Knauf U, Koch P, Link H, Maschmeyer G, Planker M, Schadeck-Gressel C, Schmitz N, von Verschuer U, Wilhelm S, Hoelzer D, Freund M. Adult acute lymphocytic and undifferentiated leukaemia in relapse: Treatment and Prognosis. *J Cancer Res Clin Oncol* 1990; 116 (Suppl.):596.(Abstr)
135. Freund M, Exeriede G, Steinmeier O, Kleine HD, Kempeni J, Barthels M, Schmoll H-J, Poliwoda H. Phase I/II trial with TNF α in CML and AML. *J Cancer Res Clin Oncol* 1990; 116 (Suppl.):1057.(Abstr)

136. Von Wussow P, Pralle H, Jakschies D, Freund M, Hochkeppel HK, Deicher H. Increased serum rIFN- α -antibody level are a clinically important side effect of rIFN- α 2-treatment. *J Cancer Res Clin Oncol* 1990; 116 (Suppl.):1114.(Abstr)
137. Fonatsch C, Hild F, Freund M. Cytogenetic follow-up in patients with CML under treatment with interferon (IFN) alpha-2b. *J Cancer Res Clin Oncol* 1990; 116 (Suppl.):1172.(Abstr)
138. Tischler H-J, Eisert R, Avenarius HJ, Poliwoda H, Freund M. "Low dose" interferon alfa-2b in the treatment of essential thrombocythaemia. *J Cancer Res Clin Oncol* 1990; 116 (Suppl.):287.(Abstr)
139. Heussner P, Freund M, Luft S, Schöber C, Schrezenmaier H, Porzsolt F, Welte K. Differential effect of GM-CSF and G-CSF in a patient with cyclic neutropenia. *Blut* 1990; 61:85.(Abstr)
140. Hild F, Fonatsch Ch, Freund M. Cytogenic follow-up in patients with CML under treatment with interferon (IFN) alpha 2b. *Blut* 1990; 61:94.(Abstr)
141. Hauf FO, Haase D, Link H, Hanauske A-R, Meran J, Fonatsch C, Poliwoda H, Freund M. Prognostic significance of cytogenetics in AML. *Blut* 1990; 61:95.(Abstr)
142. Von Wussow P, Pralle H, Sonnen R, Jakschies D, Franke M, Fibich Ch, Freund M, Deicher H. Effective natural interferon-alpha therapy in recombinant interferon-alpha antibody positive hairy cell leukemia patients. *Blut* 1990; 61:97.(Abstr)
143. Diedrich H, Link H, Exeriede G, Ebell W, Bucsky P, Peest D, Kempeni J, Möller A, Poliwoda H, Freund M. Tumor necrosis factor (TNF α) serum levels in patients with bone marrow transplantation. *Blut* 1990; 61:119.(Abstr)
144. Link H, Diedrich H, Hübner G, Ebell W, Bucsky P, Peest D, Freund M, Brune Th, Poliwoda H. Recombinant human erythropoietin after bone marrow transplantation. *Blut* 1990; 61:123.(Abstr)
145. Kleine H-D, Exeriede G, Lux E, Rieder H, Fonatsch C, Poliwoda H, Freund M. A novel cell line derived from a patient with B-ALL: B 156. *Blut* 1990; 61:128.(Abstr)
146. Freund M, Kleine H-D, Lux E, Exeriede G, Hanauske A-R, Herbst H, Vainchenker W, Schweigerer L, Fonatsch C, Poliwoda H. ELF-153: a novel cell line derived from a patient with acute myelofibrosis and AML. *Blut* 1990; 61:128.(Abstr)
147. Bauer E, Hanauske-Abel HM, De Riese W, Meyer H-J, Sandner S, Poliwoda H, Freund M, Hanauske A-R. Effects of recombinant human erythropoietin on colony formation of human tumor cells in vitro. *Blut* 1990; 61:132.(Abstr)
148. Freund M, Exeriede G, Ganser A, Heil G, Heyll A, Hiddemann W, Knauf U, Koch P, Link H, Maschmeyer G, Planker M, Schadeck-Gressel C, Schmitz N, Schöber C, von Verschuer U, Wilhelm S, Hoelzer D. Relapsing adult ALL: duration of the preceding complete remission is a main prognostic factor. *Blut* 1990; 61:170.(Abstr)
149. Wagner U, Kleine H-D, Lux E, Kempeni J, Poliwoda H, Freund M. Determination by flow cytometric cell-cycle analysis of inhibition of proliferation by TNF α of AML cells. *Blut* 1990; 61:174.(Abstr)
150. Kleine H-D, Radde P, Wagner U, Poliwoda H, Freund M. A method for detecting effects of cytokines on bone marrow aspirates from patients with hematologic malignancies. *Blut* 1990; 61:177.(Abstr)
151. Wilke H, Preusser P, Stahl M, Casper J, Harstrick A, Meyer H-J, Freund M, Achterrath W, Poliwoda H, Schmoll H-J. Etoposide (E), leukovorin (L), and FU (F) (ELF) in advanced gastric cancer patients nonresponding to carboplatin (C). *Blut* 1990; 61:180.(Abstr)
152. Jahner M, Meyerdierks Ch, Trijssenaar J, Hanauske-Abel HM, Meyer H-J, Sandner S, De Riese W, Poliwoda H, Freund M, Hanauske A-R. Deoxyhypusine-hydroxylase inhibitors arrest clonal human tumor growth in vitro. *Blut* 1990; 61:185.(Abstr)
153. Meyerdierks Ch, Jahner M, Kleine H-D, Hanauske-Abel HM, Poliwoda H, Freund M, Hanauske A-R. Deoxyhypusine hydroxylase inhibitors: effects on cell cycle transition of human breast cancer cells. *Blut* 1990; 61:186.(Abstr)
154. Freund M, Hild F, LeBlanc S, Benter T, Hiddemann W, Koch O, Von Wussow P, Link H, Wilke H, Hanauske A-R, Fonatsch C, Poliwoda H. Interferon (IFN) α -2b in CML: an update of the Hannover-Münster-Bonn Experience. *Blut* 1990; 61:190.(Abstr)
155. Von Wussow P, Jakschies D, Freund M, Hehlmann H, Brockhaus F, Hochkeppel H, Horisberger M, Deicher H. Treatment of anti rIFN-alpha 2 antibody positive CML patients with natural interferon-alpha. *Blut* 1990; 61:190.(Abstr)
156. Bokemeyer C, Schmoll H-J, Möllers M, Metzner B, Freund M, Wilke H, Poliwoda H. Late toxicities in patients with high-grade Non-Hodgkin-Lymphoma. *Ann Oncol* 1990; 1 (Suppl.): 107. (Abstr)
157. Link H, Freund M, Diedrich H, Wilke H, Austein J, Henke M, Wandt H, Fackler-Schwalbe E, Schlimok G, Hoffmann R, Poliwoda H. Mitoxantrone, cytosine-arabioside and VP-16 (MAV) for the treatment of acute myeloid leukemia. *Ann Hematol* 1991; 63:A3.(Abstr)
158. Heil G, Freund M, Link H, Mitrou PS, Hoelzer D, Wandt H, Ehninger G, Fackler-Schwalbe E, Schlimok G, Löscher A, Queißer W, Löffler B, Kurrle E. Acute myeloid leukemia: an update of treatment results with high dose ara-C consolidation therapy. *Ann Hematol* 1991; 62:A22.(Abstr)
159. Freund M, Giller S, Hinrichs F, Baars A, Meran J, Körfer A, Wilke H, Link H, Poliwoda H. Treatment of high risk relapsing or refractory AML with m-AMSA and Id-araC. *Ann Hematol* 1991; 62:A24.(Abstr)

160. Freund M, Diedrich H, Ganser A, Gramatzki M, Heil G, Heyll A, Hiddemann W, Koch P, Link H, Maschmeyer G, Planker M, Schadeck-Gressel C, Schmitz N, Weiss A, Wilhelm S, Hoelzer D. Treatment of relapsing or refractory adult acute lymphocytic leukemia (ALL). Updated results. *Ann Hematol* 1991; 62:A24.(Abstr)
161. Link H, Hübner G, Freund M, Schneider B, Wandt H, Schönrock-Nabulsi P, Gramatzki M, Queißer W, Fackler-Schwalbe E, Löffler B, Raab C, Öhl S, Brack U, Gabius S, Ehninger G. Comparative trial of postremission therapy in acute myeloblastic leukemia: better survival after allogeneic bone marrow transplantation or high dose cytosine-arabioside than after autologous bone marrow transplantation. *Ann Hematol* 1991; 62:A27.(Abstr)
162. Freund M, Fonatsch C, Von Wussow P, Hiddemann W, Koch O, Kleine HD, Link H, Poliwoda H. Interferon in the treatment of CML - the Hannover experience. *Ann Hematol* 1991; 62:A97.(Abstr)
163. Haase D, Fonatsch C, Freund M. Sequential chromosome analysis in patients with myelodysplastic syndromes receiving rhGM-CSF. *Ann Hematol* 1991; 62:A119.(Abstr)
164. Hild F, Rieder H, Freund M, Fonatsch C. Complex karyotype evolution influenced by interferon therapy in a case of Ph⁺-positive CML. *Ann Hematol* 1991; 62:A121.(Abstr)
165. Hanauske A-R, Bauer E, Danhauser-Riedl S, De Riese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J. Effects of recombinant human erythropoietin on clonogenic growth of primary human tumor specimens in vitro. *Ann Hematol* 1991; 62:A120.(Abstr)
166. Hanauske A-R, Bauer E, Danhauser-Riedl S, Welte K, De Riese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J. Effects of Interleukin-6 on soft agar colony formation of primary solid tumor specimens. *Ann Hematol* 1991; 62:A61.(Abstr)
167. Oelke M, De Riese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. Effects of IL-4, IL-5, and IL-7 on clonogenic growth of primary human tumors in vitro. *Ann Hematol* 1991; 62:A104.(Abstr)
168. Donné S, De Riese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. M-CSF fails to modulate clonogenic growth of primary human tumors in vitro while interleukin-1 stimulates colony formation. *Ann Hematol* 1991; 62:A103.(Abstr)
169. Haase D, Fonatsch C, Freund M, Bodenstein H, Bartels H. Differential response of cytogenetically abnormal cell clones in MDS to cytokines in vitro. *Ann Hematol* 1991; 62:A104.(Abstr)
170. Kleine HD, Wagner U, Poliwoda H, Freund M. Effects of TNF alpha on AML-cells measured by flow cytometric detection of bromodesoxyuridine incorporation. *Ann Hematol* 1991; 62:A124.(Abstr)
171. Raghavachar A, Hinterberger W, Kaltwasser JP, Höffken K, Herrmann F, Freund M, Platzer E, Frisch J, Heimpel H, Frickhofen N. Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) in aplastic anemia - a phase I/II trial with emphasis on very severe neutropenia and active infection. *Ann Hematol* 1991; 62:A96.(Abstr)
172. Freund M, Kleine HD, Steinmeier O, Link H, Kempeni J, Poliwoda H. Treatment of patients with AML and advanced CML with recombinant tumor necrosis factor (TNF) α . *Ann Hematol* 1991; 62:A123.(Abstr)
173. Diedrich H, Link H, Ebell W, Peest D, Kempeni J, Möller A, Poliwoda H, Freund M. Tumor necrosis factor (TNF) α in the course of allogeneic and autologous bone marrow transplantation (BMT). *Ann Hematol* 1991; 62:A116.(Abstr)
174. Freund M, Diedrich H, Kleine HD, Ebell W, Peest D, Link H. Interleukin-1 (IL-1) and interleukin-6 (IL-6) serum levels in patients with allogeneic or autologous bone marrow transplantation (BMT). *Ann Hematol* 1991; 62:A117.(Abstr)
175. Steinke B, Manegold Ch, Freund M, Reinold H-M, Arnold H, Heidemann E, Gracien E. G-CSF for dose-intensification of chemotherapy in high grade malignant non-Hodgkin's lymphomas (HG-NHL). *Eur J Cancer* 1991; Supp. 2:S234.(Abstr)
176. Steinke B, Bischoff HG, Manegold C, Freund M, Reinold HM, Arnold H, Heidemann E, Gracien E. G-CSF for dose-intensification of chemotherapy in high grade malignant non-Hodgkin's lymphomas (HG-NHL). *Onkologie* 1991; Suppl. 3:13.(Abstr)
177. Kleine HD, Lux E, Döhning G, Poliwoda H, Freund M. Effects of TNF α on bone marrow aspirates of patients with AML measured by flow cytometric cell-cycle analysis. *Onkologie* 1991; 14 (Suppl.2):84-85.(Abstr)
178. Ludwig WD, Harbott J, Bartram CR, Rieder H, Becher R, Heinze B, Sperling C, Hiddemann W, Gassmann W, Martin M, Nehmer A, Aydemir Ü, Freund M, Maschmeyer G, Völkers B, Dopfer R, Ritter J, Fonatsch C, Löffler H, Hoelzer D, Riehm H, Thiel E. Maturation stage, cell biologic features and clinical significance of myeloid-antigen positive acute lymphoblastic leukemia (My- ALL). *Onkologie* 1991; 14 (Suppl.2):100.(Abstr)
179. Freund M, Fonatsch C, Von Wussow P, Hiddemann W, Wörmann B, Koch O, Poliwoda H. New developments in the treatment of chronic myeloid leukemia. *Onkologie* 1991; 14 (Suppl.2):181.(Abstr)
180. Kleine HD, Lux E, Döhning G, Poliwoda H, Freund M. K-203: A new cell line from a patient with Pre-pre-B-ALL who shows a switch from B-lymphatic markers to myeloid and NK markers in first relapse. *Onkologie* 1991; 14 (Suppl.2):85.(Abstr)

181. Link H, Hübner G, Freund M, Schneider B, Wandt H, Schönrock-Nabulsi P, Gramatzki M, Queisser W, Fackler-Schwalbe E, Löffler B, Raab M, Öhl S, Brack U, Gabius S, Ehninger G. Postremission therapy in acute myeloblastic leukemia: comparative trial of allogeneic versus autologous bone marrow transplantation or high dose cytosine-arabioside. *Onkologie* 1991; 14 (Suppl.2):99.(Abstr)
182. Hild F, Rieder H, Freund M, Fonatsch C. Cytogenetic and molecular genetic findings in a case of Ph-positive CML with complex karyotype evolution influenced by interferon therapy. *Onkologie* 1991; 14 (Suppl.2):68.(Abstr)
183. Scheinichen D, Kleine HD, Piotrzokowski E, Lux E, Döhning G, Battmer K, Poliwoda H, Freund M. A comparison of methods for removing cells from bone marrow of patients with CLL. *Onkologie* 1991; 14 (Suppl.2):140.(Abstr)
184. Hiddemann W, Rottmann R, Wörmann B, Thiel A, Essink M, Ottensmeier C, Freund M, Büchner T, van de Loo J. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase II study. *Onkologie* 1991; 14 (Suppl.2):68.(Abstr)
185. Freund M, Heussner P, Sandoval M, Kanz L, Zeidler C, Welte K. Granulocyte colony-stimulating factor (G-CSF) for the treatment of adult patients with chronic idiopathic neutropenia and cyclic neutropenia. *Onkologie* 1991; 14 (Suppl.2):43-44.(Abstr)
186. Freund M, Fonatsch C, Von Wussow P, Hiddemann W, Wörmann B, Koch O, Kleine HD, Link H, Poliwoda H. Interferon α in the treatment of chronic myeloid leukemia. *Onkologie* 1991; 14 (Suppl. 2):44.(Abstr)
187. Tischler H-J, Exeriede G, Benter T, LeBlanc S, Avenarius HJ, Schmoll HJ, Freund M, Poliwoda H. Essential thrombocythaemia: successful treatment with 'low dose' interferon alfa-2b. *Onkologie* 1991; 14 (Suppl. 2):164.(Abstr)
188. Raghavachar A, Kaltwasser JP, Herrmann F, Freund M, Platzer E, Ganser A, Vogt HG, Schrezenmeier H, Frisch J, Heimpel H. A phase I/II trial of recombinant human interleukin-3 (rhu IL-3) added to cyclosporine and antilymphocyte globulin (ALG) in patients with refractory severe aplastic anemia. *Onkologie* 1991; 14 (Suppl. 2):129.(Abstr)
189. Atzpodiën J, Körfer A, Freund M, Link H, Buer J, Schlemmer B, Große J, Menzel T, Schomburg A, Poliwoda H, Kirchner H. Treatment of minimal residual disease in acute myeloid leukemia patients: experimental models using IL-2 activated cytotoxic lymphocytes. *Onkologie* 1991; 14 (Suppl.2):6.(Abstr)
190. Steinke B, Manegold Ch, Freund M, Reinold H-M, Arnold H, Heidemann E, Hecht Th. G-CSF for dose-intensification in high grade malignant Non-Hodgkin's lymphoma (HG-NHL). *Proc Am Soc Clin Oncol* 1991; 10:287.(Abstr)
191. Steinke B, Manegold Ch, Freund M, Arnold M, Reinold R-M, Lutz M, Hecht Th. G-CSF zur Therapieintensivierung bei hochmalignen Non-Hodgkin-Lymphomen. *Klin Wochenschr* 1991; 69 (Suppl. XXIII):219.(Abstr)
192. Kleine HD, Scheinichen D, Lux E, Poliwoda H, Freund M. Effects of TNF α and IFN α -2b on B-CLL cells determined by flow cytometric detection of bromodesoxyuridine incorporation. *Blood* 1991; 78 Suppl. 1:427a.(Abstr)
193. Link H, Hübner G, Freund M, Schneider B, Wandt H, Schönrock-Nabulsi P, Gramatzki M, Queisser W, Fackler-Schwalbe E, Löffler B, Raab M, Öhl S, Brack U, Gabius S, Fischer JT, Greer T, Ehninger G. Daunorubicin, Ara-C and VP16 (DAV) for adult acute myeloblastic leukemia followed by a prospective comparison of intensive postremission therapy. *Ann Hematol* 1992; 64:A89.(Abstr)
194. Freund M, Bodenstern H, Kleine H-D, Poliwoda H. A 12-years follow-up of 101 patients with acute myeloid leukemia (AML) treated in two studies. *Ann Hematol* 1992; 64:A89.(Abstr)
195. Kleine H-D, Wagner U, Lux E, Döhning G, Poliwoda H, Freund M. Effects of TNF α on AML-cells determined by flow cytometric technique based on bromodesoxyuridine incorporation. *Ann Hematol* 1992; 64:A108.(Abstr)
196. Donné S, Oelke M, De Riese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. Effects of M-CSF on tumor colony forming units from freshly explanted human malignancies in vitro. *J Cancer Res Clin Oncol* 1992; 118 (Suppl.):R26.(Abstr)
197. Donné S, Oelke M, De Riese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. IL-1 α and IL-1 β modulate clonogenic growth of primary human tumors and tumor cell lines in vitro. *J Cancer Res Clin Oncol* 1992; 118 (Suppl.):R26.(Abstr)
198. Donhuijsen K, Haedicke C, Freund M, Hattenberger S. GM-CSF-related eosinophilia and Loeffler's endocarditis. *J Cancer Res Clin Oncol* 1992; 118 (Suppl.):R53.(Abstr)
199. Kleine H-D, Scheinichen D, Lux E, Poliwoda H, Freund M. Effects of TNF α and IFN α -2b on B-CLL-cells determined by flow cytometric cell-cycle-analysis. *J Cancer Res Clin Oncol* 1992; 118 (Suppl.):R53.(Abstr)
200. Freund M, Fonatsch C, Von Wussow P, Grote-Metke A, Wörmann B, Nowak R, Kleine H-D, Poliwoda H. Treatment with interferon α and cytosin-arabioside of chronic myeloid leukemia. *J Cancer Res Clin Oncol* 1992; 118 (Suppl.):R104.(Abstr)
201. Tischler HJ, Avenarius HJ, Freund M, Poliwoda H. Essential thromocythaemia: successful treatment with "low-dose" interferon alfa-2b. *J Cancer Res Clin Oncol* 1992; 118 (Suppl.):R142.(Abstr)

202. Steinke B, Manegold Ch, Freund M, Reinold H-M, Fischer J-Th, Arnold M, Lengfelder E, Münz A. rG-CSF for dose-intensification of chemotherapy in high grade malignant Non-Hodgkin's lymphomas (HG-NHL). *J Cancer Res Clin Oncol* 1992; 118 (Suppl.):R166.(Abstr)
203. Oelke M, DeRiese W, Raab H-R, Meyer H-J, Neukam D, Hanauske U, Freund M, Poliwoda H, Rastetter J, Hanauske A-R. Interleukin-4 (IL-4), IL-5, IL-7: Assessment of growth-modulating effects on clonogenic tumor cells in vitro. *Ann Oncol* 1992; 3 (Suppl.1):171.(Abstr)
204. Freund M. Clinical significance of interferons in the treatment of malignant lymphomas. *Onkologie* 1992; 15:5.(Abstr)
205. Freund M, Heussner P, Sandoval M, Kanz L, Ottmann OG, Zeidler C, Welte K. Treatment with granulocyte colony-stimulating factor (G-CSF) of adult patients with chronic idiopathic neutropenia and cyclic neutropenia. *Br J Haematol* 1992; 82 (Abstr. ISH 1992):24.(Abstr)
206. Freund M, Hild F, Dohmen M, Von Wussow P, Grote-Metke A, Nowak R, Otremba B, Fonatsch C, Poliwoda H. Treatment with a combination of interferon α -2b and cytosin-arabinside of chronic myeloid leukemia. *Br J Haematol* 1992; 82 (Abstr. ISH 1992):353.(Abstr)
207. Bokemeyer C, Schmoll H-J, von Rhee J, Schrader A, Schuppert F, Freund M, Poliwoda H. Evaluation of late effects on gonadal function after treatment of Hodgkin's disease (HD). *Ann Hematol* 1992; 65 (Suppl.):A38.(Abstr)
208. Donhuijsen K, Haedicke Ch, Freund M, Hattenberger S. GM-CSF related eosinophilia and Loeffler's endocarditis. *Ann Hematol* 1992; 65 (Suppl.):A47.(Abstr)
209. Freund M, Hild F, Dohmen M, Von Wussow P, Grote-Metke A, Nowak R, Otremba B, Fonatsch C, Poliwoda H. Treatment with a combination of interferon α -2b and cytosin-arabinside of chronic myeloid leukemia. *Ann Hematol* 1992; 65 (Suppl.):A55.(Abstr)
210. Gassmann W, Löffler H, Ludwig W-D, Sperling C, Uharek L, Thiel E, Freund M, Becher R, Donhuijsen-Ant R, Lengfelder E, Weh HJ, Aul C, Tirier C, Hagemann FG, Fuhr HG, Heil G, Kaboth W, Wandt H, Koch P, Hoelzer D, Sauerland MC, Büchner Th. The FAB classification: peroxidase cytochemistry in the diagnosis of acute leukemias. *Ann Hematol* 1992; 65 (Suppl.):A57.(Abstr)
211. Heil G, Freund M, Link H, Mitrou P, Hoelzer D, Wandt H, Ehninger G, Fackler-Schwalbe E, Schlimock G, Löscher A, Queißer W, Löffler B, Kurrle E. High-dose cytarabine and daunorubicin postremission chemotherapy for the treatment of adults with de-novo acute myelogenous leukemia (AML). *Ann Hematol* 1992; 65 (Suppl.):A66.(Abstr)
212. Kleine HD, Hinrichs H, Lux E, Döring G, Poliwoda H, Freund M. Stem cell factor (SCF) causes stimulatory effects on B-CLL-cells in serum free suspension cultures. *Ann Hematol* 1992; 65 (Suppl.):A79.(Abstr)
213. Kleine H-D, Scheinichen D, Lux E, Döring G, Poliwoda H, Freund M. High efficient immunomagnetic T-cell depletion for clonogenic and functional assays. *Ann Hematol* 1992; 65 (Suppl.):A79.(Abstr)
214. Steinke B, Manegold Ch, Freund M, Reinold H-M, Fischer J-Th, Arnold H, Döring A, Gracien E, Zwingers T. rG-CSF for dose-intensification of chemotherapy in high grade malignant non-Hodgkin's lymphomas (HG-NHL). *Ann Hematol* 1992; 65 (Suppl.):A128.(Abstr)
215. Tischler H-J, Ringe B, Bettoni C, Diedrich H, Franz A, Freund M, Kruse E, Lück R, Link H. Successful orthotopic liver transplantation for a patient with venoocclusive liver disease after bone marrow transplantation. *Ann Hematol* 1992; 65 (Suppl.):A132.(Abstr)
216. Link H, Hübner G, Meyer C, Freund M, Schneider B, Wandt H, Schönrock-Nabulsi P, Gramatzki M, Queisser W, Fackler-Schwalbe E, Löffler B, Raab M, Öhl S, Brack U, Gabius S, Ehninger G. Prospective comparative trial of postremission therapy in adult patients with acute myeloblastic leukemia: High dose cytosine-arabinside versus allogeneic and unpurged autologous bone marrow transplantation. *Blood* 1992; 80 (Suppl. 1):114a.(Abstr)
217. Kleine HD, Hinrichs H, Scheinichen D, Lux E, Poliwoda H, Freund M. Stimulatory effects of stem cell factor (SCF) on B-CLL cells could be determined by flow cytometry after depletion of cytokine producing cells. *Blood* 1992; 80 (Suppl. 2):416a.(Abstr)
218. Malich U, Tischler H-J, Petersen D, Freund M, Lux E, Link H. Pentoxifylline and levels of tumor necrosis factor alpha after bone marrow transplantation. 19th Annual Meeting of the EBMT 1993; 24.(Abstr)
219. Grauer ME, Bautsch W, Freund M, Diedrich H, Hübner G, Link H. Unusual case of systemic infection with trichosporum beigeli (cutaneum) in relapsed AML after BMT. 19th Annual Meeting of the EBMT 1993; 66.(Abstr)
220. Tischler H-J, Ringe B, Diedrich H, Bettoni C, Freund M, Schlitt HJ, Tietz S, Kuse E, Maschek H, Franke A, Link H. Successful orthotopic liver transplantation for a patient with veno-occlusive liver disease after BMT. 19th Annual Meeting of the EBMT 1993; 77.(Abstr)
221. Arseniev L, Andres J, Battmer K, Südmeyer I, Könneke A, Zaki M, Bokemeyer C, Kleine HD, Freund M, Link H. Recruitment of peripheral blood stem cells after mobilization with G-CSF alone or following high-dose chemotherapy. 19th Annual Meeting of the EBMT 1993; 102.(Abstr)
222. Könneke A, Andres J, Battmer K, Südmeyer I, Arseniev L, Bokemeyer C, Kleine HD, Freund M, Link H. Peripheral blood stem cells and immunohematopoietic reconstitution after high dose chemotherapy. 19th Annual Meeting of the EBMT 1993; 103.(Abstr)

223. Schöffski P, Karkanitsa L, Andres J, Arseniev L, Kahrs M, Heußner P, Link H, Freund M. High-dose chemotherapy with G-CSF and peripheral stem cell support in relapsing or refractory high-grade malignant non-Hodgkin's lymphomas. Bone Marrow Transplantation 1993; 12 (Suppl. 2):15.(Abstr)
224. Freund M, Andres J, Arseniev L, Könnecke A, Heußner P, Kahrs M, Kleine H-D, Schmoll H-J, Link H. High-dose chemotherapy with G-CSF and reinfusion of autologous peripheral stem cells (APBSC) in relapsing or refractory high-grade malignant non-Hodgkin's lymphomas. International Conference on Malignant Lymphomas, Lugano 1993; 5:170.(Abstr)
225. Hassan HT, Grell S, Borrmann-Danso U, Freund M. Recombinant human interferon- α and interferon- β 2/interleukin-6 but not interferon gamma induce megakaryocytic differentiation of acute megakaryoblastic leukaemia blast cells. Ann Hematol 1993; 66 (suppl. II):A 95, 82.(Abstr)
226. Hinrichs HF, Kleine H-D, Petershofen EK, Lux E, Poliwoda H, Freund M. Effects of stem cell factor (SCF) on B-CLL-cells in serum free suspension cultures. Ann Hematol 1993; 66 (suppl. II):A 88.(Abstr)
227. Spiekermann K, Roesler J, Elsner J, Freund M, Link H, Welte K, Lohmann-Matthes M-L, Emmendoerffer A. Kinetics of human neutrophil surface marker expression and chemotaxis during rhG-CSF treatment. Ann Hematol 1993; 66 (suppl. II):A 101.(Abstr)
228. Könnecke A, Andres J, Battmer K, Südmeyer I, Arseniev L, Bokemeyer C, Schmoll H-J, Freund M, Link H. Peripheral blood stem cells and immunohematopoietic reconstitution after multiple consecutive courses of intensive chemotherapy. Ann Hematol 1993; 66 (suppl. II):A 96.(Abstr)
229. Haase D, Freund M, Welte K, Zabel B, Fonatsch C. Is there an association of monosomy 7 and leukemic response to myeloid growth factors? Ann Hematol 1993; 66 (suppl. II):A 87.(Abstr)
230. Heußner P, Freund M, Ottmann OG, Haase D, Fonatsch C, Kanz L, Welte K, Poliwoda H. G-CSF in therapy of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. Ann Hematol 1993; 66 (suppl. 2):A 100.(Abstr)
231. Junghanß C, Kleine H-D, Lux E, Görlich K, Poliwoda H, Freund M. Effects of IL-2 and IL-4 and its combination on B-CLL-cells. Ann Hematol 1993; 66 (suppl. II):A 90.(Abstr)
232. Scheinichen D, Petershofen EK, Kleine H-D, Lux E, Poliwoda H, Freund M. The proliferating effect of IFN α and TNF α on peripheral B-CLL-cells is dependent upon glucocorticoid pretreatment. Ann Hematol 1993; 66 (suppl. II):A 96.(Abstr)
233. Avenarius H-J, Freund M, Deinhardt J, Heußner P, Poliwoda H. Treatment with rhG-CSF increases the CD62-expression on the surface of thrombocytes. Ann Hematol 1993; 66 (suppl. II):A 102.(Abstr)
234. Freund M, Hild F, Grote-Metke A, Nowak R, Otremba B, Kleine H-D, Link H, Hinrichs F, Balleisen L, Fonatsch C, Poliwoda H. Combination in chronic myelogenous leukemia (CML) of cytosine arabinoside and interferon α -2b. Ann Hematol 1993; 66 (suppl. II):A 102.(Abstr)
235. Freund M, Andres J, Arseniev L, Kahrs M, Schöffski P, Karkanitsa LV, Heußner P, Könnecke A, Kleine H-D, Schmoll H-J, Link H. The impact of haematopoietic support in the treatment of relapsing and resistant aggressive lymphoid malignancies. Ann Hematol 1993; 66 (suppl. II):A 158.(Abstr)
236. Heußner P, Kleine H-D, Petershofen EK, Tischler J, Freund M. Phase II study of IFN α -2b in refractory acute leukemia. Ann Hematol 1993; 66 (suppl. II):A 104.(Abstr)
237. Hassan HT, Grell S, Borrmann-Danso U, Freund M. A lineage modulatory effect for interleukin-4 in human myeloid leukaemia cells? Ann Hematol 1993; 66 (suppl. II):A 95.(Abstr)
238. Karkanitsa LV, Andres J, Welte K, Poliwoda H, Freund M. CD34-positive selection is effective to separate functionally normal hemopoietic stem cells from patients with non-Hodgkin's lymphoma treated with rhG-CSF and chemotherapy. Ann Hematol 1993; 66 (suppl. II):A 90.(Abstr)
239. Arseniev L, Andres J, Battmer K, Südmeyer I, Zaki M, Könnecke A, Schmoll H-J, Bokemeyer C, Freund M, Link H. Mobilization, collection and retransfusion of peripheral blood stem cells for the support of multiple consecutive courses of escalated dose chemotherapy in patients with NHL and NSGCT. Ann Hematol 1993; 66 (suppl. II):A 98.(Abstr)
240. Hassan HT, Grell S, Borrmann-Danso U, Freund M. Lineage modulatory effect for interleukin-4 in human myeloid leukaemia cells. Ann Hematol 1993; 67 (suppl. II):A 151, 35 (Abstr)
241. Gassmann W, Löffler H, Ludwig W-D, Sperling C, Thiel E, Uharek L, Freund M, Becher R, Donhuijsen-Ant R, Lengfelder E, Weh HJ, Aul C, Tirier C, Hagmann FG, Fuhr HG, Heil G, Kaboth W, Wandt H, Koch P, Hoelzer D, Sauerland MC, Büchner Th. FAB classification of acute leukemias: high frequency of AML M0 in German multicenter studies. XIIth meeting of the International Society of Haematology (European and African Division) Vienna Austria 1993; 4.(Abstr)
242. Hassan HT, Grell S, Borrmann-Danso U, Freund M. Recombinant human interferon-alpha and interferon-beta2 / interleukin-6 but not interferon gamma induce megakaryocytic differentiation of acute megakaryoblastic blast cells. XIIth meeting of the International Society of Haematology (European and African Division) Vienna Austria 1993; 34.(Abstr)
243. Hassan HT, Grell S, Borrmann-Danso U, Freund M. A lineage modulatory effect for interleukin-4 in human myeloid leukemia cells. XIIth meeting of the International Society of Haematology (European and African Division) Vienna Austria 1993; 105.(Abstr)

244. Maschek H, Freund M, Gutzmer R, Georgii A. Long-term therapy with GM-CSF in primary myelodysplastic syndromes (pMDS): analysis of bone marrow biopsies and hematology. XIIth meeting of the International Society of Haematology (European and African Division) Vienna Austria 1993; 107.(Abstr)
245. Junghanß Ch, Petershofen EK, Hinrichs HF, Kleine H-D, Heußner P, Scheinichen D, Poliwoda H, Freund M. The influence of cytokines on B-CLL-cell proliferation is independent of CD3+ T-cells in vitro. XIIth meeting of the International Society of Haematology (European and African Division) Vienna Austria 1993; 176.(Abstr)
246. Meyer-Schomann L, Kleine H-D, Lux E, Poliwoda H, Freund M. Serum levels of IL-1, IL-6 and LIF and correlation with clinical parameters in chronic myelogenous leukemia during interferon-alpha 2b therapy. XIIth meeting of the International Society of Haematology (European and African Division) Vienna Austria 1993; 176.(Abstr)
247. Heußner P, Petershofen E, Ottmann OG, Haase D, Fonatsch Ch, Kanz L, Welte K, Poliwoda H, Freund M. G-CSF in therapy of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. XIIth meeting of the International Society of Haematology (European and African Division) Vienna Austria 1993; 177.(Abstr)
248. Bokemeyer C, Arseniev L, Andres J, Schöffski P, Knoche M, Haupt A, Link H, Freund M, Poliwoda H, Schmoll H-J. Application of first line dose intensified PEI-chemotherapy with sequential harvesting and reinfusion of PBSC in patients with advanced testicular cancer. Ann Hematol 1993; 67 (Suppl.):A13.(Abstr)
249. Freund M. Interferons in low grade malignant non-Hodgkin's lymphomas. A critical review. Ann Hematol 1993; 67 (Suppl.):A34.(Abstr)
250. Freund M, Andres J, Arseniev L, Kahrs M, Schöffski P, Knoche M, Heußner P, Könnecke A, Schmoll H-J, Link H. High-dose chemotherapy with G-CSF and peripheral stem cell support in relapsing or refractory high-grade malignant non-Hodgkin's lymphomas. Ann Hematol 1993; 67 (Suppl.):A34.(Abstr)
251. Freund M, Hild F, Grote-Metke A, Otremba B, Nowak R, Kleine H-D, Link H, Hinrichs F, Balleisen L, Fonatsch C, Poliwoda H. Treatment of chronic myelogenous leukemia (CML) with interferon α -2b and cytosine-arabioside. Ann Hematol 1993; 67 (Suppl.):A34.(Abstr)
252. Haase D, Freund M, Kröger M, Fonatsch C. Cytogenetic response to myeloid growth factors in MDS and AML. Ann Hematol 1993; 67 (Suppl.):A44.(Abstr)
253. Hild F, Freund M, Fonatsch C. Deletions of the short arm of chromosome 7 in Ph-positive CML: A secondary chromosome aberration with adverse prognostic implication. Ann Hematol 1993; 67 (Suppl.):A52.(Abstr)
254. Junghanß C, Kleine H-D, Lux E, Görlich K, Poliwoda H, Freund M. IL-4 inhibits IL-2 induced proliferation on B-CLL cells. Ann Hematol 1993; 67 (Suppl.):A59.(Abstr)
255. Link H, Hübner G, Meyer C, Freund M, Schneider B, Wandt H, Schönrock-Nabulsi P, Gramatzki M, Queißer W, Fackler-Schwalbe E, Löffler B, Raab M, Öhl S, Brack N, Gabius S, Ehninger G. Intensive consolidation treatment in acute myeloblastic leukemia: allogeneic bone marrow transplantation versus high-dose cytosine-arabioside/daunorubicin versus unpurged autologous bone marrow transplantation. Ann Hematol 1993; 67 (Suppl.):A76.(Abstr)
256. Link H, Pawlik V, Freund M, Poliwoda H. Liposomal amphotericin B for pulmonary mycoses in neutropenic and immunosuppressed patients. Ann Hematol 1993; 67 (Suppl.):A76.(Abstr)
257. Löhmann D, Arseniev L, Battmer K, Freund M, Link H. G-CSF and subsets of CD34+ cells in peripheral blood and bone marrow after progenitor cell mobilization or allogeneic bone marrow transplantation. Ann Hematol 1993; 67 (Suppl.):A77.(Abstr)
258. Pott C, Unterhalt M, Sandfort D, Markert H, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert M, Hellriegel K, Knauf B, Nieberding R, Emmerich B, Koch P, Wörmann B, Hiddemann W. Fludarabine in a phase II study of a German low-grade lymphoma study group. Ann Hematol 1993; 67 (Suppl.):A96.(Abstr)
259. Von Wussow P, Jakschies D, Walther M, Al-Masri AN, Freund M, Deicher H. Human thrombocytes contain the type I IFN-induced MxA-protein. Ann Hematol 1993; 67 (Suppl.):A138.(Abstr)
260. Hoelzer D, Arnold R, Aydemir U, Büchner Th, Freund M, Gassmann W, Gökbüget N, Hiddemann W, Koch P, Löffler H, Ludwig W-D, Maschmeyer G, Thiel E, Völkers B. Results of intensivied consolidation therapy in four consecutive german multicenter studies for adult ALL. Blood 1993; 82 (Suppl. 1):193a.(Abstr)
261. Pott C, Unterhalt M, Sandford M, Markert H, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert M, Hellriegel K, Knauf U, Nieberding R, Emmerich B, Koch P, Wörmann B, Hiddemann W. Fludarabine in relapsed low-grade non-Hodgkin lymphomas - a phase II study of the german low grade lymphoma study group. Blood 1993; 82 (Suppl. 1):575a.(Abstr)
262. Petersen D, Freund M, Poliwoda H, Schöffski P, Paaz U, Knoche MF, Schumann G, Oellerich M. Monitoring serum concentrations of 5-fluorocytosine and dosage individualization in cancer patients. J Cancer Res Clin Oncol 1994; 120 (Suppl.):R61.(Abstr)
263. Bischoff J, Petershofen EK, Kleine HD, Poliwoda H, Freund M. Effects of IL-6 on B-CLL-cells determined by flow cytometric DNA-analysis. J Cancer Res Clin Oncol 1994; 120 (Suppl.):R113.(Abstr)

264. Schmidt U, Petershofen EK, Junghanß Ch, Hinrichs HF, Kleine H-D, Scheinichen D, Poliwoda H, Freund M. Influence of T-cells (CD3+) on cytokine-induced CLL-B-cell proliferation. *J Cancer Res Clin Oncol* 1994; 120 (Suppl.):R113.(Abstr)
265. Petershofen EK, Hassan HT, Lux E, Heil G, Poliwoda H, Freund M. MHH 225: Immunophenotype of a new human myeloid leukemia cell line. *J Cancer Res Clin Oncol* 1994; 120 (Suppl.):R122.(Abstr)
266. Freund M, Andres J, Arseniev L, Link H, Kahrs M, Schöffski P, Knoche M, Heußner P, Poliwoda H. High-dose chemotherapy with autologous peripheral blood stem cell (APBSC) reinfusion: alternative to autologous BMT? *J Cancer Res Clin Oncol* 1994; 120 (Suppl.):R127.(Abstr)
267. Freund M, Heil G, Arnold R, Bartram C, Büchner Th, Diedrich H, Fonatsch C, Ganser A, Hiddemann W, Koch P, Link H, Löffler H, Ludwig WD, Maschmeyer G, Schmitz N, Thiel E, Hoelzer D. Salvage therapy in adult ALL. *Ann Hematol* 1994; 68 (Suppl. I):A10.(Abstr)
268. Pott C, Unterhalt M, Sandford D, Markert H, Freund M, Engert A, Gassmann W, Hohlkamp W, Seufert M, Hellriegel K, Knauf B, Nieberling R, Emmerich B, Koch P, Wörmann B, Hiddemann W. Fludarabine as single agent and in combination with mitoxantrone and dexamethasone in relapsed and refractory low-grade non-Hodgkin lymphoma. *Ann Hematol* 1994; 68 (Suppl. I):A2.(Abstr)
269. Freund M. The use of growth factors in bacterial infection in neutropenic patients. Conference on chemotherapy of infectious diseases and malignancies (05,1994,Salzburg) 1994; 5:Abstr. No. 14.
270. Karkanitsa L, Komarovskaya M, Kleine H-D, Petershofen EK, Welte K, Freund M. Long and short-term ex vivo cultivation of hematopoietic progenitor cells from peripheral blood and bone marrow of patients with malignancy. *Br J Haematol* 1994; 87 (Suppl. 1):99.(Abstr)
271. Schoch C, Rieder H, Freund M, Fonatsch Ch. Twenty-three cases of acute lymphoblastic leukemia with translocation t(4;11)(q21;q32). the implication of additional chromosomal aberrations. *Br J Haematol* 1994; 87 (Suppl. 1):137.(Abstr)
272. Petershofen EK, Schmidt U, Bischoff J, Junghanß C, Kleine H-D, Freund M. IL-6 can alter the proliferating effects of IL-2 on CLL-B-cells in vitro. *Br J Haematol* 1994; 87 (Suppl. 1):159.(Abstr)
273. Petershofen EK, Bischoff J, Schmidt U, Kleine H-D, Freund M. Variations of proliferation on different CLL-B-cell species after cultivation with IL-2 and TNF- α in vitro. *Br J Haematol* 1994; 87 (Suppl. 1):159.(Abstr)
274. Avenarius HJ, Sosada M, Bergmann F, Deinhard J, Freund M, Poliwoda H. A-granules' release after admission of G-CSF. *Onkologie* 1994; 17 (Suppl. 2):5.(Abstr)
275. Bischoff J, Kleine H-D, Petershofen EK, Schmidt U, Scheinichen D, Poliwoda H, Freund M. Effects of combinations of TNF- α , IL-2, and IL-6 on B-CLL-cells determined by flow cytometric DNA-analysis. *Onkologie* 1994; 17 (Suppl. 2):11.(Abstr)
276. Heil G, Pompe K, Arnold R, Bartram C, Büchner Th, Diedrich H, Fonatsch C, Ganser A, Hiddemann W, Koch P, Kolbe K, Link H, Löffler H, Ludwig WD, Maschmeyer G, Schmitz N, Schwonzen M, Thiel E, Hoelzer D, Freund M. High-dose cytosine-arabioside in combination with idarubicin for the treatment of relapsed adults with acute lymphoblastic leukemia (ALL). *Onkologie* 1994; 17 (Suppl. 2):56.(Abstr)
277. Heußner P, Schleyer E, Amadori S, Ganser A, Guilhot F, Hanauske A, Heil G, Hiddemann W, Kolbe K, Selbach J, Stryckmans P, Willemze R, Kaeser-Fröhlich A, Schüßler M, Burk K, Freund M. A phase I/II trial of YNK01, an oral ara-C derivative in patients with AML, MDS and low-grade malignant NHL. *Onkologie* 1994; 17 (Suppl. 2):61.(Abstr)
278. Hiddemann W, Löffler W, Thiel E, Emmerich B, Freund M, Hellriegel KP, Hossfeld DK, Kanz L, Johnson S, Smith A, Björkholm M, Wyld P, Binet JL, (French Cooperative Group on CLL) , for the Multinational CLL Cooperative Group . Fludarabine versus cyclophosphamide, adriamycin, prednisone (CAP) for the treatment of chronic lymphocytic leukemia. *Onkologie* 1994; 17 (Suppl. 2):62.(Abstr)
279. Link H, Hübner G, Freund M, Meyer C, Schneider B, Schönrock-Nabulsi P, Wandt H, Gramatzki M, Löffler B, Fackler-Schwalbe E, Queisser W, Brack N, Geer T, Raab M, Öhl S, Ehninger G. Comparison of intensive postremission therapy in acute myeloblastic leukemia. *Onkologie* 1994; 17 Suppl. 2):90.(Abstr)
280. Pott C, Unterhalt M, Sandford D, Markert H, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert M, Hellriegel K, Knauf B, Nieberding R, Emmerich B, Koch P, Wörmann B, Hiddemann W. Fludarabine in combination with mitoxantrone and dexamethasone in relapsed and refractory low-grade non-Hodgkin's lymphoma. *Onkologie* 1994; 17 (Suppl. 2):114.(Abstr)
281. Schmidt U, Kleine H-D, Petershofen EK, Bischoff J, Junghanß Ch, Hinrichs HF, Poliwoda H, Freund M. Influence of T-cells (CD3+) on cytokine-induced B-CLL-cell proliferation. *Onkologie* 1994; 17 (Suppl. 2):131.(Abstr)
282. Schoch C, Gudat H, Haase D, Freund M, Büchner Th, Lengfelder E, Wandt H, Fonatsch Ch. Thirty-seven cases of acute myeloid leukemia with translocation t(8;21)(q22;q22): the implication of additional chromosomal aberrations. *Onkologie* 1994; 17 (Suppl. 2):133.(Abstr)
283. Ramsauer B, Schleyer E, Braess J, Amadori S, Burk K, Ganser A, Hanauske A, Heil G, Kaeser-Fröhlich A, Schüßler M, Selbach J, Willemze R, Freund M, Hiddemann W. Cytarabine octofosfate (YNK01) in AML, MDS and low-grade NHL - a phase I/II study of the european YNK01 study group. *Ann Oncol* 1994; 5 (Suppl. 8):183.(Abstr)

284. Unterhalt M, Koch P, Pfreundschuh M, Maschmeyer G, Freund M, Thiel E, Neubauer A, Dietzfelbinger R, Engert A, Stauder M, Herrmann R, Tiemann M, Parwaresch R, Hiddemann W. Prednimustine, Mitoxantrone (PMM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low grade non-Hodgkin lymphoma. *Blood* 1994; 84 (Suppl. 1):168a.(Abstr)
285. Heußner P, Willemze R, Ganser A, Hanauske A, Amadori S, Heil G, Schleyer E, Hiddemann W, Selbach J, Schüßler M, Freund M. YNK01, an oral ara-C derivative in patients with AML, MDS, low-grade malignant NHL and CML. *Blood* 1994; 84 (Suppl. 1):302a.(Abstr)
286. Hiddemann W, Unterhalt M, Tiemann M, Parwaresch R, Stein H, Koch P, Herrmann R, Pfreundschuh M, Maschmeyer G, Freund M, Thiel E, Neubauer A, Dietzfelbinger R, Engert A, Stauder M. Characteristics and clinical course of follicle center lymphomas and mantle cell lymphomas - a study on the clinical relevance of the R.E.A.L. classification. *Blood* 1994; 84 (Suppl. 1):449a.(Abstr)
287. Hassan HT, Grell S, Borrmann-Danso U, Freund M. Synergistic cytotoxic and catostatic interactions of carboplatin and interferon in human leukaemia cells. Seventh International Symposium on Platinum and other Metal coordination compounds in Cancer Chemotherapy; Abstract book of ISPC 95 1995; 23.(Abstr)
288. Heußner P, Willemze R, Ganser A, Hanauske A, Amadori S, Heil G, Schleyer E, Hiddemann W, Selbach J, Schüßler M, Freund M. YNK01, an oral derivative in AML and CML. *Ann Hematol* 1995; 70 (Suppl. II):170. (Abstr)
289. Hassan HT, Grell S, Borrmann-Danso U, Freund M. Human stem cell factor protects CD34 positive human myeloid leukaemia cells from chemotherapy-induced apoptosis. *Leukemia* 1995; 9:11.(Abstr)
290. Hassan HT, Grell S, Borrmann-Danso U, Freund M. Synergistic cytotoxic and cytostatic interactions between interferon alpha and chemotherapeutic drugs in human myeloid leukaemia cells. *Ann Hematol* 1995; 79 (Suppl. 1):(Abstr)
291. Hassan HT, Lux E, Kleine H-D, Freund M. A new fibroblast growth stimulating activity from the human megakaryoblastic leukaemia cell line ELF-153: in vitro and in vivo findings. *Exp Hematol* 1995; 23:877.(Abstr)
292. Kleine HD, Zech I, Andreeff M, Freund M. Continuous gating: a new scanning technique of activation markers used for analysis of proliferation patterns of normal and CML bone marrow progenitor cells. *Exp Hematol* 1995; 23:817.(Abstr)
293. Lindenmaier W, Brinkhoff C, Bonewald R, Dittmar K, Weiss S, Probst M, Buer J, Petershofen E, Kirchner H, Ganser A, Freund M, Atzpodi J. Somatic mutation of rearranged immunoglobulin heavy and light chain variable genes in two cases of B-cell chronic lymphocytic leukemia. *Onkologie* 1995; 18 (Suppl. 2):86.
294. Krammer B, Reincke J, Steiner M, Clemmensen I, Freund M. Decreased serum tetranectin in plasmocytoma and its correlation with tumor stage. *Onkologie* 1995; 18 (Suppl. 2):87.
295. Schoch C, Haase D, Büchner Th, Freund M, Link H, Lengfelder E, Haferlach T, Löffler H, Fonatsch Ch. Fourty-three cases of acute promyelocytic leukemia with translocation t(15;17)(q22;q21): incidence and implication of additional chromosome aberrations. *Onkologie* 1995; 18 (Suppl. 2):114.
296. Heußner P, Schüßler M, Freund M. YNK01, an oral ara-C derivative, in combination with interferon alfa in patients with untreated CML. *Onkologie* 1995; 18 (Suppl. 2):143.
297. Holgado S, Choritz H, Büsche G, Nafe R, Freund M, Georgii A. Cytomorphology of megakaryocytes from CML patients under low dose of interferon alpha-2b treatment. *Onkologie* 1995; 18 (Suppl. 2):145.
298. Kleine HD, Zech I, Andreeff M, Freund M. Continuous gating: a new scanning technique of flow cytometric listmode-data used for analysis of proliferation patterns of normal and CML bone marrow progenitor cells. *Onkologie* 1995; 18 (Suppl. 2):146.
299. Petersen D, Kühl J, Freund M. Evaluation of an HPLC procedure for the determination of thiotepa in patient samples. *Onkologie* 1995; 18 (Suppl. 2):182.
300. Schoch C, Haase D, Haferlach T, Büchner T, Freund M, Link H, Löffler H, Fonatsch C. Secondary chromosome aberrations in acute myeloid leukemia with t(8;21)(q22;q22), inv(16)(p13;q22) or t(15;17)(q22;q21). *Blood* 1995; 86 (Suppl. 1):43a.(Abstr)
301. Drolshagen H, Kleine HD, Freund M. Expression of APO-1-receptor and apoptosis rates can be increased by interleukin-2 in chronic lymphocytic leukemia. *Blood* 1995; 86 (Suppl. 1):347a.(Abstr)
302. Unterhalt M, Herrmann R, Nahler M, Trümper L, Bodenstein H, Landys K, Reuß M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Tiemann M, Parwaresch R, Stein H, Hiddemann W. Significant prolongation of disease free survival in advanced low grade non Hodgkin lymphomas (NHL) by interferon alpha maintenance. *Blood* 1995; 86 (Suppl. 1):439a.(Abstr)
303. Casper J, Dunn TA, Hartmann K, Freund M, Schmoll HJ. Human EC-cell lines as potential precursors for human hematopoietic stem cells. *Blood* 1995; 86 (Suppl. 1):660a.(Abstr)
304. Kleine HD, Nowak R, Oelschlägel U, Zech I, Freund M. Semiautomated detection of residual aneuploid leukemia cells in bone marrow by continuous gating: a new computer program for analysis of flow-cytometric data based on multiple overlapping gates. *Blood* 1995; 86 (Suppl. 1):766a.(Abstr)
305. Anders O, Krammer B, Henschel J, Burstein C, Steiner M, Thomas KB, Freund M. Therapy of recurrent bleeding episodes from intestinal angiodysplasia in von Willebrand disease type III. *Ann Hematol* 1995; 70 (Suppl. 1):A82

306. Burstein C, Steiner M, Reinhardt KM, Krammer B, Bauer I, Rabe F, Anders O, Freund M. Molecular markers of blood coagulation and activated protein C resistance in deep vein thrombosis. *Thromb Haemostas* 1995; 73:1371
307. Schoch C, Haase D, Büchner T, Freund M, Link H, Löffler H, Haferlach T, Fonatsch C. The incidence and prognostic implication of secondary chromosome aberrations in acute myeloid leukemia with t(8;21)(q22;q22), t(15;17)(q22;q21) or inv(16)(p13;q22). *Medizinische Genetik* 1996; 8:55
308. Heußner P, Petershofen E, Casper J, Metzner B, Decker S, Junghanß C, Kirchner H, Freund M. High-dose chemotherapy with thiotepa, busulfan, and etoposide (TBE) and autologous peripheral blood stem cell transplantation (PBSCT) in relapsing or refractory NHL. *Proc Am Soc Clin Oncol* 1996; 15:346
309. Schöffski P, Wunder R, Petersen D, Schumann G, Hertenstein B, Schubert U, Ganser A, Freund M. Amphotericin B in Intralipid: no evidence of an improved toxicity profile. Results of a randomized phase II-trial in neutropenic patients. *ICAAC* 1996
310. Kleine H-D, Zech I, Nowak R, Oelschlägel U, Freund M. Semiautomated detection of residual aneuploid leukemic cells by "continuous gating". *Ann Hematol* 1996; 73 (Suppl. 2):A22
311. Arseniev L, Link H, Kleine H-D, Battmer K, Freund M, Ganser A. An alternative multicolor compensation technique for immune phenotyping of CD34+ cells and other cell subsets via flow cytometry. *Ann Hematol* 1996; 73 (Suppl. 2):A36
312. Helbig W, Krahl R, Pönisch W, Schwenke H, Kubel M, Fiedler F, Pasold R, Herold M, Freund M, Lakner V, Grobe N, Peter N, Kämpfe D, Subert R, Steglich J, Schulze M, Schwalbe E, Huhn R, Rupprecht A, for the East German Hematology/Oncology Study Group. G-CSF before, during and after conventional dose Idarubicin/Ara-C induction therapy of adult de novo acute myelogenous leukemia (AML): results of remission induction of the prospective randomised trial AML '93. *Ann Hematol* 1996; 73 (Suppl. 2):A91
313. Casper J, Fonatsch C, Kleine H-D, Dunn T, Bronson DL, Freund M. Characterization of lymphoblastoid cell lines derived from human testicular germ cell tumors. *Ann Hematol* 1996; 73 (Suppl. 2):A99
314. Junghanß C, Knopp A, Casper J, Petershofen E, Krahl R, Feltl J, Freund M. A 73 year old patient with an acute promyelocytic leukemia (FAB M3) with complex cytogenetic aberrations and atypical clinical behaviour. *Ann Hematol* 1996; 73 (Suppl. 2):A101
315. Lakner V, Decker S, Henschel J, Junghanß C, Pasold R, Subert R, Grobe N, Schwencke M, Freund M. Continuous infusion high-dose cytosine-arabioside and mitoxantrone (CIVAM) therapy in relapsed, refractory or secondary acute myeloid leukemia: a pilot study. *Ann Hematol* 1996; 73 (Suppl. 2):A102
316. Heußner P, Petershofen E, Kleine H-D, Casper J, Metzner B, Junghanß C, Alscher A, Freund M. Autologous peripheral blood stem cell transplantation after high-dose chemotherapy with thiotepa/busulfan/etoposide in relapsing or refractory NHL. *Ann Hematol* 1996; 73 (Suppl. 2):A110
317. Junghanß C, Heußner P, Krammer-Steiner B, Decker S, Petershofen E, Freund M. Dexa-BID, a bendamustinehydrochloride containing regimen for refractory and relapsing low grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. *Ann Hematol* 1996; 73 (Suppl. II):A134
318. Lakner V, Decker S, Krammer B, Heußner P, Junghanß C, Freund M. Treatment of elderly patients with advanced non-Hodgkin's lymphoma using CNOP chemotherapy. *Ann Hematol* 1996; 73 (Suppl. II):A136
319. Krammer-Steiner B, Heußner P, Junghanß C, Decker S, Freund M. Mitoxantrone/dexamethasone chemotherapy for relapsed multiple myeloma. *Ann Hematol* 1996; 73 (Suppl. II):A141
320. Krammer-Steiner B, Anders O, Barz D, Freund M. No response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone treatment. *Ann Hematol* 1996; 73 (Suppl. II):A161
321. Petershofen EK, Bauer I, Wilhelm S, von Widdern O, Koppitz E, Haas A, Anders O, Rolfs A, Freund M. Detection of point mutation G1691A in factor V DNA with an one tube allele-specific PCR method (ASP). *Ann Hematol* 1996; 73 (Suppl. II):A172
322. Kleine H-D, Buthmann U, Freund M. Fluorescence activated cell sorting (FACS) at a single cell level for PCR and FISH. *Ann Hematol* 1996; 73 (Suppl. II):A180
323. Kleine H-D, Braylan RC, Buthmann U, Freund M. Use of 'continuous gating' for semiautomatic detection of clonal B-lymphoma cells: a new computer program for analysis of flow-cytometric data based on multiple overlapping gates. *Blood* 1996; 88:185a
324. Schöffski P, Wunder R, Petersen D, Köhne C-H, Freund M, Ganser A. Intralipid does not decrease the toxicity of amphotericin B. Results of a randomized phase II trial in neutropenic patients with fever of unknown origin or pneumonia. *Blood* 1996; 88:502a
325. Unterhalt M, Herrmann R, Koch P, Trümper L, Bodenstein H, Dietzfelbinger H, Landys K, Reuss M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, Hiddemann W, for the German Low Grade NHL Study Group. Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. *Blood* 1996; 88:453a
326. Freund M, Heil G, Arnold R, Balleisen L, Bartram C, Büchner T, Diedrich H, Eimermacher H, Fonatsch C, Ganser A, Gassmann W, Hartmann F, Hiddemann W, Kasper C, Kauf WU, Koch P, Kubica U, Link H, Löffler H, Ludwig WD, Maschmeyer G, Pompe K, Schadeck C, Schmitz N, Schönrock-Nabulsi P, Schwonzen M, Thiel E, Weib A, Hoelzer D. Treatment of relapsed ALL - studies of the German ALL Cooperative Group. *Ann Hematol* 1997; 74 (Suppl. I):A15

327. Hiddemann W, Unterhalt M, Hermann R, Koch P, Trümper L, Bodenstein H, Dietzfelbinger H, Landys K, Reub M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, for the German Low Grade NHL Study Group. Interferon alpha maintenance therapy in low-grade lymphomas. *Ann Hematol* 1997; 74 (Suppl. 1):A3
328. Schwanz J, Haase D, Fonatsch C, Schoch C, Freund M, Haferlach T, Wörmann B, Hiddemann W. The karyotype in MDS - cytogenetic profile, clinical correlations and prognostic implications in 349 patients with MDS. *Ann Hematol* 1997; 74 (Suppl. 1):A51
329. Mantovani L, Pönisch W, Herold M, Fiedler F, Lakner V, Pasold R, Kämpfe D, Hasenclever D, Krahl R, Kubel M, Helbig W, for the East-German Hematology/Oncology Study Group. High dose ara-C (HiDAC) in both induction and consolidation treatment of patients with AML. *Ann Hematol* 1997; 74 (Suppl. 1):A44
330. Kleine H-D, Nowak R, Oelschlägel U, Zech I, Freund M. Semiautomated detection of residual aneuploid leukemia cells in bone marrow by continuous gating: a new computer program for analysis of FCM list-mode-data based on multiple overlapping gates. *Acta Haematol (Basel)* 1997; 98 (Suppl. 1):11
331. Wilhelm S, Kleine H-D, Junghanß C, Alscher A, Knopp A, Casper J, Freund M. Preliminary results of autologous peripheral blood stem cells (PBSC) mobilization in chronic myeloid leukemia (CML). *Acta Haematol (Basel)* 1997; 98 (Suppl. 1):47
332. Kleine H-D, Zech I, Andreeff M, Freund M. Continuous gating: a scanning technique of flow cytometric listmode-data for analysis of proliferation patterns of CD34-positive cells in normal and CML bone marrow. *Acta Haematol (Basel)* 1997; 98 (Suppl. 1):67
333. Junghanß C, Kleine H-D, Lux E, Freund M. Tumor necrosis factor alpha and interleukin-4 serum concentrations in patients with B-cell chronic lymphocytic leukemia. *Acta Haematol (Basel)* 1997; 98 (Suppl. 1):68
334. Haase D, Schanz J, Schoch C, Freund M, Haferlach T, Wörmann B, Fonatsch C, Hiddemann W. Clinical relevance of the karyotype in MDS - an analysis of survival in defined cytogenetic subgroups in 361 patients. *Onkologie* 1997; 20 (Suppl.):10
335. Kleine H-D, Braylan RC, Buthmann U, Freund M. Semiautomatic detection of clonal B-lymphoma cells by 'continuous gating': a new tool for analysis of flow-cytometric data based on multiple overlapping gates. *Onkologie* 1997; 20 (Suppl.):74
336. Volk J, Kleine H-D, Buthmann U, Freund M. Effects of cytostatics and G-CSF on granulocytes in vivo determined by oxidative burst measurement ex vivo. *Onkologie* 1997; 20 (Suppl.):75
337. Wilhelm S, Kleine H-D, Decker S, Junghanß C, Alscher A, Lakner V, Casper J, Freund M. Experience with the positive selection of CD34+ peripheral blood progenitor cells. *Onkologie* 1997; 91
338. Schöffski P, Freund M, Wunder R, Petersen D, Ganser A. Pulmonary toxicity associated with the use of amphotericin B in intralipid results of a randomized phase II trial. *Onkologie* 1997; 20 (Suppl.):168
339. Wilhelm S, Kleine H-D, Decker S, Junghanß C, Alscher A, Knopp A, Lakner V, Casper J, Freund M. Peripheral blood stem cell mobilization and harvest in chronic myeloid leukemia (CML). *Onkologie* 1997; 20 (Suppl. 1):175
340. Pönisch W, Freund M, Dölken G, Schultze W, Krahl R, Leiblein S, Kubel M, Schwarzer A, Lehmann T, Friedrich T, Helbig W. Mobilization of peripheral blood progenitor cells in patients with chronic myeloid leukemia in chronic phase: IC 5 days versus IC 3 days. *Onkologie* 1997; 20 (Suppl. 1):184
341. Krüger A, Lakner V, Grobe N, Schäfer E, Schwenke M, Freund M. Treatment of high risk patients with Hodgkin's disease using COPBLAM chemotherapy. *Onkologie* 1997; 20 (Suppl. 1):197
342. Junghanß C, Mai S, Decker S, Wilhelm S, Lakner V, Petershofen E, Casper J, Freund M. Subglottical upper airway aspergillosis in a patient with acute myeloid leukemia. *Onkologie* 1997; 20 (Suppl. 1):204
343. Petershofen EK, Decker S, Junghanß C, Kröger J, Lakner V, Freund M. Development of an unusual v. cava superior thrombosis in a patient after high-dose chemotherapy and radiotherapy of the chest: a case report. *Onkologie* 1997; 20 (Suppl. 1):204
344. Mantovani L, Pönisch W, Herold M, Fiedler F, Pasold R, Kämpfe D, Subert R, Lakner V, Hasenclever D, Krahl R, Kubel M, Helbig W, for the East German Study Group. High-dose Ara-C (HiDAC) in both induction and consolidation treatment of patients with AML. *Onkologie* 1997; 20 (Suppl. 1):83
345. Braess J, Freund M, Hanauske A, Schüssler M, Hiddemann W, Kern W, Unterhalt M, Schleyer E. Phase I study of oral cytarabine-octophosphate (V NK01) in AML and NHL - pharmacokinetics and clinical results. *Blood* 1997; 90 (Suppl. 1):330a
346. Buske C, Unterhalt M, Hermann R, Koch P, Trümper L, Bodenstein H, Dietzfelbinger H, Landys K, Reuss M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, Hiddemann W, for the German Low Grade NHL Study Group. Treatment of low-grade B-NHL with prednimustine is not associated with an increased risk for secondary neoplasia. *Blood* 1997; 90 (Suppl. 1):344a
347. Haase D, Schanz J, Wulich J, Schoch C, Freund M, Haferlach T, Wörmann B, Staib P, Lentini G, Bartels H, Geissler HG, Germing U, Döriges U, Fonatsch C, Hiddemann W. Prognostic relevance of cytogenetic subgroups in 357 patients with myelodysplastic syndromes. *Blood* 1997; 90 (Suppl.1):501a

348. Unterhalt M, Hermann R, Koch P, Trümper L, Bodenstein H, Dietzfelbinger H, Landys K, Reuss M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, Hiddemann W. Prognostic determinants for long term outcome of low grade follicular lymphomas after cytoreductive chemotherapy and interferon alpha maintenance. Results of the German Low Grade Lymphoma Study Group (GLSG). *Blood* 1997; 90 (Suppl. 1):392a
349. Wilhelm S, Kleine H-D, Decker S, Junghanb C, Alscher A, Knopp A, Lakner V, Casper J, Freund M. Peripheral blood stem cell mobilization in chronic phase of chronic myeloid leukemia (CML). *Blood* 1997; 90 (Suppl.1):283b
350. Wilhelm S, Kleine H-D, Decker S, Junghanb C, Alscher A, Lakner V, Casper J, Freund M. Experience with the positive selection of CD34+ peripheral blood progenitor cells. *Blood* 1997; 90 (Suppl.1):338b
351. Volk J, Kleine H-D, Buthmann U, Freund M. PMA-induced oxidative burst shows risk of infectious complications during cytostatic therapy. *Proc Am Soc Clin Oncol* 1998; 17:40a
352. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Harstrick A, Bornhäuser M, Ehninger G, Josten KM, Baumgart J, Seeber S. Clinical phase I study of high-dose treosulfan with autologous peripheral blood stem-cell reinfusion (PBSCT). *Proc Am Soc Clin Oncol* 1998; 17:235a
353. Junghanß C, Heußner P, Decker S, Steiner B, Petershofen E, Lakner V, Freund M. Dexamethason, Bendamustinhydrochlorid and Idarubicin (Dexa-BID) as a regimen for refractory and relapsed low grade NHL and CLL. *J Cancer Res Clin Oncol* 1998; 124 (Suppl.):R148
354. Freund M, Heil G, Arnold R, Balleisen L, Büchner T, Diedrich H, Eimermacher H, Fonatsch C, Ganser A, Gassmann W, Hartmann F, Hiddemann W, Kasper C, Knauf WU, Koch P, Kubica U, Link H, Löffler H, Ludwig W-D, Maschmeyer G, Pompe K, Schadeck C, Schmitz N, Schönrock-Nabulsi P, Schwonzen M, Thiel E, Weiß A, Hoelzer D for the German Relapsing ALL Study Group. The role of bone marrow transplantation and high dose chemotherapy in relapsing acute lymphocytic leukemia. *Bone Marrow Transplant* 1998; 22 (suppl. 2):7
355. Heußner P, Casper E, Petershofen E, Kleine H-D, Metzner B, Junghanß C, Alscher A, Freund M. Autologous peripheral blood stem cell transplantation after high-dose chemotherapy with TBE in relapsing or refractory NHL. *Bone Marrow Transplant* 1998; 22 (suppl. 2):17
356. Casper J, Kleine H-D, Heußner P, Wilhelm S, Steiner B, Junghanß C, Leithäuser M, Alscher A, Zippel A, Freund M. Report on experience gained setting up a new blood stem cell transplantation unit - 4 years of peripheral blood stem cell and bone marrow transplantation at the University of Rostock. *Ann Hematol* 1998; 77 (suppl. II):S74 (Abstract)
357. Cwienk M, Kleine H-D, Freund M. Differences in CD34+ subpopulations in leukapheresis products depending on different mobilisation protocols. *Ann Hematol* 1998; 77 (suppl. II):S154 (Abstract)
358. Freund M, Heil G, Arnold R, Balleisen L, Büchner T, Diedrich H, Eimermacher H, Fonatsch C, Ganser A, Gassmann W, Hartmann F, Hiddemann W, Kasper C, Knauf WU, Koch P, Kubica U, Link H, Löffler H, Ludwig WD, Massenkeil G, Maschmeyer G, Metzner B, Pompe K, Schadeck C, Schmitz N, Schönrock-Nabulsi P, Schott G, Schwonzen M, Thiel E, Weiss A, Wilhelm M, Hoelzer D, for the German Relapsed Acute lymphocytic Leukemia Study Group (GRALLSG). Treatment of relapsed ALL - Studies of the German Relapsed ALL Study Group. *Ann Hematol* 1998; 77 (suppl. II):S176 (Abstract)
359. Freund M, Heil G, Arnold R, Balleisen L, Büchner T, Diedrich H, Eimermacher H, Fonatsch C, Ganser A, Gassmann W, Hartmann F, Hiddemann W, Kasper C, Knauf WU, Koch P, Kubica U, Link H, Löffler H, Ludwig WD, Massenkeil G, Maschmeyer G, Metzner B, Pompe K, Schadeck C, Schmitz N, Schönrock-Nabulsi P, Schott G, Schwonzen M, Thiel E, Weiss A, Wilhelm M, Hoelzer D, for the German Relapsed Acute lymphocytic Leukemia Study Group (GRALLSG). Salvage treatment for acute lymphocytic leukemia. *Blood* 1998; 92 (suppl. I):216b (Abstract)
360. Freund M, Krahl R, Dölken G, Fiedler F, Franke A, von Grünhagen U, Heil G, Herold M, Niederwieser D, Pasold R, Schmoll H-J, Spohn C, Uhle M, Helbig W, for the East German Study Group Hematology and Oncology (EGSGHO). Treatment of chronic myeloid leukemia with intensive chemotherapy followed by interferon alpha and autotransplantation. *Ann Hematol* 1998; 77 (suppl. II):S109 (Abstract)
361. Freund M, Krahl R, Dölken G, Fiedler F, Franke A, von Grünhagen U, Heil G, Herold M, Pasold R, Schmoll H-J, Spohn C, Uhle M, Helbig W, Niederwieser D, for the East German Study Group Hematology and Oncology (EGSGHO). Intensive chemotherapy followed by interferon alpha and autotransplantation in chronic myeloid leukemia. *Blood* 1998; 92 (suppl. I):244b (Abstract)
362. Herold M, Schulze A, Mantovani L, Franke A, Blumenstengel K, Richter P, Freund M, Ismer B, Dachsel K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann B, Klinkenstein C, Schulze M, Arzberger A, Bremer K, Hahnfeld S, Müller C, Müller C, Kettner E, for the East German Study Group (OSHO). BOP versus COP in advanced low grade Non-Hodgkin's lymphomas. *Ann Hematol* 1998; 77 (suppl. II):S148 (Abstract)
363. Heußner P, Kleine H-D, Wilhelm S, Decker S, Alscher A, Casper J, Freund M. Long-term survival after high-dose chemotherapy with TBE followed by autologous PBSCT in relapsing or refractory NHL. *Ann Hematol* 1998; 77 (suppl. II):S.146 (Abstract)
364. Heußner P, Schmialek A, Brzezinka C, Putzar K, Kortus B, Hauenstein K-H, Freund M. Early detection of intrapulmonary infiltration by high resolution spiral CT scanning in neutropenic patients. *Ann Hematol* 1998; 77 (suppl. II):S197 (Abstract)
365. Hübner G, Pethig K, Krauter J, Freund M, Ganser A. Myelodysplastic syndrome and acute myelogenous leukemia secondary to heart transplantation. *Ann Hematol* 1998; 77 (suppl. II):S59 (Abstract)

-
366. Junghanß C, Wilhelm S, Kleine H-D, Kortus B, Decker S, Leithäuser M, Heußner P, Steiner B, Alscher A, Casper J, Freund M. Mobilization of peripheral blood progenitor cells with high-dose etoposid and G-CSF in patients that failed to mobilize to prior treatments. *Ann Hematol* 1998; 77 (suppl. II):S154 (Abstract)
 367. Kleine H-D, Zech I, Buthmann U, Freund M. Automated detection of aneuploid multiple myeloma clones in bone marrow aspirates by continuous gating analysis. *Blood* 1998; 92 (suppl. I):266b (Abstract)
 368. Kleine H-D, Zech I, Buthmann U, Freund M. Automated detection of aneuploid multiple myeloma clones in bone marrow by continuous gating. *Ann Hematol* 1998; 77 (suppl. II):S182 (Abstract)
 369. Kortus B, Decker S, Junghanß C, Freund M. Efficacy of antibiotic treatment with early therapeutic drug monitoring (TDM) and dose adaptation of aminoglycoside in hematological and oncological patients with fever. *Ann Hematol* 1998; 77 (suppl. II):S72 (Abstract)
 370. Kortus B, Junghanß C, Decker S, Steffen A, Freund M. Paravertebral lymphoma: spondylodiscitis tuberculosa; bacterial spondylodiscitis? A case report. *Ann Hematol* 1998; 77 (suppl. II):S66 (Abstract)
 371. Leithäuser M, Wilhelm S, Kleine H-D, Junghanß C, Buthmann U, Alscher A, Casper J, Freund M. Differences in CD34-positive cell numbers in peripheral blood after reinfusion of purged and unpurged stem cell products. *Ann Hematol* 1998; 77 (suppl. II):S160 (Abstract)
 372. Mantovani L, Hasenclever D, Krahl R, Pönnisch W, Herold M, Pasold R, Fiedler F, Dölken G, Kömpfe D, Seiser B, Supert R, Kubel M, Freund M, Helbig W, Niederwieser D, for the OSHO. Treatment of acute myelogenous leukemia (AML) with intermediate-dose cytarabine for both induction and postremission therapy: an East German Hematology and Oncology Study Group (OSHO) protocol. *Ann Hematol* 1998; 77 (suppl. II):S175 (Abstract)
 373. Pekrun G, Heußner P, Hake K, Casper J, Schneider W, Freund M. A randomized trial of psychological treatment for patients and their relatives on a newly established bone marrow transplantation unit. *Ann Hematol* 1998; 77 (suppl. II):S.207 (Abstract)
 374. Schulte-Vels C., Kleine H-D, Buthmann U, Freund M. A new highly efficient immunomagnetic cell depletion device used for purging of T-cells in bone marrow and leukapheresis samples. *Ann Hematol* 1998; S208 (Abstract)
 375. Schulte-Vels C, Kleine H-D, Buthmann U, Freund M. A new highly efficient immunomagnetic cell depletion device used for purging of T-cells in bone marrow and leukapheresis samples. *Blood* 1998; 92 (suppl. I):651a (Abstract)
 376. Steffen A, Decker S, Steiner B, Freund M. Avascular necrosis of bone following chemotherapy with high dose steroids. *Ann Hematol* 1998; 77 (suppl. II):S144 (Abstract)
 377. Volk J, Kleine H-D, Buthmann U, Freund M. Oxidative burst measurement in patients treated with cytostatics. *Ann Hematol* 1998; 77 (suppl. II):S189 (Abstract)
 378. Volk J, Kleine H-D, Buthmann U, Freund M. Infections during cytostatic treatment are related to suppressed oxidative burst before therapy. *Blood* 1998; 92 (suppl. I):51b (Abstract)
 379. Volk J, Kleine H-D, Buthmann U, Freund M. Infections during cytostatic treatment are related to suppressed oxidative burst before therapy. *Ann Hematol* 1998; 77 (suppl. II):S139 (Abstract)
 380. Wilhelm S, Leithäuser M, Alscher A, Kleine H-D, Junghanß C, Heußner P, Krammer-Steiner B, Casper J, Freund M. Combination of the positive selection of CD34+ cells with isolex 3001 and T-cell depletion with the TCD-system from leukapheresis - first experience. *Ann Hematol* 1998; 77 (suppl. II):S209 (Abstract)
 381. Wilhelm S, Leithäuser M, Kleine H-D, Decker S, Junghanß C, Kortus B, Alscher A, Knopp A, Lakner V, Casper J, Freund M. Peripheral blood stem cell (PBSC) mobilization and autologous PBSC transplantation in acute myeloid leukemia. *Ann Hematol* 1998; 77 (suppl. II):S203 (Abstract)
 382. Wilhelm S, Leithäuser M, Kleine H-D, Junghanß C, Freund A, Buthmann U, Cwienk M, Heußner P, Krammer-Steiner B, Casper J, Freund M. Varying of CD34+ cell quantities in peripheral blood after autologous transplantations of purged and unpurged stem cells. *Blood* 1998; 92 (suppl. I):149b (Abstract)
 383. Junghanß C, Kleine H-D, Wilhelm S, Kortus B, Leithäuser M, Steiner B, Alscher A, Casper J, Freund M. High-dose etoposid mobilizes peripheral blood progenitor cells in patients that prior failed to mobilize. *Bone Marrow Transplant* 1999; 23 (Suppl. 1):S214 (Abstract)
 384. Leithäuser M, Wilhelm S, Junghanß C, Steiner B, Heußner P, Casper J, Freund M. Factor XIII-deficiency in graft versus host disease - a case report. *Bone Marrow Transplant* 1999; 23 (Suppl. 1):S94 (Abstract)
 385. Pönnisch W, Freund M, Schultze W, Krahl R, Leiblein S, Ulrich E, Lange T, Kubel M, Lehmann T, Wilhelm S, Helbig W, Niederwieser D. Mobilization of peripheral blood progenitor cells in patients with chronic myeloid leukemia in chronic phase: IC 5 days versus IC 3 days. *Bone Marrow Transplant* 1999; 23 (Suppl. 1):S218 (Abstract)
 386. Steiner B, Leithäuser M, Wilhelm S, Junghanß C, Heußner P, Casper J, Zettl U, Freund M. Cerebral candidosis after allogeneic bone marrow transplantation - a case report. *Bone Marrow Transplant* 1999; 23 (Suppl. 1):S122 (Abstract)
 387. Wilhelm S, Knopp A, Leithäuser M, Junghanß C, Steiner B, Heußner P, Casper J, Freund M. Importance of cytogenetic and molecular methods after BMT - a case report. *Bone Marrow Transplant* 1999; 23 (Suppl. 1):S234 (Abstract)

-
388. Wilhelm S, Leithäuser M, Alscher A, Kleine H-D, Junghanß C, Heußner P, Krammer-Steiner B, Casper J, Freund M. Positive selection of CD34+ cells with isolex 3001 and T-cell depletion with the TCD-System from leukapheresis - a case report. *Bone Marrow Transplant* 1999; 23 (Suppl. 1):S211 (Abstract)
389. Poenisch W, Mitrou PS, Rieth A, Herold M, Schulze A, Assmann M, Schirmer V, Wilhelm G, Dachzelt K, Richter P, Subert R, Freund M, Friedrich T, Helbig W, Niederwieser D. A randomized multicenter study of bendamustine/prednisone versus melphalan/prednisone in the treatment of multiple myeloma. *Proc Am Soc Clin Oncol* 1999; 18:18a (Abstract)
390. Anders O, Thude H, Freund M. Analysis of the thrombomodulin gene in patients with thrombosis of unknown molecular origin. *Onkologie* 1999; 22 (suppl. 1):122
391. Etzrodt D, Junghanß C, Jain SK, Freund M. Induction of apoptosis in the myeloid leukemic cell lines HL60 and K562 by homoharringtonine. *Onkologie* 1999; 22 (suppl. 1):110
392. Freund M on behalf of the German Section of the European Epoetin Alfa Study Group. Epoetin alfa in a double-blind placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy (CT). *Onkologie* 1999; 22 (suppl. 1):175
393. Hallek M, Wilhelm M, Emmerich B, Döhner H, Fostitsch HP, Sezer O, Herold M, Knauf W, Busch R, Schmitt B, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Thiel E, Hiddemann W, Brittinger G, & the GCLLSG. Fludarabine plus cyclophosphamide (FC) and dose-intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL). Results of two phase II studies (CLL2 protocol) of the German CLL Study Group (GCLLSG). *Onkologie* 1999; 22 (suppl. 1):50
394. Krahl R, Lehmann T, Fiedler F, Franke A, Dachzelt K, Pasold R, Uhle R, Schwarzer A, Hoffmann FA, Steglich J, Freund M, Herold M, Subert R, Schwenke H, von Grünhagen U, Schwalbe E, Dölken G, Fink R, Schwabe E-M, Helbig W, Niederwieser D, for the East German Hematology and Oncology Group (OSHO). Efficacy and toxicity of interferon alpha (IFN alpha) in combination with hydroxyurea (HU) in a fixed ration in chronic myelogenous leukemia (CML): a preliminary report. *Onkologie* 1999; 22 (suppl. 1):51
395. Krammer-Steiner B, Wilhelm S, Kortus B, Steiner M, Schuff-Werner P, Freund M. Severe hypophosphatemia in a patient undergoing hematopoietic reconstruction after allogeneic peripheral blood stem cell transplantation - a case report. *Onkologie* 1999; 22 (suppl. 1):209
396. Kunst D, Lück A, Steiner B, Decker S, Kortus B, Steffen A, Junghanß C, Wilhelm S, Heußner P, Leithäuser M, Kleine H-D, Köhne H, Casper J, Freund M. Reduction of early mortality after 4 years experience in autologous bone marrow transplantation. *Onkologie* 1999; 22 (suppl. 1):212
397. Leithäuser M, Wilhelm S, Kleine H-D, Junghanß C, Steiner B, Steffen A, Buthmann U, Casper J, Freund M. Cell adhesion molecule expression on CD34-positive cells after autologous transplantation. *Onkologie* 1999; 22 (suppl. 1):186
398. Mantovani L, Krahl R, Pönisch W, Fiedler F, Pasold R, Freund M, Herold M, Franke A, Peter N, Subert R, Kettner E, Schmoll H-J, Dölken G, Kämpfe D, Steglich J, Grobe N, Schulze M, Huhn R, Assmann M, Opitz B, Schwalbe E, Dachzelt K, Ittel TH, Helbig W, Niederwieser D. Intermediate-dose cytarabine treatment delivered at prolonged infusion rates for de novo acute myeloid leukemia. *Onkologie* 1999; 22 (suppl. 1):105
399. Meran JG, Freund M, Kessen-Albers M, Ganser A, Ludwig H. Cyclosporin A (CsA) in steroid-refractory, chronic idiopathic immune-thrombocytopenia (ITP). *Onkologie* 1999; 22 (suppl. 1):121
400. Pönisch W, Freund M, Schultze W, Krahl R, Leiblein S, Lange T, Lehmann T, Helbig W, Niederwieser D. Mobilization of peripheral blood progenitor cells in 53 patients with chronic myeloid leukemia in chronic phase: IC 5 days versus IC 3 days. *Onkologie* 1999; 22 (suppl. 1):51
401. Seidel M, Kleine H-D, Buthmann U, Alscher A, Freund M. Determination of CD34+ subpopulation in leukapheresis products derived by different mobilization protocols. *Onkologie* 1999; 22 (suppl. 1):211
402. Steffen A, Decker S, Kleine H-D, Eisenberger B, Freund M. Neutrophil leukemia - a case report. *Onkologie* 1999; 22 (suppl. 1):115
403. Steiner M, Kohlschein P, Kleine H-D, Leithäuser M, Freund M, Schuff-Werner P. Analysis of haematopoietic progenitor/stem cells in peripheral blood using the SE-9000 automated haematological system - analytical evaluation and initial clinical experience. *Onkologie* 1999; 22 (suppl. 1):211
404. Wilhelm S, Leithäuser M, Junghanß C, Steiner B, Kleine H-D, Heußner P, Kortus B, Alscher A, Casper J, Freund M. Mobilization of peripheral blood progenitor cells - determination of optimal time point of start apheresis depending on mobilization regime. *Onkologie* 1999; 22 (suppl. 1):206
405. Hallek M, Wilhelm M, Emmerich B, Döhner H, Fostitsch HP, Sezer O, Herold M, Knauf W, Busch R, Schmitt R, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Thiel E, Hiddemann W, Brittinger G, & the GCLLSG. Fludarabine plus cyclophosphamide (FC) and dose - intensified chlorambucil (DIC) für the treatment of chronic lymphocytic leukemia (CLL): results of two phase II studies (CLL2-Protocol) of the German CLL Study Group (GCLLSG). *Blood* 1999; 94 (suppl. 1, pt. 1):313a
406. Herold M, Schulze A, Mantovani L, Franke A, Freund M, Ismer B, Dachzelt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann B, Klinkenstein C, Schulze M, Arzberger A, Bremer K, Hahnfeld S, Müller C, Müller C, Kettner E, for the East German Study Group Hematology Oncology (OSHO). BOP versus COP in advanced low grade non-Hodgkin's lymphomas - results of a randomized multicenter study. *Blood* 1999; 94 (Suppl. 1, pt. 1):262b

407. Hoelzer D, Arnold R, Buechner T, Freund M, Gassmann W, Goekbuget N, Heil G, Hiddemann W, Lipp T., Löffler H, Ludwig W-D, Maschmeyer G, Messerer D, Schwartz S, Thiel E. Characteristics, outcome and risk factors in adult T-lineage acute lymphoblastic leukemia (ALL). *Blood* 1999; 94 (Suppl. 1, pt. 1):657a
408. Junghanss C, Etzrodt D, Jain SK, Freund M. Homoharringtonine induces apoptosis in HL60, K562 and Jurkat cells, but not in Raji. *Blood* 1999; 94 (Suppl. 1, pt. 1):192b
409. Krahl R, Pönisch W, Lehmann T, Fiedler F, Freund M, Herold M, Franke A, Pasold R, Schultze W, Spohn C, Subert R, Uhle R, Hoffmann FA, Kämpfe D, Dölken G, Richter P, von Grünhagen U, Deininger M, Helbig W, Niederwieser D. Successful mobilization of hematopoietic progenitor cells with very low Ph+ contamination in patients in early phase CML. *Blood* 1999; 94 (Suppl. 1, pt. 1):533a
410. Kroeger H, Wilhelm S, Koppitz E, Freund M, Lorenz M, Petrowsky H, Köhne C-H. Hypermethylation of p15 and p16 genes in esophageal carcinoma. *Proc Am Soc Clin Oncol* 2000; 19:320a
411. Schuler U, Jenke A, Wilhelm S, Freund M, Ehninger G. Busulfan overdose in the conditioning for BMT. *Proc Am Soc Clin Oncol* 2000; 19:63a
412. Casper J, Wilhelm S, Steiner B, Hammer U, Wegener R, Freund M. Treosulfan and fludarabine conditioning for allogeneic blood stem cell transplantation. *Bone Marrow Transplant* 2000; 25 (suppl. 1):S129
413. Deininger MWN, Krahl R, Pönisch W, Lehmann T, Peter N, Kettner E, Dachselt K, Steglich J, Stelzer E, Schwalbe E, Fiedler F, Freund M, Franke A, Pasold P, Schultze W, Spohn C, Subert R, Uhle R, Hoffmann FA, Dölken G, Richter P, von Grünhagen U, Haak U, Grobe N, Helbig W, Niederwieser D. Mobilisation of Ph-negative progenitor cells from CML patients in early chronic phase: superior results with a less toxic regimen. *Bone Marrow Transplant* 2000; 25 (suppl. 1):S9
414. Jenke A, Schuler U, Ehninger G, Wilhelm S, Freund M, Müller W, S. Accidental busulfan overdose in the conditioning for stem cell transplantation. *Bone Marrow Transplant* 2000; 25 (suppl. 1):S139
415. Steiner B, Wilhelm S, Casper J, Saka B, Freund M. Laser surgery in the treatment of polypous mucosa hyperplasia after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 2000; 25 (suppl. 1):S213
416. Wilhelm S, Steiner B, Kortus B, Leithäuser M, Casper J, Reisinger E, Freund M. Allogeneic BMT in a patient with active cerebral and ocular toxoplasmosis - a case report. *Bone Marrow Transplant* 2000; 25 (suppl. 1):S195
417. Casper J, Steiner B, Wolff D, Etzrodt D, Kleine H-D, Wilhelm S, Hammer U, von Wurm N, Röber S, Wegener R, Freund M. Toxicity reduced conditioning with teosulfan and fludarabine for allogeneic blood stem cell transplantation. *Onkologie* 2000; 23 (suppl. 7):120
418. Deininger M, Krahl R, Pönisch W, Lehmann T, Al Ali H, Fiedler F, Freund M, Herold M, Franke A, Pasold R, Schultze W, Spohn C, Subert R, Uhle R, Hoffmann FA, Kämpfe D, Dölken G, Richter P, von Grünhagen U, Haak U, Grobe N, Dachselt K, Helbig W, Niederwieser D, for the East German Hematology and Oncology Group (OSHO). Treatment of chronic phase CML: equal efficacy but less toxicity of interferon alpha plus hydroxurea (IFN/HU) compared to IFN plus cytarabine (IFN/ARA-C). Preliminary results from a randomized trial by the OSHO. *Onkologie* 2000; 23 (suppl. 7):137
419. Knauf WU, Fischer J, Thiel E, Freund M. Escalating doses of 2-CDA in the treatment of relapsed adult acute lymphoblastic leukemia. *Onkologie* 2000; 23 (suppl. 7):141
420. Knopp A, Kleine H-D, Leithäuser M, Decker S, Feltl J, Buthmann U, Eisenberger B, Wolff D, Freund M. Two cases of acute myeloid leukemia with chromosomal translocations typical for lymphoid malignancies. *Onkologie* 2000; 23 (suppl. 7):99
421. Kroeger H, Wilhelm S, Koppitz E, Freund M, Lorenz M, Petrowsky H, Köhne CH. Hypermethylation of inhibitors of CDK4/6 in esophageal cancer. *Onkologie* 2000; 23 (suppl. 7):67
422. Kunst D, Lück A, Kleine H-D, Zingler C, Freund M, Casper J. Production of hematopoietic growth factors by yolk sac tumour cell lines. *Onkologie* 2000; 23 (suppl. 7):103
423. Leithäuser M, Wilhelm S, Steiner B, Freund M. critical care score systems in hematological and oncological patients before transfer to intensive care units. *Onkologie* 2000; 23 (suppl. 7):172
424. Niederwieser D, Pönisch W, Becker C, Mantovani L, Wedding U, Herold M, Subert R, Freund M, Fiedler F, Pasold R, Peter N, Meran J, Fasshauer E, Dachselt K, Grobe N, Assmann M, Kettner E, Steglich J, Huhn R, Schulze M, Ittel T, Klinkenstein C, Doepper J, Winkelmann C, Knauf W, Schmoll H-J, Krahl R, Helbig W. Treatment of acute myeloid leukemia (AML) in patients upper the age of 60 years: report of the AML97-038 study of the East German Hematology and Oncology Study Group (OSHO). *Onkologie* 2000; 23 (suppl. 7):29
425. Pappas M, Kleine H-D, Leithäuser M, Buthmann U, Alscher A, Freund M. Influence of cryopreservation on the expression of adhesion molecules on CD34+ peripheral blood stem cells (PBSC). *Onkologie* 2000; 23 (suppl. 7):38
426. Steiner B, Riebold D, Wolff D, Möller F-W, Reisinger EC, Nizze H, Freund M. Detection of eggs of strongyloides in the urine: a case of macrohaematuria after allogeneic blood stem cell transplantation. *Onkologie* 2000; 23 (suppl. 7):167
427. Steiner B, Wilhelm S, Decker S, Casper J, Freund M. Allogeneic stem cell transplantation in patients with NHL following TBI and VP16 conditioning regimen - preliminary single center experience. *Onkologie* 2000; 23 (suppl. 7):125

428. Uharek L, Mantovani L, Hasenclever D, Pönisch W, Becker C, Krahl R, Pasold R, Fiedler F, Herold M, Freund M, Peter N, Franke A, Subert R, Kettner E, Dölken G, Meran J, Schmoll H-J, Kämpfe D, Grobe N, Huhn R, Steglich J, Schulze M, Assmann M, Opitz B, Ittel TH, Schultze M, Schwalbe E, Schirmer V, Dachsel K, Niederwieser D, for the East German Hematology and Oncology Group (OSHO). Intermediate-dose cytarabine treatment delivered at prolonged infusion rates for acute myeloid leukemia (AML). *Onkologie* 2000; 23 (suppl. 7):140
429. Wilhelm S, Koppitz E, Freund M, Lorenz M, Pawlowski H, Köhne CH. Polymorphism in the cyclin D1 gene influences survival of esophageal cancer patients. *Onkologie* 2000; 23 (suppl. 7):67
430. Casper, J., Wilhelm, S., Steiner, B., Wolff, D., Hammer, R., Wegener, R., Kleine, H.-D., and Freund, M. Toxicity-reduced conditioning with treosulfan and fludarabine prior to allogeneic blood stem cell transplantation. *Blood* 96, Abstract 5029. 2000.
431. Herold, M., Assmann, M., Dachsel, K., Ehninger, G., Eschenburg, H., Freund, M, Franke, A., von Grünhagen, U., Hahnfeld, S., Hoffmann, F.-A., Ittel, T., Kettner, E., Klinkenstein, C., Knauf, W., Niederwieser, D., Pasold, R., Rohrberg, R., Steglich, J., Srock, S., and Wolf, H. Efficacy and toxicity of MCP versus MCP plus rituximab - interim analysis of a clinical phase III study. *Blood* 96, Abstract 4761. 2000.
432. Wilhelm, S., Bittorf, T., Leithäuser, M., Lüdtke, B., Steiner, B., Casper, J., Kleine, H. D., Brock, J., and Freund, M. Activation of STAT proteins in allogeneic stem cell transplantation - differences between conventional and non myeloablative regimens. *Blood* 96, Abstract 3317. 2000.
433. Wilhelm, S., Bittorf, T., Leithäuser, M., Lüdtke, B., Steiner, B., Casper, J., Brock, J., and Freund, M. Activation of stat proteins in allogeneic stem cell transplantation - influence of conditioning regimens and CMV-infection. *Bone Marrow Transplantation* 27 (Suppl. 1), Abstract P500. 2001.
434. Casper, J., Steiner, B., Wolff, D., Kleine, H.-D., Wilhelm, S., Hammer, U., von Wurmb, N., Roeber, S., Wegener, R., and Freund, M. Conditioning with treosulfan and fludarabine for allogeneic blood stem cell transplantation. *Bone Marrow Transplantation* 27 (Suppl. 1), Abstract P715. 2001.
435. Wolff, D., Krammer-Steiner, B., Wilhelm, S., Leithäuser, M., Casper, J., and Freund, M. GvHD associated with peripheral eosinophilia after hematopoietic stem cell transplants. *Bone Marrow Transplantation* 27 (Suppl. 1), Abstract. 2001.
436. Casper, J., Köhne, C., Lück, A., Steiner, B., Wolff, D., and Freund, M. Allogeneic transplantation of patient with primary or secondary cardiac amyloidosis. *Onkologie* 24 (S6), 124. 2001.
437. Casper, J., Knauf, W., Steiner, B., Wolff, D., Lück, A., Kleine, H., Hammer, U., Wegener, R., and Freund, M. Treosulfan and fludarabine as toxicity reduced conditioning regimen in allogeneic blood stem cell transplantation. *Onkologie* 24 (S 6), 220. 2001.
438. Freund, M., Sezer, O., Ammon, A., Aldaoud, A., Aulitzky, W., Brudler, O., Derigs, H., Dürk, H., Einsele, H., Emmerich, B., Fischer, J., Fuchs, R., Haus, U., Herold, M., Hoffmann, R., Kaiser, U., Kleeberg, U., Maintz, C., Mittermüller, J., Niederwieser, D., Nowrousian, M., Pasold, R., Peest, D., Pflüger, K., Rohrberg, R., Schmidt-Wolf, I., Seipelt, G., Weinkauff, B., Wolf, H., Wolf, H. H., and Wörmann, H. A randomized study of zoledronate versus control in patients with multiple myeloma stage I. *Onkologie* (24 (S 6)), -86. 2001.
439. Freund, M., Arnold, R., Heil, G., Ludwig, W., Lipp, T., Niederwieser, D., Rieder, H., Thiel, E., Fiedler, F., Grobe, N., Grote-Metke, A., Hähling, D., Hartmann, F., Gökbüget, N., and Hoelzer, D. Treatment of relapsing acute lymphocytic leukemia. *Onkologie* 24 (S 6), 40. 2001.
440. Herold, M., Fiedler, F., Pasold, R., Srock, S., Knauf, W., Freund, M., Naumann, R., Aßmann, M., Rohrberg, R., von Grünhagen, U., Klinkenstein, R., Gericke, U., Franke, A., Kaiser, U., Niederwieser, D., Steglich, J., Clemens, M.-R., Kettner, E., Mey, U., Richter, P., Hoffmann, F.-A., Bremer, K., Dölken, G., Eschenburg, H., Hahnfeld, S., Haak, U., Lakner, V., and Subert, R. Efficacy and toxicity of rituximab plus MCP versus MCP alone in advanced indolent NHL - New interim results of a clinical phase III study of the East German Study Group Hematology/Oncology (OSHO). *Onkologie* 24 (S 6), 73. 2001.
441. Kleine, H.-D., Etzrodt, D., Buthmann, U., and Freund, M. Detection of aneuploid multiple myeloma clones in bone marrow samples by flow cytometry. *Onkologie* 24 (S 6), 51. 2001.
442. Köhne, C.-H., Scheithauer, W., Cunningham, D., DiCostanzo, F., Glimelius, B., Aranda, E., Rougier, P., Palmer, M., Wils, J., Hecker, H., Hartung, G., and Freund, M. Equal prognosis of elderly and non-elderly patients with metastatic colorectal cancer receiving 5-FU treatment. A retrospective study. *Onkologie* 24 (S6), 174. 2001.
443. Leithäuser, M., Kahl, C., Neuber, K., Wilhelm, S., Kunst, D., Rutjes, J., Podbielski, A., and Freund, M. Catheter-related blood stream infections in hematological and oncological patients - a surveillance study. *Onkologie* 24 (S6), 139. 2001.
444. Seule, M., Steiner, M., Laser, N., Freund, M., Schuff-Werner, P., and Köhne, C. Frequency of dihydropyrimidine dehydrogenase mutation DPYD2*A (c.1905+1G/A). *Onkologie* 24 (S6), 181. 2001.
445. Straka, C., Wandt, H., Freund, M., Kubin, T., Fischer, J., Metzner, B., Kropff, M., Frickhofen, N., Brack, N., Döhner, H., Einsele, H., and Emmerich, B. DSMM pilot study: Age-adapted tandem melphalan with PBSCT in patients 60-70 years with multiple myeloma. *Onkologie* 24 (S6), 179. 2001.

446. Uharek, L., Krahl, R., Pönisch, W., Becker, C., Mantovani, L., Wedding, U., Herold, M., Freund, M., Franke, A., Fiedler, F., Pasold, R., Peter, N., Subert, R., Meran, J., Faßhauer, E., Dachzelt, K., Grobe, N., Aßmann, M., Kettner, E., Dölken, G., Kämpfe, D., Steglich, J., Huhn, R., Schulze, M., Schultze, W., Winkelmann, C., Knauf, W., Schmoll, H. J., Schott, G., Helbig, W., and Niederwieser, D. Treatment of acute myeloid leukemia (AML) in patients under the age of 60: Report of the AML96-#033 and AML97-#038 study of the East German Hematology and Oncology Study Group. *Onkologie* 24 (S 6), 40. 2001.
447. Wilhelm, S., Holle, A., Leithäuser, M., Casper, J., and Freund, M. Ultrasonographic process of a hepatic veno-occlusive disease after autologous peripheral blood stem cell transplantation - a case report. *Onkologie* 24 (S 6), 206. 2001.
448. Wolff, D., Krammer-Steiner, B., Lakner, V., Casper, C., Richter, I., Dölken, G., and Freund, M. The development of allogeneic stem cell transplantation in Mecklenburg-Vorpommern (MV) from 1991 to 2000. *Onkologie* 24 (S6), 157. 2001.
449. Casper, J., Wilhelm, S., Steiner, B., Wolff, D., Hammer, R., Wegener, R., Kleine, H.-D., and Freund, M. Toxicity-reduced conditioning with treosulfan and fludarabine prior to allogeneic blood stem cell transplantation. *Blood* 96, Abstract 5029. 2001.
450. Herold, M., Assmann, M., Dachzelt, K., Ehninger, G., Eschenburg, H., Freund, M., Franke, A., von Grünhagen, U., Hahnfeld, S., Hoffmann, F.-A., Ittel, T., Kettner, E., Klinkenstein, C., Knauf, W., Niederwieser, D., Pasold, R., Rohrberg, R., Steglich, J., Srock, S., and Wolf, H. Efficacy and toxicity of MCP versus MCP plus rituximab - interim analysis of a clinical phase III study. *Blood* 96, Abstract 4761. 2001.
451. Wilhelm, S., Bittorf, T., Leithäuser, M., Lüdtke, B., Steiner, B., Casper, J., Kleine, H. D., Brock, J., and Freund, M. Activation of STAT proteins in allogeneic stem cell transplantation - differences between conventional and non myeloablative regimens. *Blood* 96, Abstract 3317. 2001.
452. Beelen, D. W., Trenchel, R., Casper, J., Freund, M., Basara, N., Fauser, A., Hertenstein, B., Scheulen, M. E., Hilger, R. A., and Holler, E. Evaluation of safety, efficacy and pharmacokinetics of dose-escalated treosulfan (Treo) / cyclophosphamide (CY) conditioning prior to allogeneic transplantation of high-risk leukemia patients. *Blood* 100, 415a. 2002.
453. Borowski, A., Steiner, B., Wolff, D., Zurborn, K. H., Casper, J., and Freund, M. Feasibility of a specific in-patient early rehabilitation program for patients after allogeneic bone marrow transplantation: early experience. *Onkologie* 25 (Suppl. 4), 244. 2002.
454. Buesche, G., Freund, M., Hecker, H., Heinze, B., Pfirrmann, M., Heimpel, H., Hehlmann, R., Hasford, J., Ganser, A., Geogii, A., Buhr, T., and Kreipe, H. Dose-dependent effect of interferon alpha on myelofibrosis in chronic myeloid leukemia. *Onkologie* 25 (Suppl. 4), 174. 2002.
455. Casper, J., Knauf, W., Schwenke, M., Steiner, B., Wolff, D., Lueck, A., Leithäuser, M., and Freund, M. Allogeneic blood stem cell transplantation after treosulfan and fludarabine conditioning. *Bone Marrow Transplantation* 29 (Suppl. 2), P599. 2002.
456. Casper, J., Knauf, W., Dölken, G., Wolff, D., Steiner, B., Kleine, H.-D., Hammer, U., Wegener, R., and Freund, M. Treosulfan and fludarabine as conditioning for allogeneic blood stem cell transplantation - final analysis of a phase I/II study. *Onkologie* 25 (Suppl. 4), 93. 2002.
457. Freund, M. Structures in the organization of cancer care in Germany. *Onkologie* 25 (Suppl. 4), 280. 2002.
458. Goekbuget, N., Boehme, A., Freund, M., Herrmann, S., Horst, H., Schmid, M., Krauter, J., Zander, I., and Hoelzer, D. New treatment options for relapsed and rapidly progressive T-ALL and T-lymphoblastic lymphoma (LBL). *Blood* 100, 765a. 2002.
459. Gökbüget, N., Arnold, R., Bartram, C. R., Böhme, A., Freund, M., Ganser, A., Kneba, M., Lipp, T., Ludwig, W. D., Maschmeyer, G., Rieder, H., Thiel, E., Messerer, D., Weiss, A., and Hoelzer, D. Treatment of T-ALL and T-lymphoblastic lymphoma (T-LBL). *Onkologie* 25 (Suppl. 4), 260. 2003.
460. Hähling, D., Subert, R., and Freund, M. 24-year-old gravida at 21 weeks with Philadelphia-chromosome-positive acute lymphoblastic leukemia. *Onkologie* 25 (Suppl. 4), 14. 2002.
461. Hegenbart, U., Krahl, R., Kliem, C., Rudolph, M., Grommisch, L., Pönisch, W., Wedding, U., Herold, M., Subert, R., Freund, M., Fiedler, F., Pasold, R., Peter, N., Meran, J., Fasshauer, E., Dachzelt, K., Grobe, N., Assmann, M., Kettner, E., Steglich, J., Huhn, R., Schulze, M., Ittel, T., Klinkenstein, E., Doepper, J., Winkelmann, C., Knauff, W., and Niederwieser, N. Treatment of acute myeloid leukemia (AML) in patients older than 60 years: report of the AML97-#38 study of the east german hematology and oncology group (OSHO). *Onkologie* 25 (Suppl. 4), 18. 2002.
462. Herold, M., Schulze, A., Niederwieser, D., Franke, A., Fricke, H.-J., Richter, P., Freund, M., Ismer, B., Dachzelt, K., Boewer, C., Schirmer, V., Weniger, J., Pasold, R., Winkelmann, B., Klinkenstein, C., Schulze, M., Arzberger, A., Bremer, K., Hahnfeld, S., Mueller, C., and Mueller, C. BOP versus COP in advanced indolent lymphomas - results of a randomized multicentre phase III study of the East German Study Group Hematology/Oncology (OSHO). *Blood* 100, 779a. 2002.
463. Kahl, C., Kleine, H.-D., and Freund, M. Coexpression of CD38, HLA-DR and CDw90 in CD133 positive and negative stem cells using multiparametric four-colour flow cytometry (MFC). *Onkologie* 25 (Suppl. 4), 87. 2002.
464. Kahl, C., Leithäuser, M., Wilhelm, S., Wolff, D., Steiner, B., Hartung, G., Casper, J., and Freund, M. Impact of high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation in the treatment of peripheral t-cell lymphomas. *Onkologie* 25 (Suppl. 4), 59. 2002.

-
465. Kleine, H.-D., Stamm, C., Westphal, B., Petzsch, M., Kittner, C., Nienaber, C. A., Steinhoff, G., and Freund, M. Bone marrow stem cell transplantation for myocardial regeneration after myocardial infarction: a clinical phase-I trial. *Blood* 100, 512a. 2003.
466. Kleine, H.-D., Buthmann, U., and Freund, M. Flow cytometric detection of aneuploid plasma cells in bone marrow and apheresis material. *Journal of Cancer Research and Clinical Oncology* 128 (Suppl.1), S24. 2002.
467. Kortus-Götze, B., Nötzel, E., Schnabel, S., Holle, A., Liebe, S., and Freund, M. An unusual course of a Klatsin's tumor: A case report. *Onkologie* 25 (Suppl. 4), 38. 2002.
468. Kortus-Götze, B., Kleine, H.-D., and Freund, M. Establishment of new computer-based databases for the quality assurance at the Division of Hematology and Oncology, Department of Internal Medicine, University of Rostock. *Onkologie* 25 (Suppl. 4), 225. 2002.
469. Leithäuser, M., Kahl, C., Wilhelm, S., Wolff, D., Junghanß, C., Hartung, G., Casper, J., and Freund, M. Prolonged infusion time of amphotericin B - first experience. *Onkologie* 25 (Suppl. 4), 201. 2002.
470. Niederwieser, D., Wedding, U., Hegenbart, U., Pönisch, W., Herold, M., Subert, R., Freund, M., Fiedler, F., Pasold, R., Peter, N., Meran, J., Fasshauer, E., Dachsel, K., Grobe, N., Assmann, M., Kettner, E., Uharek, L., Steglich, J., Huhn, R., Schulze, M., Schultze, W., Ittel, T., Klinkenstein, C., Doepper, J., Winkelmann, C., Knauf, W., Schmoll, H.-J., Krahl, R., Helbig, W., and for the East German Study Group. Treatment of acute myeloid leukemia dependign on biological risk factors: the AML studies of the East German Study Group (OSHO). *Onkologie* 25 (Suppl. 4), 136. 2002.
471. Niederwieser, D., Hegenbart, U., Wedding, U., Herold, M., Subert, R., Freund, M., Fiedler, F., Pasold, R., Peter, N., Meran, J., Fasshauer, E., Dachsel, K., Grobe, N., Assmann, M., Kettner, E., Steglich, J., Huhn, R., Schulze, M., Schultze, W., Ittel, T., Klinkenstein, C., Krahl, R., Pönisch, W., Kliem, C., Grommisch, L., Rudolph, M., Doepper, J., Winkelmann, C., Knauf, W., and Helbig, W. Treatment of acute myeloid leukemia (AML) in patients upper the age of 60 years: report of the AML97-#38 study of the East german Hematology and Oncology Group (OSHO). *Blood* 100, 345a. 2002.
472. Schulze, A., Klein, P., Niederwieser, D., Franke, A., Fricke, H. J., Richter, P., Freund, M., Ismer, B., Dachsel, K., Boewer, C., Schirmer, V., Weniger, J., Schwarzer, A., Pasold, R., Winkelmann, B., Klinkenstein, C., Schulze, M., Arzberger, A., Bremer, K., Hahnfeld, S., Müller, C., and Herold, M. BOP versus COP in advanced indolent lymphomas - follow up results of a randomised multicenter study of the East German study group hematology/oncology (OSHO). *Onkologie* 25 (Suppl. 4), 63. 2002.
473. Steiner, B., Wolff, D., Heussner, P., Leithäuser, M., Kahl, C., Wilhelm, St., Casper, J., and Freund, M. Is it safe to treat blood stem cell transplant recipients with viral or fungal infections at home? *Onkologie* 25 (Suppl. 4), 244. 2002.
474. Steiner, B., Lazar, Y., Kittner, C., Rutjes, J., Leithäuser, M., Kahl, C., Wolff, D., Casper, J., Hartung, G., and Freund, M. Treatment options for leukaemic meningeosis: intrathecal application of Rituximab and yttrium radioisotopes. *Onkologie* 25 (Suppl. 4), 179. 2002.
475. Uharek, L., Mantovani, L., Hasenclever, D., Pönisch, W., Becker, C., Krahl, R., Herold, M., Pasold, R., Franke, A., Freund, M., Fiedler, F., Peter, N., Subert, R., Meran, J., Wedding, U., Kämpfe, D., Kettner, E., Schott, G., Dölken, G., Florschütz, A., Schultze, W., Ittel, T. H., Dachsel, K., Huhn, R., Schmoll, H.-J., Opitz, B., Schulze, M., Assmann, M., Schott, G., Steglich, J., Schirmer, V., and Helbig, W. Results of a phase-III-study comparing the effectiveness and toxicity of ara-C given at two different infusion rates in patients with de novo secondary acute myeloid leukemia (AML). *Blood* 100, 766a. 2002.
476. Uhrarek, L., Mantovani, L., Krahl, R., Hasenklever, D., Pönisch, W., Herold, M., Pasold, R., Franke, A., Freund, M., Fiedler, F., Peter, N., Subert, R., Meran, J., Wedding, U., Kämpfe, E., Kettner, E., Grobe, N., Dölken, G., Florschütz, A., Schultze, W., Ittel, T. H., Dachsel, K., Huhn, R., Schmoll, H.-J., Opitz, B., Schulze, M., Aßmann, M., Schott, G., Steglich, J., Schirmer, V., Helbig, W., and Niederwieser, D. The infusion rate of Ara-C has no impact on remission rate, toxicity and event-free survival in patients with de novo or secondary acute myeloid leukemia (AML): Results of a phase III-trial. *Onkologie* 25 (Suppl. 4), 22. 2002.
477. Wilhelm, S., Kahl, C., Leithäuser, M., Wolff, D., Steiner, B., Hartung, G., Casper, J., and Freund, M. Osteolytic granulocytic sarcoma (chloroma) before allogeneic PBSC transplantation. *Onkologie* 25 (Suppl. 4), 42. 2002.
478. Wolff, D., Steiner, B., Zingler, C., Wilhelm, S., Lazar, Y., Leithäuser, M., Hartung, G., Casper, J., and Freund, M. Acute GVHD is associated with elevated sIL-2R and IL-10 whereas IL-5 predicts severity of acute GVHD. *Blood* . 2002.
479. Wolff, D., Steiner, B., Lazar, Y., Zingler, C., Wilhelm, S., Leithäuser, M., Hartung, G., Casper, J., and Freund, M. Acute GvHD is associated with elevated sIL-2R and IL-10 wereas IL-5 may predict severity of acute GvHD. *Blood* 100, 422a. 2002.
480. Wolff, D., Casper, J., Steiner, B., Kleine, H.-D., Wilhelm, S., Leithäuser, M., Junghanss, C., and Freund, M. Treatment of steroid resistant acute GvHD with daclizumab and etanercept. *Bone Marrow Transplantation* . 2001.
481. Wolff, D., Casper, J., Steiner, B., Kleine, H.-D., Wilhelm, S., Leithaeuser, M., Junghanss, C., and Freund, M. Treatment of steroid resistant acute GvHD with daclizumab and etanercept. *Bone Marrow Transplantation* 29 (Suppl. 2), P690. 2002.
482. Wolff, D., Steiner, B., Kleine, H.-D., Wilhelm, S., Leithäuser, M., Junghanß, C., Casper, J., and Freund, M. Treatment of steroid resistant acute GvHD with daclizumab and eterncept. *Blood* 100, 421a. 2002.

-
483. Becker, C., Krahl, R., Hegenbart, U., Pönisch, W., Uharek, L., Wedding, U., Herold, M., Subert, R., Freund, M., Fiedler, F., Pasold, R., Peter, N., Meran, J., Fasshauer, E., Dachsel, K., Grobe, N., Assmann, M., Kettner, E., Steglich, J., Huhn, R., Schulze, M., Schultze, W., Ittel, T., Klinkenstein, C., Doepper, J., Winkelmann, C., Knauf, W., Helbig, W., Niederwieser, D., and on behalf of the East German Hematology and Oncology Group (OSHO). Treatment of acute myeloid leukemia in patients over the age of 60: Report of the prospective AML97 study of the East German Hematology and Oncology Group. *Onkologie* 26 S5, 87. 2004.
484. Casper, J., Volin, L., Wandt, H., Aschan, J., Zander, A. R., Holowiecki, J., Ruutu, T., Freund, M., and for the Baltic Study Group on Treosulfan. Allogeneic blood stem cell transplantation after dose-escalated treosulfan and fludarabine conditioning in patients with hematological malignancies. *Onkologie* 26 S5, 77. 2004.
485. Casper, J., Blau, W., Volin, L., Ruutu, T., Wandt, H., Schaefer-Eckart, K., Holowiecki, J., Giebel, S., Aschan, J., Zander, A. R., Kroeger, N., Freund, M., and Knauf, W. U. Allogeneic hematopoietic stem cell transplantation after treosulfan/fludarabine conditioning in high-risk patients with hematologic malignancies. *Blood* 102(11), Abstract 1704. 2003.
486. Casper, J., Wilhelm, S., Kahl, C., Vasarhelyi, A., Ewert, A., Bock, A., Wolff, D., Steiner, B., Hartung, G., and Freund, M. Successful treatment of a Trichosporon beigelii infection in a patient after mismatched unrelated allogeneic stem cell transplantation for myelodysplastic syndrome. *Onkologie* 26 S5, 153. 2003.
487. Casper, J., Wandt, H., Volin, L., Aschan, J., Blau, W., Thiel, E., Ruutu, T., Freund, M., Knauf, W., and for the Baltic Study Group on Treosulfan. Treosulfan / fludarabine as conditioning regimen for allogeneic blood stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. *Onkologie* 26 S5, 77. 2004.
488. Casper, J., Aschan, J., Ruutu, T., Volin, L., Wandt, H., Schaefer-Eckart, K., Freund, M., and Knauf, W. Treosulfan and fludarabine conditioning prior to allogeneic transplantation of patients with multiple myeloma. *Bone Marrow Transplantation* 31, Suppl. 1, Abstract: P435. 2003.
489. Freund, M., Kakkar, A. Y., Haas, S., Heilmann, L., von Tempelhoff, G.-F., Brom, J., and Weidinger, G. A randomized trial of the low molecular weight heparin certoparin against placebo in the long-term prevention of venous thromboembolism in patients with metastatic breast cancer. *Blood* 102(11), Abstract 734. 2003.
490. Hirchenhain, C., Steiner, B., Zingler, C., Wolff, D., and Freund, M. Bone metabolism and risk-adjusted ibandronate drug therapy after allogeneic blood stem cell transplantation. *Onkologie* 26 S5, 158. 2003.
491. Holler, E., Trenchel, R., Casper, J., Freund, M., Hilger, R., Scheulen, M., Basara, N., Fauser, A., Hertenstein, B., Andreesen, R., and Beelen, D. Treosulfan/cyclophosphamide conditioning in high-risk leukemia patients - a clinical phase I and pharmacokinetic study. *Bone Marrow Transplantation* 31, Suppl. 1, Abstract: P642. 2003.
492. Knauf, W. U., Blau, W., Ruutu, T., Einsele, H., Thiel, E., Freund, M., and Casper, J. Treosulfan / fludarabine as conditioning regimen for allogeneic stem cell transplantation in multiple myeloma. *Blood* 102(11), Abstract 2630. 2003.
493. Knauf, W. U., Blau, I. W., Ruutu, T., Einsele, H., Thiel, E., and Freund, M. Treosulfan / fludarabine as conditioning regimen for allogeneic stem cell transplantation in multiple myeloma. *Onkologie* 26 S5, 77. 2004.
494. Knopp, A., Wolff, D., Weirich, V., Koppitz, E., Steiner, B., Leithäuser, M., Kleine, H.-D., Junghans, C., Casper, J., Hartung, G., and Freund, M. Relapse of Philadelphia-positive ALL with loss of the Y-chromosome after sexmismatched allo PBST and ongoing GvHD. *Onkologie* 26 S5, 216. 2003.
495. Koenigsmann, M., Mohren, M., Franke, A., Becker, E., Heim, M., Kahl, C., Freund, M., and Casper, J. Tandem high-dose therapy including treosulfan, melphalan and thiotepa with autologous stem cell transplantation for relapsed or refractory high-grade lymphoma. *Bone Marrow Transplantation* 31, Suppl. 1, Abstract: P409. 2003.
496. Kroger, N., Zabelina, T., Schieder, H., Ayuk, F., Stute, N., Kratochville, A., Fehse, N., Hassenpflug, J., Panse, J., Casper, J., Freund, M., and Zander, A. Dose-reduced conditioning with treosulfan/fludarabine followed by allogeneic stem cell transplantation from related and unrelated donors in patients with AML and MDS/sAML. *Blood* 102(11), Abstract 5060. 2003.
497. Kröger, N., Zabelina, T., Schieder, H., Kratochville, A., Ayuk, F., Stute, N., Fehse, N., Hassenpflug, W., Panse, J., Casper, J., and Freund, M. Dose-reduced conditioning with treosulfan/fludarabine followed by allogeneic stem cell transplantation from related and unrelated donors in patients with AML and MDS/AML. *Onkologie* 26 S5, 70. 2004.
498. Waak, M., Knopp, A., Kleine, H.-D., Hilgendorff, I., Kundt, G., Freund, M., and Junghans, C. Prognostic factors for acute myeloid leukemia patients at the time of first diagnosis. *Onkologie* 26 S5, 88. 2004.
499. Wilhelm, S., Kahl, C., Freytag, J., Hickstein, H., Wolff, D., Steiner, B., Leithäuser, M., Casper, J., and Freund, M. Supportive treatment of acute graft-versus-host disease with use of molecular adsorbents recirculating system (MARS). *Onkologie* 26 S5, 158. 2003.
500. Wilhelm, S., Kahl, C., Hickstein, H., Freytag, J., Wolff, D., Steiner, B., Leithäuser, M., Casper, J., and Freund, M. Use of mars in treatment of acute graft-versus-host disease with hepatic encephalopathy. *Bone Marrow Transplantation* 31, Suppl. 1, 141. 2003.

501. Wolff, D., Steiner, B., Zingler, C., Wilhelm, S., Lazar, Y., Kahl, C., Leithäuser, M., Hartung, G., Casper, J., and Freund, M. Acute GVHD is associated with elevated sIL-2R, IL-10 and IL-5. *Bone Marrow Transplantation* 31, Suppl. 1, Abstract: P548. 2003.
502. Wolff, D., Steiner, B., Frei, E., Sievert, K., Terpe, H., Schrenk, H., Hartung, G., and Freund, M. Methotrexate-albumin and aminopterin-albumin are effective in prophylaxis of experimental acute GVHD. *Blood* 102(11), Abstract 5347. 2003.
503. Wolff, D., Steiner, B., Leithäuser, M., Wilhelm, S., Decker, S., Kleine, H.-D., Zimmermann, R., Hartung, G., Casper, J., and Freund, M. Treatment with Campath-1H for relapsed CLL after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GvHD. *Onkologie* 26 S5, 217. 2003.
504. Becker, C., Al Ali, H., Krahl, R., Poenisch, W., Wedding, U., Fiedler, F., Pasold, P., Freund, M., Subert, R., Kaempfe, D., Meran, J., Herold, M., Peter, N., Knauf, W., Kettner, E., Schultze, W., Dachzelt, K., Wolff, H. H., Kreibich, U., Schulze, M., Ittel, T., Assmann, M., Grobe, N., Huhn, R., Steglich, J., Schirmer, V., Klinkenstein, C., Opitz, B., Winkelmann, C., Haak, U., Helbig, W., and Niederwieser, D. High Complete Remission Rate in Patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group. *Blood* 104, #880. 2004.
505. Becker, C., Krahl, R., Al Ali, H., Pönisch, W., Wedding, U., Fiedler, F., Pasold, R., Freund, M., Subert, R., Kämpfe, D., Meran, J., Herold, M., Peter, N., Knauf, W., Kettner, E., Schultze, W., Dachzelt, K., Wolf, H. H., Schott, G., Schultze, M., Ittel, T., Assmann, M., Grobe, N., Huhn, R., Steglich, J., Schirmer, V., Klinkenstein, C., Doepper, J., Winkelmann, C., Helbig, W., and Niederwieser, D. Treatment of Acute Myeloid Leukemia (AML) in patients above the age of 60 years: A report of the AML97#38 study of the East German Hematology and Oncology Study Group. *Onkologie* 27 (Suppl. 3), 123. 2004.
506. Becker, C., Krahl, R., Al Ali, H., Moosmann, P., Pönisch, W., Wedding, U., Herold, M., Subert, R., Freund, M., Fiedler, F., Pasold, R., Peter, N., Meran, J., Fasshauer, E., Dachzelt, K., Grobe, N., Assmann, M., Kettner, E., Steglich, J., Huhn, R., Schultze, M., Schultze, W., Ittel, T., Klinkenstein, C., Doepper, J., Winkelmann, C., Knauf, W., Helbig, W., and Niederwieser, D. Treatment of Acute Myeloid Leukemia (AML) in Patients Below and Above the Age of 60 Years: Influence Factors for CR and Hematological Recovery. Study of the East German Hematology Oncology Study Group (OSHO). *Onkologie* 27 (Suppl. 3), 124. 2004.
507. Casper, J., Knauf, W., Blau, W., Volin, L., Ruutu, T., Wandt, H., Schaefer-Eckart, K., Holowiecki, J., Giebel, S., Aschan, J., Zander, A., Kroeger, N., and Freund, M. Allogeneic haematopoietic stem cell transplantation after treosulfan/fludarabine conditioning in high-risk patients with haematologic malignancies. *Bone Marrow Transplantation* 33 (Suppl. 1), P480. 2004.
508. Einsele, H., Hebart, H., Liebisch, P., Bargou, R., Meisner, C., Metzner, B., Wandt, H., Wolf, H., Sezer, O., Casper, J., Freund, M., Pfreundschuh, M., Dölken, G., Maschmeyer, G., Griminger, W., Straka, C., Trümper, L., Kröger, N., Hegewisch-Becker, S., Müller, P., Hertenstein, B., Peest, D., Frickhofen, N., Mitterer, M., Coser, P., Kanz, L., and Bensinger, S. W. I. Comparison of Two High-Dose Chemotherapy Regimens and Autologous Stem Cell Transplantation in Patients with De Novo Multiple Myeloma. *Onkologie* 27 (Suppl. 3), 34. 2004.
509. Fietz, T., Fiedler, F., Franke, A., Freund, M., Niederwieser, D., Thiel, E., and Knauf, W. U. Treatment of Primary Mediastinal Large B-Cell Lymphoma with an Alternating Chemotherapy Regimen based on High-Dose Methotrexate. *Onkologie* 27 (Suppl. 3), 190. 2004.
510. Fietz, T. J., Fiedler, F., Franke, M., Freund, M., Niederwieser, D., Thiel, E., and Knauf, W. U. Primary Mediastinal Large B-Cell Lymphoma: Long Term Results with an Alternating Chemotherapy Regimen Based on High-Dose Methotrexate. *Blood* 104, #3301. 2004.
511. Herold, M., Pasold, R., Srock, S., Nesper, S., Niederwieser, D., Neubauer, A., Doelken, G., Naumann, R., Fietz, T., Freund, M., Rohrberg, R., Hoeffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., von Gruenhagen, U., Dachzelt, K., Schwenke, H., Bleyl, D., Wolf, H., Hahnfeld, S., Hoffmann, F.-A., Lakner, V., Richter, P., Hähling, D., Wolf, H. H., Eschenburg, H., and Grobe, N. Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL). *Blood* 104, #584. 2004.
512. Hieke, K., Pasold, R., Nesper, S., Niederwieser, D., Neubauer, A., Doelken, G., Naumann, R., Fietz, T., Freund, M., Rohrberg, R., Hoeffken, K., Franke, A., Ittel, T. H., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., von Gruenhagen, U., Dachzelt, K., Schwenke, H., Bleyl, D., Wolf, H., Hahnfeld, S., Hoffmann, F.-A., Lakner, V., Richter, P., Hähling, D., Wolf, H.-H., Eschenburg, H., Grobe, N., Clemens, M.-R., and Herold, M. Cost Evaluation of Rituximab Plus MCP vs. MCP Alone in Advanced Stage Indolent Non-Hodgkin's-Lymphoma Based on a Randomized Controlled Multicenter Trial. *Blood* 104, #87. 2004.
513. Kröger, N., Zabelina, T., Schieder, H., Kratochwille, A., Ayuk, F., Stute, N., Fehse, N., Hassenpflug, J., Panse, J., Casper, J., Freund, M., and Zander, A. Treosulfan/fludarabine as dose-reduced conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with AML and MDS/sAML. *Bone Marrow Transplantation* 33 (Suppl. 1), P921. 2004.

514. Lenz, G., Dreyling, M., Wandt, H., Freund, M., Hess, G., Trümper, L., Diehl, V., Kropff, M., Kneba, M., Schmitz, N., Metzner, B., Unterhalt, M., and Hiddemann, W. Autologous Stem Cell Transplantation in First Remission Significantly Improves Progression-Free Survival in Follicular Lymphoma - Results of a Randomized Trial of the German Low-Grade Lymphoma Study Group (GLSG). *Onkologie* 27 (Suppl. 3), 39. 2004.
515. Nickenig, C., Dreyling, M., Schiegnitz, E., Wandt, H., Huber, C., Trümper, L., Ludwig, W.-D., Freund, M., Metzner, B., Schmitz, N., Parwaresch, R., Hasford, J., Unterhalt, M., and Hiddemann, W. CHOP Significantly Improves Overall Response and Overall Survival in Patients with Advanced Follicular Lymphoma – Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). *Onkologie* 27 (Suppl. 3), 15. 2004.
516. Steiner, B., Wolff, D., and Freund, M. Bone metabolism and risk-adjusted ibandronate drug therapy after allogeneic blood stem cell transplantation. *Bone Marrow Transplantation* 33 (Suppl. 1), -P796. 2004.
517. Steiner, M., Soriano, D., Steiner, B., Rolfs, A., Wangnick, M., Burstein, C., Freund, M., and Schuff-Werner, P. Antithrombin Rostock (Ala184-Pro): a novel exon 3B missense mutation (G6451C) causing type I deficiency with thrombophilia. *Hämostaseologie* 24, A51. 2004.
518. Steiner, M., Steiner, B., Rolfs, A., Wangnick, M., Burstein, C., Freund, M., and Schuff-Werner, P. Heterozygote Antithrombinmutation 5356-5364*delCTT als Ursache eines Antithrombinmangels vom Typ I und Thrombophilie. *Medizinische Klinik* 99, 114-115. 2004.
519. Wilhelm, S., Wolff, D., Steiner, B., Kahl, C., Casper, J., and Freund, M. High-Dose Cytarabine and total Body Irradiation with G-CSF Priming as Preparative Regimen for Allogeneic Transplantation. *Onkologie* 27 (Suppl. 3), 176. 2004.
520. Wilhelm, S., Wolff, D., Steiner, B., Junghanss, C., Casper, J., and Freund, M. Replacement of calcineurin inhibitors with daclizumab as treatment for acute graft-versus-host disease associated thrombotic thrombocytopenic purpura. *Bone Marrow Transplantation* 33 (Suppl. 1), R1116. 2004.
521. Angermund, R., Knauf, W., Freund, M., Nowrousian, M. R., Einsele, H., Goldschmidt, H., Berdel, W. E., Poenisch, W., Straka, C., Kellermann, L., and Bammer, S. Role of bortezomib in the treatment of multiple myeloma – first results from a representative multicentre treatment survey in Germany (GER). *Blood* 106, #5156. 2005.
522. Becker, C., Al Ali, H., Krahl, R., Poenisch, W., Hasenclever, D., Mantovani, L., Freund, M., Subert, R., Hegenbart, U., Wedding, U., Meran, J., Herold, M., Peter, N., Knauf, W., Kettner, E., Ittel, T., Franke, A., Dachsel, K., Wolf, H. H., Kreibich, U., Schulze, M., Assmann, M., Grobe, N., Huhn, R., Zschuppe, E., Schirmer, V., Haak, U., Klinkenstein, C., Opitz, B., Pasold, R., Fiedler, F., Winkelmann, C., Helbig, W., and Niederwieser, D. Cytogenetics and de novo/secondary AML but not age are the main determinants for CR rate and hematological recovery in acute myeloid leukemia (AML) using intermediate doses of cytarabine (AraC) delivered at the presumptive saturating infusion rate. *Blood* 106(11), #1851. 2005.
523. Becker, C., Al Ali, H., Krahl, R., Pönisch, W., Wedding, U., Hegenbart, U., Fiedler, F., Pasold, R., Freund, M., Subert, R., Herold, M., Meran, J., Kettner, E., Peter, N., Kreibisch, U., Knauf, W., Dachsel, K., Wolf, H. H., Schulze, M., Assmann, M., Ittel, T., Grobe, N., Huhn, R., Zschuppe, E., Schirmer, V., Franke, A., Klinkenstein, C., Opitz, B., Winkelmann, C., Haak, U., Helbig, W., and Niederwieser, D. Treatment in patients with acute myeloid leukemia (AML) over the age of 70 years: A report of the AML97#38 study of the East German Hematology and Oncology Study Group. *Onkologie* 28 (suppl. 3), 155. 2005.
524. Buesche, G., Hehlmann, R., Ganser, A., Hecker, H., Freund, M., Heimpel, H., Heinze, B., Schlegelberger, B., Fonatsch, C., Tobler, A., Georgii, A., and Kreipe, H. Emerging marrow fibrosis is a significant early indicator of failure of imatinib therapy in chronic myeloid leukemia even in the case of a hematologic and cytogenetic response. *Onkologie* 28 (suppl. 3), 218. 2005.
525. Buesche, G., Hehlmann, R., Ganser, A., Hecker, H., Freund, M., Heimpel, H., Heinze, B., Gadzicki, D., Schlegelberger, B., Fonatsch, C., Frye, B., Tobler, A., Georgii, A., and Kreipe, H. Emerging marrow fibrosis is an early indicator of imatinib failure and shortened survival time in CML independent of hematologic, cytogenetic and molecular response. *Blood* 106(11), #1106. 2005.
526. Buske, C., Kneba, M., Forstpointner, R., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.-E., Freund, M., Woermann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Truemper, L. H., Aldaoud, A., Parwaresch, R., Dreyling, M. H., Unterhalt, M., and Hiddemann, W. Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with advanced stage follicular lymphoma – Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). *Onkologie* 28 (suppl. 3), 37. 2005.
527. Casper, J., Wilhelm, S., Steiner, B., Wolff, D., Grobe, N., Haehling, D., Hartung, G., Hilgendorf, I., Lueck, A., Junghanss, C., Kahl, C., Pichlmeier, U., and Freund, M. Allogeneic blood stem cell transplantation in patients with hematologic diseases after conditioning with treosulfan and fludarabine. session type. *Blood* 106, #2744. 2005.
528. Casper, J., Leithäuser, M., Lück, A., Wilhelm, S., Jost, K., Steiner, B., Kahl, C., Vahle, L., Große-Thie, C., Respondek, E., Hilgendorf, I., Wolff, D., Kleine, H.-D., Junghanss, C., Hartung, G., and Freund, M. Chemotherapy induced nausea and vomiting: Quality management and quality control. *Onkologie* 28 (suppl. 3), 207. 2005.

529. Casper, J., Blau, W., Volin, L., Ruutu, T., Wandt, H., Schäfer-Eckart, K., Holowiecki, J., Giebel, S., Aschan, J., Zander, A., Kröger, N., and Freund, M. Feasibility of allogeneic hematopoietic stem cell transplantation after dose-escalated treosulfan/fludarabine conditioning in high-risk patients with hematologic malignancies. *Bone Marrow Transplantation* 35 Suppl. 2, 203. 2005.
530. Casper, J., Uharek, L., Schäfer-Eckart, K., Wilhelm, S., Knauf, W., Blau, I. W., Steiner, B., Krüger, W., Trentschel, R., Aschan, J., Ringdén, O., Volin, L., Ruutu, T., Wolff, D., Giebel, S., Kröger, N., Holowiecki, J., Zander, A., Hilgendorf, I., Dölken, G., Beelen, D., Thiel, E., Wandt, H., and Freund, M. Toxicity-reduced conditioning with treosulfan and fludarabine prior to allogeneic blood stem cell transplantation for patients with acute myeloid leukemia (AML). *Onkologie* 28 (suppl. 3), 193. 2005.
531. Casper, J., Knauf, W., Kleine, H.-D., Steiner, B., Wolff, D., Lück, A., Hammer, U., Wegener, R., and Freund, M. Treosulfan and fludarabine conditioning for allogeneic blood stem cell transplantation. *The Hematology Journal* 1 - Suppl. 1, 216 (#797). 2005.
532. Einsele, H., Liebisch, P., Bargou, R., Meisner, C., Metzner, B., Wandt, H., Wolf, H., Sezer, O., Casper, J., Freund, M., Pfreundschuh, M., Doelken, G., Maschmeyer, G., Grimminger, W., Straka, C., Truemper, L., Kroeger, N., Hegewisch-Becker, S., Mueller, R., Hertenstein, B., Peest, D., Frickhofen, N., Mitterer, M., Coser, P., Hebart, H., and Bensinger, W. Intensified conditioning therapy followed by a single auto-PBSCT versus tandem high dose melphalan: preliminary analysis. *Bone Marrow Transplantation* 35 Suppl. 2, 48. 2005.
533. Freund, M. Legal and financial regulations of clinical studies in Germany. *Onkologie* 28 (suppl. 3), 140. 2005.
534. Freund, M. R. F., Knauf, W., Goldschmidt, H., Einsele, H., Nowrousian, M. R., Berdel, W. E., Poenisch, W., Straka, C., Kellermann, L., Bammer, S., and Angermund, R. Treatment situation for newly diagnosed multiple myeloma (MM) patients in Germany (GER)- first results from a representative multicentre treatment survey. *Blood* 106, #5158. 2005.
535. Grosse-Thie, C., Leithaeuser, M., Lueck, A., Respondek, E., Jost, K., Herchenroeder, O., Lademann, M., Hartung, G., Casper, J., Freund, M., and Junghanss, C. Treatment of non-Hodgkin's lymphomas in patients with concomitant chronic viral infections. *Onkologie* 28 (suppl. 3), 265. 2005.
536. Hartung, G., Wilhelm, S., Leithäuser, M., Rabbel, B., Eschenburg, H., Wolff, D., Steiner, B., Casper, J., and Freund, M. First-line treatment of advanced gastric cancer with biweekly cisplatin plus weekly 24-h infusion with 5-fluorouracil and folinic acid. *Onkologie* 28 (suppl. 3), 239. 2005.
537. Hartung, G., Eschenburg, H., Wolff, D., Thiele, B., Pollmann, D., Schildhauer, S., Jost, K., Laser, N., Steiner, B., Freund, M., and Lüftner, D. Phase II study of a weekly irinotecan plus 24-h infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. *Onkologie* 28 (suppl. 3), 238. 2005.
538. Herold, M., Pasold, R., Srock, S., Nesper, S., Niederwieser, D., Neubauer, A., Dölken, G., Hirt, C., Naumann, R., Fietz, T., Knauf, W., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., von Grünhagen, U., Dachsel, K., Schwenke, H., Bleyl, D., Wolf, H., Hoffmann, F.-A., Lakner, V., Richter, P., Hähling, D., Wolf, H. H., Eschenburg, H., Clemens, M.-R., Grobe, N., and Behringer, D. The addition of rituximab to mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) does not improve the outcome in advanced mantle cell lymphoma (MCL) – Results of a phase III study (M39023). *Onkologie* 28 (suppl. 3), 36. 2005.
539. Hilgendorf, I., Leithaeuser, M., Lueck, A., Respondek, E., Grosse-Thie, C., Henschel, J., Aepinus, C., Berger, E., Freund, M., and Junghanss, C. Visual deterioration after gram-negative sepsis in neutropenia – a case report of endophthalmitis. *Onkologie* 28 (suppl. 3), 106. 2005.
540. Hirschhain, C., Wolff, D., Casper, J., Freund, M., and Steiner, B. Steroid-induced osteoporosis and aseptic osteonecrosis after allogeneic stem cell transplantation: Bone metabolism and bisphosphonate drug therapy. *Onkologie* 28 (suppl. 3), 251. 2005.
541. Hofmeister, N., Frei, E., Sievert, K., Schrenk, H.-H., Junghanß, C., Freund, M., Hartung, G., and Wolff, D. Albumin-uptake of human albumin-conjugates in mononuclear cells of the blood. *Onkologie* 28 (suppl. 3), 194. 2005.
542. Lange, S., Hilgendorf, I., Vogel, H., Weirich, V., Sekora, A., Koppitz, E., Wolff, D., Freund, M., and Junghanss, C. Hematopoietic cell lysate vaccinations fail to promote long term engraftment in a canine nonmyeloablative allogeneic stem cell transplantation model. *Onkologie* 28 (suppl. 3), 26. 2005.
543. Lange, S., Lange, B., Vogel, H., Weirich, V., Hilgendorf, I., Wolff, D., Hofmeister, N., Freund, M., and Junghanss, C. Influence of hematopoietic cell lysate vaccinations and dendritic cell enriched marrow grafts on engraftment after nonmyeloablative hematopoietic stem cell transplantation. *Blood* 106, #5231. 2005.
544. Leithaeuser, M., Kahl, C., Lueck, A., Jost, K., Wilhelm, S., Kundt, G., Hartung, G., Casper, J., Freund, M., and Junghanss, C. Outcome prediction in patients with malignant diseases prior to admission to intensive care units. *Onkologie* 28 (suppl. 3), 109. 2005.
545. Lück, A., Leithäuser, M., Respondek, E., Grosse-Thie, C., Jost, K., Hartung, G., Freund, M., and Junghanss, C. Metastatic alveolar rhabdomyosarcoma with diffuse bone marrow infiltration and disseminated intravascular coagulation - A case report. *Onkologie* 28 (suppl. 3), 270. 2005.
546. Mielke, M., Vajz, M., Wittke, C., Hilgendorf, I., Lange, S., Koppitz, E., Sekora, A., Freund, M., and Junghanss, C. AML-derived dendritic cells - functional properties and continuous expression of tumor-associated antigens. *Bone Marrow Transplantation* 35 Suppl. 2, S155. 200.

547. Morgner, A., Herbst, R., Löffler, C., Leonhardt, G., Hänel, M., and Freund, M. Orally given cytarabin (YNK01) combined with Interferon alpha induced long term complete cytogenetic remission in a CML patient: A case report. *Onkologie* 28 (suppl. 3), 217. 2005.
548. Respondek, E., Leithaeuser, M., Lueck, A., Große-Thie, C., Steiner, B., Aepinus, C., Casper, J., Hartung, G., Freund, M., and Junghanss, C. Spondylodiscitis due to *Staphylococcus epidermidis* – A rare complication following allogeneic stem cell transplantation. *Onkologie* 28 (suppl. 3), 105. 2005.
549. Steiner, B., Wolff, D., Wilhelm, S., Hilgendorf, I., Leithäuser, M., Casper, C., and Freund, M. Erythropoietin administration to correct transfusion-dependent anemia in patients with chronic GvHD after allogeneic SCT. *Bone Marrow Transplantation* 35 Suppl. 2, S338. 2005.
550. Steiner, B., Wolff, D., Wilhelm, S., Hilgendorf, I., Casper, J., and Freund, M. Erythropoietin administration to correct transfusion dependent anaemia in patients with chronic graft versus host disease after allogeneic stem cell transplantation. *Onkologie* 28 (suppl. 3), 243. 2005.
551. Steiner, B., Gombert, B., Ilg, J., Burstein, C., and Freund, M. Establishment of a web-based documentation system for quality assurance of haemophilia treatment in mecklenburg/western pommerania: A pilot study. *Onkologie* 28 (suppl. 3), 214. 2005.
552. Wilhelm, S., Hilgendorf, I., Steiner, B., Kahl, C., Wolff, D., Leithäuser, M., Junghans, C., Casper, J., and Freund, M. Central nervous complication with abnormal neuroradiological examination after allogeneic bone marrow transplantation. *Onkologie* 28 (suppl. 3), 12. 2005.
553. Wilhelm, S., Wolff, D., Hilgendorf, I., Steiner, B., Casper, J., and Freund, M. Daclizumab treatment in graft versus host disease in patients with thrombocytopenic purpura and renal insufficiency. *Bone Marrow Transplantation* 35 Suppl. 2, S42. 2005.
554. Wolff, D., Wilhelm, S., Hahn, J., Gentilini, C., Hilgendorf, I., Steiner, B., Kahl, C., Junghanss, C., Casper, J., Uharek, L., Holler, E., and Freund, M. Daclizumab can improve thrombotic thrombocytopenic purpura (TTP) and renal insufficiency in patients with acute and chronic Graft-versus-Host disease. *Onkologie* 28 (suppl. 3), 68. 2005.
555. Wolff, D., Bertz, H., Stadler, M., Hahn, J., Stelljes, M., Hertenstein, B., Casper, J., Freund, M., Finke, J., and Holler, E. Sirolimus in treatment of steroid refractory chronic GvHD – results of an interim analysis of a German multicentre phase II study. *Bone Marrow Transplantation* , S84, P449. 2006.
556. Hofmeister, N., Junghanss, C., Sievert, K., Terpe, H., Sekora, A., Freund, M., Hartung, G., and Wolff, D. Induction of chronic graft-versus-host disease in rats through bone marrow transplantation followed by donor lymphocyte infusion. *Bone Marrow Transplantation* , S80, P437. 2006.
557. Lange, S., Brandt, B., Ribeau, F., Vogel, H., Weirich, V., Hilgendorf, I., Wolff, D., Hofmeister, N., Freund, M., and Junghanss, C. Haematopoietic cell lysate vaccinations and bone marrow enrichment with donor-derived dendritic cells for engraftment promotion after non-myeloablative haematopoietic stem cell transplantation. *Bone Marrow Transplantation* , S62, P386. 2006.
558. Jost, K., Leithäuser, M., Große-Thie, C., Hilgendorf, I., Andree, H., Postel, T., Casper, J., Freund, M., and Junghanss, C. Perforation of the superior vena cava - a rare complication of central venous catheters. *Onkologie* 31 (Suppl. 3), P887. 2006.
559. Grosse-Thie, C., Jost, K., Hilgendorf, I., Leithäuser, M., Postel, T., Andree, H., Casper, J., Freund, M., and Junghanss, C. Palifermin: an effective prophylaxis of mucositis not only in autologous hematopoietic stem cell transplantation. *Onkologie* 31 (Suppl. 3), P889. 2006.
560. Hilgendorf, I., Wolff, D., Knopp, A., Jost, K., Große-Thie, C., Leithäuser, M., Casper, J., Freund, M., and Junghanss, C. Failure of long-lasting graft-versus-tumor effect in metastatic alveolar rhabdomyosarcoma. *Onkologie* 31 (Suppl. 3), P563. 2006.
561. Lange, T., Schwarzer, A., Uhle, R., von Grünhagen, U., Spohn, C., Lakner, V., Ittel, T., Assmann, M., Freund, M., Al-Ali, H. K., Krahl, R., Niederwieser, D., and the The East German Study Group (OSHO). Interim results of the phase I/II study imatinib +/- hydroxyurea of the East German Study group in patients with chronic myeloid leukemia in first chronic phase (Imatinib OSHO#68). *Onkologie* 31 (Suppl. 3), P506. 2006.
562. Ruck, S., Knopp, A., Krentz, H., Jost, K., Hilgendorf, I., Kahl, C., Wolff, D., Leithäuser, M., Casper, J., Freund, M., and Junghanss, C. Outcome of allogeneic hematopoietic stem cell transplantation compared to intensive chemotherapy in acute myelogenous leukemia according to cytogenetic risk groups: a matched pairs analysis. *Onkologie* 31 (Suppl. 3), P487. 2006.
563. Rabe, J., Krentz, H., Leithäuser, M., Jost, K., Hilgendorf, I., Kahl, C., Casper, J., Freund, M., and Junghanss, C. Outcome of 55 cancer patients with CNS involvement - a retrospective analyses. *Onkologie* 31 (Suppl. 3), P851. 2006.
564. Herold, M., Haas, A., Srock, S., Nesper, S., Al-Ali, H., Neubauer, A., Dölken, G., Naumann, R., Fietz, T., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Assmann, M., von Grünhagen, U., Dachselt, K., Schwenke, H., Bleyl, D., Wolf, H., Hahnfeld, S., Hoffmann, F., Lakner, V., Richter, P., Hähling, D., Wolf, H., Eschenburg, H., Clemens, M., Grobe, N., and Behringer, D. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma. *Onkologie* 31 (Suppl. 3), 164. 2006.
565. Gökbuget, N., Arnold, R., Böhme, A., Bartram, C., Fietkau, R., Freund, M., Ganser, A., Kneba, M., Lipp, T., Ludwig, W., Maschmeyer, G., Messerer, D., Rieder, H., Thiel, E., and Hoelzer, D. Outcome of adult patients with relapsed acute T-lymphoblastic leukemia. *Onkologie* 31 (Suppl. 3), V139. 2006.

566. Herold, M., Haas, A., Srock, S., Nesper, S., Al Ali, K. H., Neubauer, A., Doelken, G., Naumann, R., Fietz, T., Freund, M., Rohrberg, R., Hoeffken, K., Franke, A., Ittel, T. H., and Kettner, E. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma - 4 year follow-up results of a phase III trial of the East German Study Group Hematology and Oncology (OSHO#39). *ASH Annual Meeting Abstracts* 108(11), #484. 16-11-2006.
567. Niederwieser, D., Becker, C., Krahl, R., Al Ali, H. K., Heyn, S., Cross, M., Lange, T., Gerhardt, A., Schulze, A., Haehling, D., Schulze, M., Freund, M., Kettner, E., Dolken, G., Assmann, M., Wolf, H.-H., Zschuppe, E., Peter, N., Franke, A., Wedding, U., Uharek, L., Kreibich, U., Grobe, N., Ittel, T., Florschuetz, A., Opitz, B., Senfleben, K., Schirmer, V., Fiedler, F., Huhn, R., and Helbig, W. Increased leukaemia free survival (LFS) in patients with cytogenetic high risk AML after related or unrelated hematopoietic cell transplantation (HCT) compared to chemotherapy in the OSHO 96 and 2002 studies. *ASH Annual Meeting Abstracts* 108(11), #264. 16-11-2006.
568. Becker, C., Krahl, R., Al Ali, H., Heyn, S., Poenisch, W., Cross, M., Lange, T., Gerhardt, A., Schulze, A., Haehling, D., Schulze, M., Freund, M., Kettner, E., Doelken, G., Assmann, M., Wolf, H.-H., Zschuppe, E., Peter, N., Franke, A., Wedding, U., Uharek, L., Kreibich, U., Grobe, N., Ittel, T., Florschuetz, A., Opitz, B., Senfleben, K., Schirmer, V., Fenchel, K., Fiedler, F., Huhn, R., Zojer, N., Helbig, W., and Niederwieser, D. Early allogeneic transplantation improves overall survival (OS) and event free survival (EFS) independently of the applied chemotherapy in AML patients with unfavourable cytogenetic karyotype. *ASH Annual Meeting Abstracts* 108(11), #1921. 16-11-2006.
569. Angermund, R., Knauf, W., Freund, M., Nowrousian, M., Einsele, H., Goldschmidt, H., Berdel, W., Poenisch, W., Straka, C., Kellermann, L., and Pliskat, H. Uptake of new therapeutics in the treatment of multiple myeloma (MM) in Germany (GER) - results from a representative multicentre treatment survey 2006. *ASH Annual Meeting Abstracts* 108(11), #5110. 16-11-2006.
570. Klautke, G., Ludwig, K., Klar, E., Freund, M., and Fietkau, R. Toxicity and efficacy of four schedules of intensified neoadjuvant chemoradiotherapy (RCT) with irinotecan and 5-Fu or Capecitabine in patients with locally advanced rectal cancer (LARC). *Journal of Clinical Oncology* 24 (2006 ASCO Annual Meeting Proceedings Part 1.)(June 20 Supplement), 18S. 2006.
571. Hofmeister-Miehlke, N., Junghanss, C., Sievert, K., Terpe, H., Sekora, A., Freund, M., and Wolff, D. Induction of chronic graft-versus-host disease in rats through bone marrow transplantation followed by donor lymphocyte infusion (DLI). *Onkologie* 31 (Suppl. 3), P535. 2006.
572. Lange, S., Mueller, S., Dahlhaus, M., Hilgendorf, I., Wolff, D., Drewelow, B., Freund, M., and Junghanss, C. Pharmacokinetics of mycophenolate mofetil in dogs after non-myeloablative stem cell transplantation. *Onkologie* 31 (Suppl. 3), P536. 2006.
573. Leithäuser, M., Aepinus, C., Jost, K., Hilgendorf, I., Respondek, E., Große-Thie, C., Kahl, C., Wolff, D., Casper, J., Freund, M., and Junghanss, C. Invasive Zygomycose bei Patienten mit graft-versus-Host-Krankheit nach allogener Stammzelltransplantation. *Onkologie* 31 (Suppl. 3), P882. 2006.
574. Goekbuget, N., Arnold, R., Böhme, A., Fietkau, R., Freund, M., Ganser, A., Kneba, M., Lipp, T., Ludwig, W.-D., Maschmeyer, G., Messerer, D., Rieder, H., Thiel, E., and Hoelzer, D. Risk adapted treatment of adolescents with acute lymphoblastic leukemia (ALL) according the German Multicenter Study Group (GMALL) studies 06/99 and 07/03 yields significantly different outcome for subgroups. *Haematologica* 92 (Suppl. 1), 135. 2007.
575. Goekbuget, N., Arnold, R., Böhme, A., Fietkau, R., Freund, M., Ganser, A., Kneba, M., Lipp, T., Ludwig, W.-D., Maschmeyer, G., Messerer, D., Rieder, H., Thiel, E., and Hoelzer, D. Outcome of adult patients with relapsed acute T-lymphoblastic leukemia (T-ALL) can be improved with sequential salvage therapies and sct in second CR. *Haematologica* 92 (Suppl. 1), 10. 2007.
576. Andree, H., Hilgendorf, I., Leithäuser, M., Junghanss, C., Kahl, C., Casper, J., Freund, M., and Wolff, D. Enteral budesonide in treatment of mild and moderate chronic GvHD. *Bone Marrow Transplantation* 39 (suppl. 1s), S120. 2007.
577. Viehweg, M., Heussner, P., Andree, H., Hilgendorf, I., Leithäuser, M., Junghanss, C., Casper, J., Freund, M., and Wolff, D. Prospective evaluation of the physical functioning in patients before and after allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplantation* 39 (suppl. 1s), S294. 2007.
578. Holowiecki, J., Giebel, S., Wojnar, J., Holowiecka-Goral, A., Krawczyk-Kulis, M., Markiewicz, M., Wylezol, I., Kruzel, T., Casper, J., Kopera, M., and Freund, M. Low toxicity conditioning with treosulfan and fludarabine for chronic myeloid leukaemia – final results of a phase II clinical study . *Bone Marrow Transplantation* 39 (suppl. 1s), S8. 2007.
579. Knopp, A., Kistner, G., Junghanss, C., Große-Thie, C., Wolff, D., Andree, H., Hilgendorf, I., Kahl, C., Ruck, S., Jost, K., Leithäuser, M., Freund, M., and Casper, J. Prognostic significance of t(9;11) (p22;p15) in acute myeloid leukaemia. *Onkologie* 30 (suppl. 3), 220. 2007.
580. Heyne, U., Leithäuser, M., Neugebauer, C., Jost, K., Hilgendorf, I., Kahl, C., Wolff, D., Ruck, S., Rohde, S., Casper, J., and Freund, M. Iron overload in patients with acute leukaemias or haematopoietic stem cell transplantation. *Onkologie* 30 (suppl. 3), 209. 2007.
581. Kahl, C., Nogai, A., Kundt, G., Wolff, D., Leithäuser, M., Thiel, E., Uharek, L., Casper, J., and Freund, M. Allogeneic haematopoietic stem cell transplantation in advanced diseases - a retrospective analysis. *Onkologie* 30 (suppl. 3), 208. 2007.

582. Koenigsmann, M., Casper, J., Reichle, A., Mohren, M., Al-Ali, K. K., Uharek, L., Sayer, H., Krüger, W., Metzner, B., Behre, G., Theurich, S., Franke, A., Niederwieser, D., and Freund, M. Relapsed and refractory aggressive non-Hodgkin lymphoma - a risk-adapted high-dose therapy concept by the OSHO (Ostdeutsche Studiengruppe für Hämatologie und Onkologie). *Onkologie* 30 (suppl. 3), 203. 2007.
583. Lange, T., Schwarzer, A., Uhle, R., von Grünhagen, U., Spohn, C., Lakner, V., Ittel, T., Assmann, M., Freund, M., Schulze, M., Al-Ali, K. K., Krahl, R., and Niederwieser, D. Interim results of a phase I/II study Imatinib ± hydroxyurea of the East German Study group (OSHO) in patients with chronic myeloid leukaemia in first chronic phase (CML2004). *Onkologie* 30 (suppl. 3), 191. 2007.
584. Becker, C., Krahl, R., Al-Ali, K. K., Heyn, S., Pönisch, W., Cross, M., Lange, T., Gerhardt, A., Schulze, A., Mahlknecht, U., Hähling, D., Schulze, M., Freund, M., Kettner, E., Dölken, G., Wolf, H., Zschuppe, E., Peter, N., Franke, A., Wedding, U., Uhrarek, L., Kreibich, U., Florschütz, A., Opitz, B., Zojer, N., Helbig, W., and Niederwieser, D. Early allogeneic transplantation improves overall survival and event-free survival independently of the applied chemotherapy in AML patients with unfavourable cytogenetic karyotype. *Onkologie* 30 (suppl. 3), 185. 2007.
585. Hofmeister-Mielke, N., Klopffleisch, R., Teifke, J., Sinn, H., Sievert, K., Freund, M., Frei, E., Hartung, G., and Wolff, D. Albumin-steroid-conjugates for prevention of acute graft-versus-host disease. *Onkologie* 30 (suppl. 3), 130. 2007.
586. Schmidt-Hieber, M., Casper, J., Freund, M., Thiel, E., and Blau, I. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. *Onkologie* 30 (suppl. 3), 127. 2007.
587. Hilgendorf, I., Claus, R., Andree, H., Kahl, C., Casper, J., Junghanß, C., Leithäuser, M., Freund, M., and Wolff, D. Occurrence of autoantibodies in patients with chronic graft-versus-host disease. *Onkologie* 30 (suppl. 3), 130. 2007.
588. Herold, M., Haas, A., Srock, S., Nesper, S., Al-Ali, K. K., Neubauer, A., Dölken, G., Naumann, R., Fietz, T., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T., Kettner, E., Mey, U., Aßmann, M., Haak, U., and von Grünhagen, U. Immunochemotherapy is not superior to chemotherapy alone in advanced mantle cell lymphoma: 42 -month update. *Onkologie* 30 (suppl. 3), 85. 2007.
589. Angermund, R., Knauf, W., Freund, M., Nowrousian, M., Einsele, H., Goldschmidt, H., Berdel, W., Poenisch, W., Straka, C., Kellermann, L., and Pliakat, H. Uptake of new therapeutics in the treatment of multiple myeloma in Germany - results from a representative multicentre treatment survey 2006. *Onkologie* 30 (suppl. 3), 81. 2007.
590. Gökbüget, N., Arnold, R., Böhme, A., Fietkau, R., Freund, M., Ganser, A., Kneba, M., Lipp, T., Ludwig, W., Maschmeyer, G., Messerer, D., Rieder, H., Thiel, E., and Hoelzer, D. Improved outcome in high-risk and very high-risk ALL treated according to the GMALL protocol 07/2003. *Onkologie* 30 (suppl. 3), 44. 2007.
591. Casper, J., Goebel, D., Hilgendorf, I., Hickstein, H., Kahl, C., Leithäuser, M., Decker, S., Gliesche, T., Freund, M., and Lakner, V. Sunitinib treatment in dialysis patients with metastatic renal carcinoma. *Onkologie* 30 (suppl. 3), 35. 2007.
592. Herold, M., Haas, A., Srock, S., Nesper, S., Al Ali, K. H., Neubauer, A., Doelken, G., Naumann, R., Fietz, Th., Freund, M., Rohrberg, R., Hoeffken, K., Mohren, M., Ittel, T. H., and Kettner, E. Immunochemotherapy (R-MCP) Is Not Superior to Chemotherapy (MCP) Alone in Advanced Mantle Cell Lymphoma 42 Months Follow Up Results of the OSHO 39 Study. *Blood* 110(11), 189b; Abstract #4474. 2007.
593. Straka, C., Liebisch, P., Hennemann, B., Metzner, B., Salwender, H., Kanz, L., Adler-Reichel, S., Ludwig, W.-D., Wandt, H., Bentz, M., Bruemmendorf, T., Hentrich, M., Truemper, L., Freund, M., Wolf, H.-H., Sezer, O., Bargou, R., Doelken, G., Schmitz, N., Bernhard, H., Gramatzki, M., Frickhofen, N., Ostermann, H., Schmidmaier, R., Ibach, S., Hinke, A., Einsele, H., and Emmerich, B. The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study. *Blood* 110(11), 138a; Abstract #446. 2007.
594. Becker, C., Krahl, R., Al-Ali, H. K., Poenisch, W., Cross, M., Heyn, S., Gerhardt, A., Schulze, A., Mahlknecht, U., Haehling, D., Schulze, M., Freund, M., Kettner, E., Doelken, G., Wolf, H. H., Zschuppe, E., Peter, N., Franke, A., Wedding, U., Uharek, L., Kreibich, U., Florschütz, A., Opitz, B., Zojer, N., Helbig, W., and Niederwieser, D. High CR-Rate after Intensive Chemotherapy but Disappointing Results after Palliative Treatment in Patients with Acute Myeloid Leukemia Above the Age of 60 Years: An Analysis of the AML97#38 Study of the East German Hematology and Oncology Study Group (OSHO). *Blood* 110(11), 549a; Abstract #1854. 2007.
595. Gökbüget, N., Arnold, R., Böhme, A., Fietkau, R., Freund, M., Ganser, A., Kneba, M., Lipp, Th., Ludwig, W.-D., Maschmeyer, G., Messerer, D., Rieder, H., Thiel, E., and Hoelzer, D. Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003. *Blood* 11(110), 11a; Abstract #12. 2007.
596. Niederwieser, D., Becker, C., Krahl, R., Al-Ali, H., Lange, T., Gerhardt, A., Schulze, A., Hähling, D., Schulze, M., Freund, M., and East German Study Group (OSHO). Hematopoietic cell transplantation (HCT) after low-dose, total body irradiation-based regimen increased leukemia-free survival (LFS) in elderly patients with cytogenetic high-risk AML compared to chemotherapy (OSHO 97 study). *Journal of Clinical Oncology* 2007 ASCO Annual Meeting Proceedings Part I. Vol 25(No. 18S (June 20 Supplement)), 357s; Abstract #7003. 2007.

597. Wolff, D., Herzberg, P., Heussner, P., Mumm, F., von Harsdorf, F., Rieger, K., Hilgendorf, I., Hahn, J., Holler, E., and Freund, M. Evaluation of the NIH staging criteria in chronic GVHD and correlation to quality of life - results of an interim analysis of a prospective German multicenter validation study. *Blood* 110(11), 21a; Abstr. #42. 2007.
598. Wolff, D., Herzberg, P., Heussner, P., Mumm, F., von Harsdorf, F., Rieger, K., Hilgendorf, I., Hahn, J., Holler, E., and Freund, M. Evaluation of the NIH staging criteria in chronic GVHD and correlation to quality of life - results of an interim analysis of a prospective German multicenter validation study. *Onkologie* 30 (suppl. 3), 130. 2007.
599. Junghanss, C., Rohde, S., Haversath, M., Kundt, G., Wolff, D., Hilgendorf, H., Andree, H., Casper, J., Leithaeuser, M., Kahl, C., and Freund, M. Incidence and Outcome of Non-CMV Viral Infections in 202 Consecutive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients. *Blood* 110(11), 584a; Abstract #1965. 2007.
600. Lange, S., Rathsack, S., Wacke, R., Altmann, S., Weirich, V., Vogel, H., Drewelow, B., Freund, M., and Junghanss, C. Everolimus and Cyclosporine in Combination with 2Gy TBI as Pre- and Posttransplant Immunosuppression in a Canine Transplantation Model. *Blood* 110(10), 290b; Abstract #4861. 2007.
601. Lange, S., Rathsack, S., Adam, C., Wacke, R., Altmann, S., Wolff, D., Drewelow, B., Freund, M., and Junghanss, C. Pharmacokinetics of everolimus in a canine transplantation model. *Bone Marrow Transplantation* 39 (suppl. 1s), S90. 2007.
602. Junghanss, C., Koester, U., Schmidt, C., Thalheimer, M., Ehlken, B., Schaff, M., Berger, K., Goertz, A., Leithaeuser, M., and Freund, M. Costs related to febrile neutropenia (FN) in patients with acute leukemia (AL) or in autologous stem cell transplantation (ASCT) recipients treated in German hospitals. *Journal of Clinical Oncology* 26 (May 20 Suppl.), Abstr. 18023. 2009.
603. Beelen, D. W., Gromke, T., Trenchel, R., Hilgendorf, I., Wolff, D., Elmaagacli, A., Freund, M., and Casper, J. Treosulfan compared to total body irradiation-based preparative regimens before allogeneic stem cell transplantation for acute myeloid leukemia : a retrospective long-term study. *ASH Annual Meeting Abstracts* 112(11), #2149. 16-11-2008.
604. Goekbuget, N., Arnold, R., Baumann, A., Beck, J., Diedrich, H., Freund, M., Huttmann, A., Kneba, M., Kreuzer, K. A., Leimer, L., Lipp, T., Messerer, D., Naumann, R., Reichle, A., Rieder, H., Schafer-Eckart, K., Schmalzing, M., Schmid, M., Schmitz, N., Serve, H., Stelljes, M., Thiel, E., and Hoelzer, D. General condition and early complications have in addition to disease-specific factors a significant impact on outcome - prognostic factors revisited in 1657 adult ALL patients (15-55 years). *ASH Annual Meeting Abstracts* 112(11), #1927. 16-11-2008.
605. Schult, C., Dahlhaus, M., Boldt, S., Glass, A., Ruck, S., Sawitzky, M., Lange, S., Amoroso, F., Freund, M., Neri, L. M., and Junghanss, C. The multikinase inhibitor sorafenib inhibits proliferation in B- and T-Lymphoblastic cell lines via the PI3K/akt pathway. *ASH Annual Meeting Abstracts* 112(11), #1910. 16-11-2008.
606. Ruutu, T., Volin, L., Beelen, D. W., Trenchel, R., Finke, J., Schnitzler, M., Holowiecki, J., Giebel, S., Uharek, L., Blau, I. W., Stelljes, M., Kienast, J., Larsson, K., Zander, A. R., Gramatzki, M., Repp, R., Einsele, H., Stuhler, G., Freund, M., and Casper, J. Reduced toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: results of an international prospective phase II trial. *ASH Annual Meeting Abstracts* 112(11), #3274. 16-11-2008.
607. Junghanss, C., Koester, U., Schmidt, C., Thalheimer, C., Ehlken, B., Schaff, M., Berger, K., Goertz, A., Leithäuser, M., and Freund, M. Febrile neutropenia (FN) in patients with acute leukemia (AL) or in autologous stem cell transplantation (ASCT) recipients - treatment cost from the perspective of German hospitals. *Onkologie* 31 (suppl. 4), P679. 2008.
608. Leithäuser, M., Jost, K., Gläser, D., Borchert, K., Ruck, S., Freund, M., Kahl, C., and Junghanss, C. Primary antifungal prophylaxis during induction chemotherapy for acute myeloid leukemia. *Onkologie* 31 (suppl. 4), P676. 2008.
609. Thiele, M., Leithäuser, M., Kristen, K., Jost, K., Borchert, K., Gläser, D., Kahl, C., Freund, M., and Junghanss, C. The visual analogue scale as a quality control tool in pain management of oncological inpatients. *Onkologie* 31 (suppl. 4), P572. 2008.
610. Lange, T., von Grünhagen, U., Schwarzer, A., Uhle, R., Spohn, C., Lakner, V., Ittel, T., Assmann, M., Freund, M., Schulze, M., Al-Ali, H. K., Krahl, R., and Niederwieser, D. Responses and toxicities of newly diagnosed CML patients treated with imatinib +/- hydroxyurea within a phase I/II study of the East German Study group (OSHO, CML2004). *Onkologie* 31 (suppl. 4), P270. 2008.
611. Gromke, T., Casper, J., Trenchel, R., Wolff, D., Freund, M., and Beelen, D. W. Retrospective comparative analysis of the clinical outcome after Treosulfan-based conditioning vs. standard conditioning therapy in adult patients with acute myeloid leukemia. *Onkologie* 31 (suppl. 4), P110. 2008.
612. Mueller, S., Lange, S., Altmann, S., Weirich, V., Vogel, H., Freund, M., and Junghanss, C. Kinetics of Langerhans cell chimerism in the skin of dogs following 2 Gy TBI allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplantation* 41 (Suppl. 1), P523. 2008.
613. Altmann, S., Pommerencke, J., Lange, S., Murua Escobar, H., Bullerdiek, J., Nolte, I., Freund, M., and Junghanss, C. High mobility group box 1-protein (HMGB1) expression decreases during CD34+ derived dendritic cell differentiation and exhibits T-lymphocyte proliferative activity. *Bone Marrow Transplantation* 41 (Suppl. 1), P1040. 2008.

-
614. Rathsack, S., Lange, S., Altmann, S., Wacke, R., Drewelow, B., Freund, M., and Junghanss, C. Everolimus in combination with cyclosporin A as a potential alternative immunosuppressant in non-myeloablative haematopoietic stem cell transplantation. *Bone Marrow Transplantation* 41 (Suppl. 1), P519. 2008.
615. Schult, C., Dahlhaus, M., Ruck, S., Sawitzky, M., Lange, S., Amoroso, F., Freund, M., Neri, L., and Junghanss, C. Sorafenib inhibits proliferation in B- and T-lymphoblastic cell lines via the PI3K/Akt pathway. *Onkologie* 31 (suppl. 4), 21. 2008.
616. Ruck, S., Aepinus, C., Jost, K., Leithäuser, M., Andree, H., Hilgendorf, I., Kahl, C., Freund, M., and Junghanss, C. Nocardia abscessus pulmonary infection in an allogeneic hematopoietic stem cell recipient. *Onkologie* 31 (suppl. 4), 232. 2008.
617. Hilgendorf, I., Wolff, D., Andree, H., Knopp, A., Junghanss, C., and Freund, M. The dosis makes the poison. Report on a patient with malignant pheochromocytoma and the need of alloHSCT. *Onkologie* 31 (suppl. 4), 158. 2008.
618. Ruck, S., Jost, K., Hilgendorf, I., Steffen, A., Lampe, H., Leithäuser, M., Kahl, C., Freund, M., and Junghanss, C. Decitabine as palliative therapy in AML patients. *Onkologie* 31 (suppl. 4), 68. 2008.
619. Jost, K., Leithäuser, M., Prall, F., Andree, H., Ruck, S., Hilgendorf, I., Kahl, C., Freund, M., and Junghanss, C. Isolated mediastinal myeloid sarcoma presenting as superior vena cava syndrome. *Onkologie* 31 (suppl. 4), 54. 2008.
620. Andree, H., Hilgendorf, I., Jost, K., Ruck, S., Wolff, D., Leithäuser, M., Kahl, C., Freund, M., and Junghanss, C. Limited toxicity and effective remission induction by nelarabine in acute lymphoblastic leukaemic relapse before second allogeneic stem cell transplantation. *Onkologie* 31 (suppl. 4), 47. 2008.
621. Schult, C., Hilgendorf, I., Wittke, C., Kruse, C., Lange, S., Freund, M., and Junghanss, C. Expression and functional properties of the multi KH-domain protein vigilin in acute lymphoblastic leukemia. *Onkologie* 31 (suppl. 4), 21. 2008.
622. Glaeser, D., Hilgendorf, I., Prall, F., Leithäuser, M., Junghanss, C., Freund, M., and Kahl, C. Composite angioimmunoblastic T-cell lymphoma and high grade B-cell lymphoma - A case report. *Onkologie* 31 (suppl. 4), 12. 2008.
623. Haversath, M., Rohde, S., Kundt, G., Wolff, D., Hilgendorf, I., Casper, J., Leithäuser, M., Kahl, C., Freund, M., and Junghanss, C. Incidence and onset of CMV infections following treosulfan based reduced-intensity conditioning and allogeneic stem cell transplantation. *Bone Marrow Transplantation* 41(suppl. 1), S269. 2008.
624. Hilgendorf, I., Mueller-Hilke, B., Claus, R., Casper, J., Junghanss, C., Leithäuser, M., Freund, M., and Wolff, D. Autoantibodies are detected in patients with chronic GVHD as well as in the absence of GVHD after allogeneic HSCT. *Bone Marrow Transplantation* 41(suppl. 1), S233. 2008.
625. Casper, J., Hilgendorf, I., Wolff, D., Gromke, T., Trentschel, R., Kordelas, L., Dischkowski, M., Steckel, N., Freund, M., and Beelen, DW. A long-term retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning regimen for allogeneic HSCT in patients with primary or therapy-related myelodysplastic syndrome. *Bone Marrow Transplantation* 41(suppl. 1), S213. 2008.
626. Endler, F., Wolff, D., Hilgendorf, I., Kahl, C., Andree, H., Gerlach, M., Freund, M., and Casper, J. Conditioning with treosulfan and fludarabine splitted over 5 days before allogeneic stem cell transplantation. *Bone Marrow Transplantation* 41(suppl. 1), S211. 2008.
627. Viehweg, M., Heussner, P., Herzberg, P., Andree, H., Hilgendorf, I., Leithäuser, M., Junghanss, C., Casper, J., Freund, M., and Wolff, D. Prospective evaluation of the physical functioning in patients before and after allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplantation* 41 (suppl. 1), S85. 2008.
628. Wang, X., Schmitt, A., Xu, X., Chen, B. A., Freund, M., and Schmitt, M. Efficient selection of WT1-specific donor lymphocytes by streptamer technology. *ASH Annual Meeting Abstracts* 114(22), #3311. 20-11-2009.
629. Goekbuget, N., Brueggemann, M., Arnold, R., Bartram, C. R., Fietkau, R., Freund, M., Ganser, A., Kneba, M., Lipp, T., Ludwig, W. D., Maschmeyer, G., Messerer, D., Raff, T., Rieder, H., Thiel, E., and Hoelzer, D. New definition of treatment response in adult acute lymphoblastic leukemia (ALL): use of molecular markers for minimal residual disease (MRD). *ASH Annual Meeting Abstracts* 114(22), #90. 20-11-2009.
630. Knop, S., Liebisch, P., Hebart, H., Holler, E., Engelhardt, M., Bargou, R. C., Metzner, B., Peest, D., Aulitzky, W. E., Wandt, H., Sezer, O., Hentrich, M., Ostermann, H., Peschel, C., Hess, G., Hertenstein, B., Freund, M., Kropff, M. H., Wolf, H.-H., Jung, W., Frickhofen, N., Maschmeyer, G., Mergenthaler, H. G., Heidemann, E., Kroger, N., Straka, C., Engel, C., Kanz, L., Meisner, C., and Einsele, H. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma - an interim analysis of the German DSMM V trial. *ASH Annual Meeting Abstracts* 114(22), #51. 20-11-2009.
631. Wandt, H., Schaefer-Eckart, K., Pilz, B., Thalheimer, M., Ho, A. D., Schaich, M., Kaufmann, M., Aulitzky, W. E., Haenel, M., Herbst, R., Doelken, G., Klenner, A. F., Freund, M., Junghanss, C., and Ehninger, G. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukemia: preliminary results of a randomized multicenter study after enrolment of 175 patients. *ASH Annual Meeting Abstracts* 114(22), #20. 20-11-2009.

-
632. Schult, C., Dahlhaus, M., Sekora, A., Lange, S., Freund, M., and Junghanss, C. The dual PI3K and mTOR kinase inhibitor NVP-BEZ235 induces cell cycle arrest in acute lymphoblastic leukemia cells and potentiates the cytotoxicity of dexamethasone, cytarabine and doxorubicin. *ASH Annual Meeting Abstracts* 114(22), #4115. 20-11-2009.
633. Lampe, H., Jun, X., and Freund, M. Evaluation of complementary treatments in oncology, especially Traditional Chinese Medicine. *Onkologie* 32 (Suppl. 4), 143. 2009.
634. Kahl, C., Hirt, C., Decker, S., Prall, F., Gläser, D., Rohde, S., Jost, K., Respondek-Dryba, E., Hilgendorf, I., Leithäuser, M., Junghanss, C., and Freund, M. Primary spinal epidural follicular lymphoma - a retrospective analysis. *Onkologie* 32 (Suppl. 4), 38. 2009.
635. Leithäuser, M., Wilhelm, S., Kahl, C., Eschenburg, H., Jost, K., Hilgendorf, I., Junghanss, C., and Freund, M. Palliative chemotherapy for advanced and metastatic gastric cancer in the community. *Onkologie* 32 (Suppl. 4), 136. 2009.
636. Wang, X., Schmitt, A., Xu, X., Freund, M., and Schmitt, M. Leukemia antigen-specific donor lymphocyte infusions made possible through streptamer-based selection. *Onkologie* 32 (Suppl. 4), 110. 2009.
637. Borchert, K., Grosse-Thie, C., Donat, M., Leithäuser, M., Freund, M., and Junghanss, C. Fatal outcome of systemic infection with *scedosporium prolificans* after allogeneic stem cell transplantation. *Onkologie* 32 (Suppl. 4), 185. 2009.
638. Hilgendorf, I., Müller-Hilke, B., Holler, E., Hoffmann, P., Edinger, M., Junghanss, C., Leithäuser, M., Freund, M., and Wolff, D. Chronic GVHD is associated with a deficiency of CD27+IgD+IgM+ B cells. *Onkologie* 32 (Suppl. 4), 105. 2009.
639. Kröger, N., Einsele, H., Freund, M., Wandt, H., and Zander, A. Long-term follow-up of myeloablative intensified conditioning regimen with in-vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. *Onkologie* 32 (Suppl. 4), 35-36. 2009.
640. Casper, J., Holowiecki, J., Giebel, S., Beelen, D., Trenschele, R., Wandt, H., Schäfer-Eckardt, K., Ruutu, T., Volin, L., Einsele, H., Stuhler, G., Uharek, L., Blau, I. W., Bornhäuser, M., Zander, A., Kröger, N., Aschan, J., Wojnar, J., Markiewicz, M., and Freund, M. Final results of a prospective international phase II allogeneic transplant protocol with Treosulfan/Fludarabine conditioning in 75 AML patients. *Onkologie* 32 (Suppl. 4), 29-30. 2009.
641. Schmitt, A., Tonn, T., Grigoleit, G. U., Busch, D., Ringhoffer, M., Wiesneth, M., Seifried, E., Freund, M., Döhner, H., Bunjes, D., Einsele, H., and Schmitt, M. Adoptive transfer of cytomegalovirus-specific CD8+ T cells selected by GMP-conform streptamers results in enduring virus clearance in patients after allogeneic stem cell transplantation. *Onkologie* 32 (Suppl. 4), 180. 2009.
642. Schmitt, A., Casalegno-Garduno, R., Freund, M., and Schmitt, M. Multimer technologies for detection and adoptive transfer of antigen specific T cells. *Onkologie* 32 (Suppl. 4), 180. 2009.
643. Ruutu, T., Beelen, D., Finke, J., Holowiecki, J., Uharek, L., Kienast, J., Larsson, K., Zander, A., Gramatzki, M., Einsele, H., Volin, L., Trenschele, R., Schnitzler, M., Giebel, S., Blau, I. W., Stelljes, M., Repp, R., Stuhler, G., Freund, M., and Casper, J. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. *Onkologie* 32 (Suppl. 4), 151. 2009.
644. Schneidawind, D., Schmitt, A., Bunjes, D., Freund, M., and Schmitt, M. Polyomavirus BK-specific CD8+ T cell responses in patients after allogeneic stem cell transplantation. *Onkologie* 32 (Suppl. 4), 251. 2009.
645. Wang, X., Schmitt, A., Germeroth, L., Freund, M., and Schmitt, M. Generation of leukaemia antigen-specific donor lymphocyte infusions powered by streptamer-based selection. *EBMT Proceedings* , O403. 2009.
646. Ruutu, T., Beelen, D., Finke, J., Holowiecki, J., Uharek, L., Kienast, J., Larsson, K., Zander, A. R., Gramatzki, M., Einsele, H., Volin, L., Trenschele, R., Schnitzler, M., Giebel, S., Blau, I. W., Stelljes, M., Repp, R., Stuhler, G., Freund, M., and Casper, J. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic haematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. *EBMT Proceedings* , O300. 2009.
647. Krautz, J., Hilgendorf, I., Krentz, H., Drost, S., Junghanss, C., Wolff, D., Freund, M., and Casper, J. A retrospective analysis of the outcome of patients with diffuse large B-cell lymphoma after autologous or autologous-allogeneic haematopoietic stem cell transplantation. *EBMT Proceedings* , R1288. 2009.
648. Kahl, C., Wolff, D., Nogai, A., Kundt, G., Hahn, J., Holler, E., Uharek, L., Junghanss, C., Leithäuser, M., Thiel, E., and Freund, M. Limited chronic GvHD significantly improves outcome after allogeneic haematopoietic stem cell transplantation in advanced haematological diseases . *EBMT Proceedings* , P733. 2009.
649. Knueppel, A., Lange, S., Sekora, A., Killian, D., Freund, M., and Junghanss, C. Phenotypic and functional characterisation of canine regulatory T-cells in the allogeneic setting. *EBMT Proceedings* , P624. 2009.
650. Lange, S., Knueppel, A., Killian, D., Knuebel, G., Sekora, A., Kundt, G., Freund, M., and Junghanss, C. Radiation dose, recipient gender and cell dose as risk factors for graft survival in a canine non-myeloablative HSCT model. *EBMT Proceedings* , P620. 2009.
651. Hilgendorf, I., Mueller-Hilke, B., Junghanss, C., Leithäuser, M., Freund, M., and Wolff, D. Chronic GvHD is associated with a deficiency of CD27+IgD+IgM+ B cells. *EBMT Proceedings* , P556. 2009.

-
652. Viehweg, M., Herzberg, P., Andree, H., Hilgendorf, I., Leithaeuser, M., Junghanss, C., Casper, J., Freund, M., and Wolff, D. GvHD associated impairment of physical functioning, depression, and anxiety. Results from a prospective trial on physical and psychological functioning in patients before and after allogeneic haematopoietic stem cell transplantation. *EBMT Proceedings* , P542. 2009.
653. Jost, K., Leithäuser, M., Grosse-Thie, C., Hilgendorf, I., Kahl, C., Kundt, G., Freund, M., and Junghanss, C. Efficiency of high-dose etoposide phosphate and G-CSF for primary and secondary stem cell mobilisation - a single-centre retrospective analysis of 66 patients. *EBMT Proceedings* , P503. 2009.
654. Gökbüget, N., Brüggemann, M., Arnold, R., Bartram, C.-R., Fietkau, R., Freund, M., Ganser, A., Kneba, M., Lipp, T., Ludwig, W.-D., Maschmeyer, G., Messerer, D., Raff, T., Rieder, H., Serve, H., Thiel, E., and Hoelzer, D. Definition of molecular remission in adult acute lymphoblastic leukemia (ALL) based on minimal residual disease (MRD). *Onkologie* 33, Suppl. 6, Abs. V710. 2010.
655. Hilgendorf, I., Respondek-Dryba, E., Lampe, H., Wittke, C., Leithäuser, M., Junghanss, C., and Freund, M. Monthly treatment with romiplostin in a patient with severe aplastic anaemia and immune thrombocytopenia. *Onkologie* 33, Suppl. 6, Abs. P183. 2010.
656. Hilgendorf, I., Mueller-Hilke, B., Kundt, G., Holler, E., Hoffmann, P., Edinger, M., Freund, M., and Wolff, D. Lymphocyte subsets in chronic Gvhd - a key role for B cells? *ASH Annual Meeting Abstracts* 116(21), 2311. 19-11-2010.
657. Hilgendorf, I., Jilg, W., Einsele, H., Greinix, H., Halter, J., Freund, M., Lawitschka, A., Wolff, D., and Meisel, R. Vaccination of haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHD. *Onkologie* 33, Suppl. 6, Abs. V123. 2010.
658. Hilgendorf, I., Loebermann, M., Borchert, K., Junghanss, C., Freund, M., and Schmitt, M. Tenofovir for the treatment of hepatitis B virus reactivation in patients with chronic GvHD. *EBMT Proceedings* , Abstr. P792. 2010.
659. Jost, K., Leithäuser, M., Hilgendorf, I., Wittke, C., Borchert, K., Jeske, S., Heyne, U., Crusius, S., Junghanss, C., Freund, M., and Kahl, C. Meningoencephalitis and sepsis caused by *Listeria monocytogenes* after consumption of contaminated cheese in a patient with lymphoplasmacytic lymphoma. *Onkologie* 33, Suppl. 6, Abs. P240. 2010.
660. Jost, K., Killian, D., Sekora, A., Escobar, H., Nolte, I., Kahl, C., Freund, M., and Junghanss, C. HMGB1 serum levels in patients with hematologic malignancies before and following chemotherapy. *Onkologie* 33, Suppl. 6, Abs. P917. 2010.
661. Kahl, C., Sayer, H., Hinke, A., Pester, F., Freund, M., Casper, J., and für die Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO). Early versus late administration of pegfilgrastim after autologous haematopoietic stem cell transplantation. *Onkologie* 33, Suppl. 6, Abs. P567. 2010.
662. Killian, D., Kneuppel, A., Willenbrock, S., Murua Escobar, H., Heisterkamp, A., Lubatschowski, H., Nolte, I., Sekora, A., Freund, M., and Junghanss, C. Influence of high mobility group Box 1 on allogeneic immune responses. *EBMT Proceedings* , Abstr. P900. 2010.
663. Killian, D., Kneuppel, A., Lange, S., Dunkelmann, S., Fitting, J., Willenbrock, S., Wefstaedt, P., Murua Escobar, H., Nolte, I., Barth, S., Sekora, A., Freund, M., and Junghanss, C. Migration of canine dendritic cells can be detected by radioactive-labelling and varies according to injection sites. *EBMT Proceedings* , Abstr. P901. 2010.
664. Knödler, M., Egerer, G., Freund, M., Kettner, E., Euckner, J., Stoll, C., Schmitt, A., and Keilholz, U. Safety and efficacy of nonpegylated liposomal doxorubicin plus ifosfamide versus conventional doxorubicin plus ifosfamide in locally advanced or metastatic soft tissue sarcoma: interim analysis of a randomized phase II trial. *Onkologie* 33, Suppl. 6, Abs. P594. 2010.
665. Kneuppel, A., Killian, D., Lange, S., Sekora, A., Freund, M., and Junghanss, C. Intra-bone marrow transplantation of allogeneic DLA-identical CD34 + cells allows successful engraftment in DLA-identical canine litters following non-myeloablative conditioning. *EBMT Proceedings* , Abstr. P897. 2010.
666. Kneuppel, A., Killian, D., Lange, S., Sekora, A., Freund, M., and Junghanss, C. Recovery of regulatory T-cells following non-myeloablative DLA-identical littermate allogeneic stem cell. *EBMT Proceedings* , Abstr. P896. 2010.
667. Lampe, H. and Freund, M. Evidence-based complementary and alternative medicine (CAM) in oncology. *Onkologie* 33, Suppl. 6, Abs. V296. 2010.
668. Lampe, H., Liu, J., Leithäuser, M., Lakner, V., Hildebrandt, G., Kraft, K., and Freund, M. Chinese Medicine after exhaustion of existing standard treatments. *Onkologie* 33, Suppl. 6, Abs. P262. 2010.
669. Schmitt, A., Xu, X., Wang, X., Hilgendorf, I., Borchert, K., Freund, M., and Schmitt, M. WT1 and RHAMM specific CD8 + T-cells can be isolated and purified by streptamers for adoptive transfer. *EBMT Proceedings* , Abstr. O362. 2010.
670. Schmitt, M., Sayer, H. G., Hilgendorf, I., Treschl, A., Junghanss, C., Borchert, K., Königsmann, M., Casper, J., Freund, M., and Kahl, C. Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma (NHL). *Onkologie* 33, Suppl. 6, Abs. P556. 2010.
671. Schneidawind, D., Mani, J., Schmitt, A., Bunjes, D., Freund, M., and Schmitt, M. Polyomavirus-specific CD8+ T cell responses in patients after allogeneic stem cell transplantation. *Onkologie* 33, Suppl. 6, Abs. V124. 2010.

-
672. Schneidawind, D., Schmitt, A., Bunjes, D., Freund, M., and Schmitt, M. Patients after allogeneic stem cell transplantation can generate polyomavirus-specific CD8 + T-cell responses. EBMT Proceedings , Abstr. P700. 2010.
673. Schult, C., Fischer, K., Dahlhaus, M., Goetz, M., Lange, S., Freund, M., and Junghanss, C. Concomitant treatment of Sorafenib with dexamethasone enhances antiproliferative effects in lymphoblastic cells. *Onkologie* 33, Suppl. 6, Abs. P796. 2010.
674. Sezer, O., Jakob, C., Aldaoud, A., Schwarzer, A., Maintz, C., Kropff, M., Blumenstengel, K., Mittermüller, J., Aulitzky, W., Wolf, H., Duerk, H., Cordes, H. J., Beck, C., Einsele, H., Schmidt, K., Friedrichs, U., Haus, U., and Freund, M. Zoledronic Acid Therapy Versus Control in Patients with Multiple Myeloma in Stage I (Durie & Salmon): Results of a Phase III Study of the "Deutsche Studiengruppe Multiples Myelom (DSMM)" and "Ostdeutsche Studiengruppe Haematologie und Onkologie (OSHO)". EHA 2010 #998 . 2010.
675. Sezer, O., Jakob, C., Aldaoud, A., Schwarzer, A., Maintz, C., Kropff, M., Blumenstengel, K., Mittermüller, J., Aulitzky, W., Wolf, H., Duerk, H., Cordes, H., Beck, C., Einsele, H., Schmidt, K., Friedrichs, U., Haus, U., Freund, M., and DSMM and OSHO. Zoledronic acid therapy versus control in patients with Multiple Myeloma in stage I (Durie & Salmon): Results of a phase III study of the "Deutsche Studiengruppe Multiples Myelom (DSMM)" and "Ostdeutsche Studiengruppe Haematologie und Onkologie (OSHO)". *Onkologie* 33, Suppl. 6, Abs. V347. 2010.
676. Wandt, H., Schaefer-Eckart, K., Pilz, B., Thalheimer, M., Ho, A., Schaich, M., Kaufmann, M., Aulitzky, W., Haenel, M., Herbst, R., Doelken, G., Klenner, A., Freund, M., Junghanss, C., and Ehninger, G. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia: final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. *Onkologie* 33, Suppl. 6, Abs. V28. 2010.
677. Wittke, C., Prall, F., Jost, K., Jeske, S., Freund, M., and Kahl, C. Bone pain, leftward shift in peripheral blood and elevated liver enzymes: A case report. *Onkologie* 33, Suppl. 6, Abs. P533. 2010.
678. Xun, X., Stockhammer, F., Mani, J., Schmitt, A., Casalegno-Garduno, R., Freund, M., and Schmitt, M. Functional dendritic cells can be generated from the peripheral blood of patients with glioblastoma even during treatment with temozolomide. *Onkologie* 33, Suppl. 6, Abs. P913. 2010.